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"God and Nature first made us what we are, and then out of our 
own created genius we make ourselves what we want to be . . . Let 
the sky and God be our limit and Eternity our measurement. "' 
"If you want to see God smile, tell him your plans. "2 
"The keenest sorrow is to recognize ourselves as the sole cause 
of all our adversities. "3 
I. INTRODUCTION 
Prior to the advent of amniocentesis in the 1960s, prospective parents' 
control over the genetic makeup of their children was limited to deciding 
with whom to procreate. Today, the limits on that control have been re­
duced to the genes of prospective parents or the donors of ova and sperm 
they deem acceptable, the number of viable embryos produced, the genetic 
screening available, and the financial resources necessary to put genetic 
screening and other assisted reproduction technologies to use.4 And ongo­
ing biomedical research promises to further minimize these limitations. An 
I GREGORY STOCK, REDESIGNING HUMANS I (2002) (quoting Marcus Garvey (1887-1940)). 
2 A PRIMER FOR HEALTH CARE ETHICS: EsSAYS FOR A PLURALISTIC SOCIETY 152 (Kevin 
O'Rourke ed., Georgetown Univ. Press 2d ed. 2000) [hereinafter PRIMER). 
3 THE MOST BRILLIANT THOUGHTS OF ALL TIME 9 (John M. Shanahan ed., 1999) (quoting 
Sophocles (c. 496-406 B.C.)). 
4 In fact, as observed by Professor Storrow, today a child could have up to eight "parents"-the 
egg donor, the sperm donor, their spouses, a surrogate and her husband, and the intending mother and 
father. Richard F. Storrow, Parenthood by Pure Intention: Assisted Reproduction and the Functional 
Approach to Parentage, 53 HASTINGS L.J. 597, 602 (2002). 
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exponential increase in identified gene and protein functions, the capacity 
to screen for hundreds-eventually for many thousands-of genetic char­
acteristics in a matter of minutes from a single sample and for a fraction of 
the present costs of running genetic tests5 and, ultimately, the advent of 
5 Presently, there are market impediments keeping predictive genetic testing off of the market. 
See generally Michael J. Malinowski, Separating Predictive Genetic Testing from Snake Oil: Regula­
tion, Liabilities, and Lost Opportunities, 41 JURIMETRICS J. 23 (2000) [hereinafter Snake Oil] (propos­
ing that predictive genetic testing should be introduced on a regulatory framework like other medical 
technology). Some of the testing that is available is costly and the subject of extensive intellectual 
property filings, which has been resulting in disputes. For example, Myriad Genetics' test for BRCAl 
and BRCA2, genetic alleles associated with breast and ovarian cancers, is priced at $3,850, whlch has 
resulted in a dispute between Myriad and the Canadian provinces of Alberta and Ontario. See Gene­
Patent Policy Review Urgently Needed, EDMONTON J., Jan. 10, 2003, at 
http://lists.essential.orglpipermaillip-health/2003-January/004055.htrnl (iast visited Sept. 24, 2003) (on 
file with the Connecticut Law Review). While there is ample recognition that intellectual property 
rights are a prerequisite for research and development ("R&D") to make genetic tests, some commenta­
tors assert that intellectual property rights in genotype-phenotype linkages impede access to resulting 
genetic tests for medical use-an argument subStantiated by the Myriad dispute. See Mildred K. Cho et 
al., Effects of Patents and Licenses on the Provision of Clinical Genetic Testing Services, 5 J. MO­
LECULAR DIAGNOSTICS 3, 8 (2003) ("We conclude that patents and licenses have had a significant 
negative effect on the ability of clinical laboratories to continue to perform already developed genetic 
tests .... "); Sherizaan Minwalla, A Modest Proposal to Amend the Patent Code 35 U.S. C.§ 287(c) to 
Allow Health Care Providers to Examine Their Patients' DNA, 26 S. ILL. U. L.J. 471, 473, 503-04 
(2002) (proposing to expand the provision in the Patent Act that protects physicians from infringement 
actions for pei:forming medical procedures to include genetic tests); John A. Robertson, Extending 
Preimplantation Genetic Diagnosis: The Ethical Debate, 18 HUMAN REPRODUCTION 465, 467 (2003) 
(discussing Myriad Corp's patent on the BRCAl and 2 genes). However, this awkward period of only 
a relatively limited number of commercially available genetic tests is giving way to a deluge of genetic 
screening capabilities based upon the extensive compilations of genetic subtleties and the bioinformat­
ics capabilities---such as cost-effective DNA chip technology-to manage them and to derive medici­
nal meaning, albeit based upon probabilities, meaning an innate element of speculation. See discussion 
infra Part V. See generally Michael J. Malinowski, Law, Policy, and Mar�t Implications of Genetic 
Profiling in Drug Development, 2 Hous. J. HEALTH L. & POL'Y 31 (2002) [hereinafter Market Impli­
cations] (discussing the use and implications of genetic profiling in drug development and the delivery 
of health care); Lars Noah, The Coming Pharmdcogenomics Revolution: Tailoring Drugs to Fit Pa­
tients· Genetic Profiles, 43 JURIMETRICS J. 1, 7-11 (2002) (analyzing the effects genetic research may 
have in discovering more refined treatments for disease); Snake Oil, supra, at 28-31 (examining the 
definitional meaning of predictive genetic testing and its emerging significance in the field of medi­
cine). This deluge of genetic information is a predictable byproduct of ongoing pharmaceutical R&D. 
See Mar�t Implications, supra, at 39-43 (discussing the trends in pharmaceutical R&D that have led to 
the entrance of genetic testing in the medical setting as an accompaniment to drug delivery); Sna� Oil, 
supra, at 33 (noting the use of genetic profiling by pharmaceutical and biotechnology industries in all 
aspects of drug development); Noah, supra, at 7 (noting that existing research on the effects of genetic 
differences involving enzymes that metabolize drugs could potentially be put to use in pharmacology). 
The biomedical R&D community now is identifying, compiling, and processing a multitude of genetic 
subtleties through bioinformatics and creating database "commons" to make these subtleties useful. 
See, e.g., Orchid Biosciences, Inc., Overview of Orchid, at http://www.orchid.com (last visited Aug. 26, 
2003) (on tile with the Connecticut Law Review) (claiming to be a "leading provider of services and 
products for profiling genetic uniqueness"). In October 2003, several companies announced the market 
availibility of whole-genome DNA chips. Andrew Pollack, Human Genome Placed on Chip; Biotech 
Rivals Put It Up for Sale, N.Y. TIMES, Oct. 2, 2003, at CJ. See also Mar�t Implications, supra, at 40-
41; Sna� Oil, supra, at 32. In fact, "Craig Venter is already offering the very rich the chance to buy a 
map of their genomes at a staggering $710,000, but even he anticipates selling them for much less-
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genetic engineering capabilities will add new dimensions to the concept of 
"planned pregnancy.'MS 
Through the advancement of ongoing science, preimplantation genetic 
screening ("PGD") will significantly improve existing medical standards 
for prenatal care by enabling many-ideally all-prospective parents to 
complete desired families without the trauma of miscarriages and seriously 
health-impaired children.7 Moreover, the constitutional right of a woman 
$1,000-in years to come." Tim Radford, Fear of 'Genetic A.partMid'-Debate Urged on Conse­
quences of Health Predictions, THE GUARDIAN, Mar. 4, 2003, at P9, LEXIS, News Library, Guardn 
File; see also Jonathan Leake, Gene Map of Your Life Will Cost Pounds 400,000, TIMES (London), 
Sept. 22, 2002, at 5, LEXIS, News Library, Ttimes File. Carry-over of this technology from research to 
personal health care use is imminent, especially through the ongoing identification of millions of very 
slight genetic variations (single nucleotide polymorphisms, also known as "SNPs"), that impact respon­
siveness to pharmaceuticals. See id.; Market Implications, supra, at 52-58; Noah, supra, at 7-1 I. 
Companies such as Orchid Biosciences, Inc. that sell researchers access to SNPs databases may provide 
the access to individuals to enable them to monitor the connections made between SNPs, individuals' 
DNA blueprints, and commercial pharmaceuticals. See Radford, supra; Snake Oil, supra, at 32-33. 
6 See discussion infra Part V; FRANCIS FUKUYAMA, OUR POSTHUMAN FUTURE 72-83 (2002) 
(discussing "designer babies" in the context of modem genetic technology); Mark A. Hall, foreword, 
Symposium, Genetic Technology: Social Values and Personal Autonomy in the 21st Century, 34 WAKE 
FOREST L. REv. 557 (1999) ("The genetics revolution has spawned a tremendous amount of thought in 
recent years on ethical, legal, and social implications . . . .  "). See generally STOCK, supra note 1 
(examining the consequences of emerging reproductive technologies used for selecting and altering 
human embryos); Making Babies (PBS television broadcast. June 1, 1999) (questioning how far hu­
mans will go to "engineer a baby"); 18 Ways to Make a Baby (PBS television broadcast. Oct. 9, 2001) 
("A new revolution in makins babies is underway, one that could allow us to influence and even shape 
the genetic fate of our children."); How to Build a Human: Predictor (BBC television broadcast, 2002) 
(anai)'Zing the arguments for and against genetically engineering humans). 
1 See generally Robertson, supra note 5 (providing a framework for ethical evaluation of uses of 
POD, and concludini that, with the exception of sex selection of first-born children, most ongoing uses 
of PGD are ethically acceptable). Se� Carey Goldberg, Screening of Embryos Helps Avert Miscarriage, 
BOSTON GLOBE, June 13, 2003, at AI, LEXIS, News Library, Bglobe File ("[POD) began more than a 
decade ago as a form of futuristic baby making .... Fertility experts say that preimplantation screening 
is now becoming common at cutting-edge clinics."). As summarized by Professor John Robertson: 
POD has been available since 1990 for testing of aneuploidy [(the gain or toss of 
individual chromosomes)) in low prognosis infertility patients, and for single gene 
and X-tinked diseases in at-risk couples. A report inJu,ly, 2001 on worldWide use of 
POD since 1990 reported that embryo or polar body.biopsy occurred in more than 
3000 clinical cycles, With a 24% pregnancy rate, which is comparable With assisted 
reproductive practices which do not involve biopsy .. . .  More than 1000 children 
have now been born after POD, and many pregnancies arc ongoing .. . 
Robertson, supra note 5, at 465. Today, approximately 1,000 POD screenings presently are done each 
year in the U.S., and that number is rising rapidly. Goldberg, supra. It has been reported that present 
use of POD centers on avoiding miscarriages: "In about three out of four cases, it is used not to choose 
disease-free babies, but to help women who are older or who have had repeated miscarriages to produce 
viable babies." !d. Basic POD generally adds about $3,500 to the cost of an IVF cycle. /d. ntinois 
and New Jersey have expanded mandatory coverage for infertility to include treatments for recurrent 
miscarriage, including POD, and Massachusetts also is considering such legislation. 215 ILL. COMP. 
STAT. ANN. § 5/356m(c) (2000) (definition of "infertility" includes the "inability to sustain a successful 
pregnancy''); N.J. STAT. ANN. § 17:48E-35.22(a) (2003} ("'infertility' is defined to include the inability 
to "carry a pregnancy to live birth"}; see also Goldberg, supra. 
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has been.established law in the United States for three decades.8 Neverthe­
less, contemporary biomedical research has raised a question that bears 
upon this right but, arguably, is increasingly distinguishable:9 Beyond ex­
isting scientific capabilities and personal financial constraints, should there 
be any legal checks placed on the right of prospective parents to choose the 
genetic makeup of their children through assisted reproduction technology 
("ART")? This article answers affirmatively based upon several considera­
tions. First, in the absence of mandatory and comprehensive law and pol-
·. 8 This right was established in Roe v. Wade, 410 U.S. 113 (1973), and has been affirmed through 
that case's progeny. See_ Planned Parenthood of Southeastern Pa. v, Casey, 505 U.S. 833 (1992); Sten­
berg v. Carhart, 530 U.S. 914 (2000). The right has been stated as a freedom from undue state burden, 
not ari entitlement to access the medical procedure. Stenberg, 530 U.S. at 921 (holding that a state 
regulation that places a substantial obstacle in the path of a woman seeking an abortion of a nonviable 
fetus constitutes an undue burden); accord Casey, 505 U.S. at 852 ("Though abortion is conduct, it 
does not follow that the State is entitled to proscnbe it in all instances."). In fact, the Court has ex­
pressly held that there is no affirmative right to abortion. See Harris v. McRae, 448 U.S. 297 (1980) 
("[Roe] does not confer im.entitlement to such funds as necessary to take advantage of that freedom."). 
Legislation enacted to ban the partial birth abortion procedure and the prospect of Supreme Court 
vacancies under the Bush Administration have reinvigorated the abortion debate. See Editorial, 'Par­
tial Birth' Mendacity, Again, N.Y. nMES, June 4, 2003, at A30. ("Their strategy is to curtail access to 
abortion further as the inevitable legal chall�ge wends its way back to the Supreme Court for another 
showdown. They obviously hope that by that ·time, there will have been a personnel change that will 
shift the outcome their way."); Susan Milligan, House Close to Abortion Procedure Ban: Challenge 
Against 1st Federal Curb Vowed, BOSTON GLOBE, June 4, 2003, at A3, LEXIS, News Library, Bglobe 
File ("AdvoCates of the bill said the courts should defer to the legislative findings in the bill, which say 
ihere are no health reasons to perform such a procedure); Robin Toner & Neil A. Lewis, Lobbying 
Starts as Groups Foresee Vacancy on Court, N.Y. TIMES, June 8, 2003, at AI (''The expectation of 
change on the court is based, in part, on its record-breaking stability in recent years; no one has stepped 
down· since President Bill Clinton appointed Stephen G. Breyer in 1994, providing for the longest 
period without a turnover since the 1820's."); Joan Vennochi, Abortion Issue Sharpens for '04, Bos.. 
TON GLOBE, June 24, 2003, at Al5, LEXIS, News Library, Bglobe File (noting that, when President 
Bush signed into law a measure prohibiting doctors from performing the partial birth abortion proce­
dure, polls showed that the majority of Americans support a woman's right to an abortion in the first 
three months of pregnancy). ·In addition, the Supreme Court decided on June 27, 2003 to not interfere 
with a nationwide judicial order barring antiabortion forces from publishing identifying information 
about abortion doctors on ''wanted" posters via the Internet. Lyle Denniston, High Court Rejects Ap­
peal Over Antiabortion Posters, BOSTON GLOBE, June 28, 2003, at A3, LEXIS, News Library, Bglobe 
File. 
9 As observed by this author in 1994, given the potential psychological ramifications and social 
considerations, choosing to terminate an otherwise wanted pregnancy due to a particular genetic char­
acteristic or cltaracteristics may be readily distinguishable from choosing to terminate an unwanted 
pregnancy. Michael J. Malinowski, Coming into Being: Law, Ethics, and the Practice of Prenatal 
Genetic Screening, 45 HASTINGS L.J. 1435, 1485-86 (1994) [hereinafter Coming into Being] (distin­
guishing the choice to terminate' an unwanted pregnancy from the choice to terminate a wanted preg­
nancy based upon genetic information stemming from differences from the pregnant woman's perspec­
tive). Completion of mapping of the human genome, the identification of genotype-phenotype connec­
tions through enabling technologies such as bioinformatics, and the general advancement of biomedical 
research subsequent to 1994 presumably underscores this distinction. See supra note 5 and accompa­
'nying text. See generally discussion infra Part V; Noah, supra note 5; Market Implications, supra note 
5; Snake Oil, supra note 5. 
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Third, unless we choose to block our ears and look away, the United 
States' haunting eugenics13 legacy beckons us to remember the conse­
quences of allowing the appeal of genetic improvement and controlling 
evolution to reach well beyond the limitations of science and to skew the 
practice of medicine and related law and policy.14 These lessons suggest 
that enhanced capability to intervene with and potentially control procrea­
tion at the most fundamental level through science will raise the temptation 
ble of reshaping the legal definition of the family"); Janet L. Dolgin, Choice, Tradition, and the New 
Genetics: The Fragmentation of the Ideology of Family, 32 CONN. L. REv. 523, 540 (2000) (stating 
ART introduces confusion about "the implications of biological 'parentage"); Janet Dolgin, The Ideo­
logical Context of the Disability Rights Critique: Where Modernity and Tradition Meet, 30 FLA. ST. U. 
L. REv. 343 (2003) [hereinafter Ideological Context] (exploring the balance between individual choice 
and the sacrifice of communal responsibility to individual preferences). Consider that, while we grap­
ple with the possibilities of human cloning in the midst of the genetics revolution, the first meaningful 
population of in-vitro fertilization ("IVF') children and children born to arrangements such as surro­
gacy is just now reaching adulthood. In conjunction with ART, the practice of surrogacy is steadily 
increasing. See David P. Hamilton, She's Having Our Baby: Surrogacy·Is on the Rise as In-Vitro 
Improves, WALL ST. J., Feb. 4, 2003,2003 WL-WSJ 3958406. "The latest figures from the Centers for 
Disease Control and Prevention, which [reportedly] tracks roughly 95% of advanced fertility proce­
dures in the U.S., show 1,210 attempted gestational surrogacies in 2000, double the number attempted 
just three years earlier." /d. · 
13 See infra notes 24-27 and accompanying text. See generally EDWIN BLACK, EVGENICS AND 
AMERICA'S CAMPAIGN TO CREATE A MASTER RACE (2003). "Eugenics" originates from the Greek 
word "eugenes," which means "good in birth." DIANE B. PAUL, CONTROLLING HUMAN HEREDITY: 
1865 TO THE PRESENT 3 (1995). Today, medical geneticists tend to delineate genetics and eugenics by 
limiting "eugenics" to expressly encompass social coercion. /d. at 133. However, a definition that 
requires coercion leads to seemingly absurd conclusions�.g., that Francis Galton, a forefather of the 
eugenics movement, see infra Part II.A, was not a eugenicist. See PAUL, supra, at 133; infra note 27 
and accompanying text. In fact, "eugenics" is a broad term with a stained past: 
We have come to identify eugenics with the most terrible parts of its history. When 
we think of eugenics, it is usually not Margaret Sanger or Havelock Ellis who comes 
to mind but Madison Grant or Adolf Hitler. We do not think of free love and birth 
control but of compulsory sterilization or euthanasia. Eugenics evokes the-image not 
of Denmark but of Germany. Indeed, over every contemporary discussion of eugen­
ics falls the shadoW of the Third Reich. No wonder geneticists resist the label. To 
call their enterprise "eugenics" is thereby to condemn it. 
PAUL, supra, at 133-34. 
. 14 The legacy referred encompasses Nazi medicine and genocide, for the United States' move­
ment was an impetus for an international eugenics movement, which then was carried to this extreme 
under the Third Reich. For discussion of eugenics movements in the United States and Europe from 
the late 1800s through the 1930s, see discussion infra Part II; JOHN J. MICHALCZYK, NAZI MEDICINE: 
IN THE SHADOW OF THE REICH (First Run Features 1997) [hereinafter SHADOW OF THE REICH) (dis­
cussing the origins of eugenics movements in Germany and the Nazi doctors' experimentation on 
prisoners in the concentratimi' campsf See generally INTERNATIONAL AUSCHWITZ COMMITTEE, NAZI 
MEDICINE: DOCTORS, VICTIMS AND MEDICINE IN AUSCHWITZ (1986) (documenting the criminal ex­
periments undertaken by the Nazi doctors); ROBERT JAY LIFTON, THE NAZI DocTORS (1986) (examin­
ing the Nazi ''biomedical vision" as evidenced by the doctors' cruel medical experiments in the concen­
tration camps); THE NAZI DoCTORS AND THE NUREMBERG CODE (George J. Annas & Michael A 
Grodin eds., 1992) (discussing the practices of the Nazi doctors that led to the Nuremberg trial and the 
implications of these practices on present day medical research and experimentation). For discussion 
of the genetics revolution cautioning that advances in human genetics threaten to dehumanize, sec 
generally BILL MCKIBBEN, ENOUGH: STAYING HUMAN IN AN ENGINEERED AGE (2003) (analyzing the 
possibility of technology replacing humanity). 
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to put that capability to use prematurely and to overuse whatever means are 
available.15 Temptation never has been greater: The present largely con­
sumer-driven law and policy environment for assisted reproduction16 sim­
ply cannot support jolting, ongoing advances in human genetics through 
the advent of enabling technologies such as bioinformatics capabilities17 
without threatening to bring us dangerously close to past mistakes. We 
must pay attention to the pace of advancement of biomedical science over 
the last two decades, including completion of a map of the human genome 
years ahead of schedule18 and the resulting pressures on both the medical 
community and prospective parents to use this technology prematurely. 19 
The medical profession arid general public alike are living in the mush­
rooming, rapidly burgeoning cloud of innovation categorically referred to 
as the "genetics revolution."20 Given the dynamism of this science, its in-
1 s See generally discussion infra Part 1 . 
16 As explained infra Part Vt.A:, tremendous reliance is placed on the industry and medical pro­
fessional participants to self-report and self-police. 
17 See Market Implications, supra note 5, at 31-32; Snake Oil, supra note 5, at 30-31; Noah, supra 
note 5, at 7-8, 10; Predictive Pharmacogenomics: Revolutionizing Health Care, M2 PRESSWIRE, Dec. 
17, 2002, LEXIS, News Library, M2pw file (identifying a ranse of SNP applications); Pharmacoge­
nomics-Personalized Approach to Medicine-Companies Leading the Personalized Medicine Revolu­
tion, M2 PRESSWIRE, July 18, 2002, LEXIS, News Library, M2pw file (providing a guide to ' 'the de­
velopment of personalized medicines with its related research areas �d technology that span the bio­
technology, diagnostics, bioinformatics, pharmacological and aenomic markets"). See generally dis-
cussion infra Part IV. · 
18 
. 
Completion of a rough map of the human genome was announced on June 26, 2000. See gen-
erally 291 SCIENCE 1145 (Feb. 16, 2001) (highlighting the near completion of the human genome); 409 
NATURE 745 (Feb. 15, 2001) (discussin1 the release of a draft map of the human genome). Updated 
information about the Human Genome Project ("HGP") is available at the Internet site of the National 
Human Genome Research Institute (''NHGRI"), at www.genorne.aov (last visited Aug. 26, 2003) (on 
file with the Connecticut Law Review). 
19 The public is embracing biomedical research as health care, as made evjdent by the public's 
demand for information about and access to experimental clinical trials and assisted reproduction 
technologies, and the U.S. government's efforts to provide access to that information and technologies. 
See Michael J. Malinowski, Institutional Conflicts and Responsibilities in an Age of Academic-Industry 
Alliances, 8 WIDENER L. SYMP.l47, 53-56 & n.l (2001) (discussing the proliferation of information 
via Internet sites like http://www.clinicaltrials.gov and the Health Care Financing Administration's 
September 19, 2000 decision to cover the routine costs of qualifying clinical trials) [hereinafter Institu­
tional Conflicts]. See generally Market Implications, supra note 5, at 42-43 (addressing trends associ­
ated with phannaceutical R&D, including the integration of experimentation and treatment). 
20 See generally THE GENOMIC REVOLUTION: UNVEILING THE UNITY OF LIFE (Michael Yudell & 
Robert DeSalle eds., 2002) (concluding that "[t]he knowledge gained [from the Human Genome Pro­
ject] could cure cancer, prevent heart disease, and feed millions. At the same time, its improper use can 
discriminate, stigmatize, and cheapen life through frivolous enhancement technologies."); Climbing the 
Helical Staircase, THE EcONOMIST, Mar. 29 •. 2003 (discussing the biological revolution, which ''prom­
ises much: more and better drugs, medical treatment tailored to the individual's biological makeup; 
new crops; new industrial processes; even, whisper it gently, new humans"); GENOMICS AND WORLD 
HEALTH: REPORT OF THE ADVISORY COMMmEE ON HEALTH REsEARCH, WORLD HEALTH 0RG. 
(2002) (discussing the positive implications of the genetics revolution on medical research and patient 
care while also considering the potential risks of such research resulting from various ethical considera-
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tense,· explosive, and highly complicated nature even for those trained in 
science and medicine, the emotional nature of human rq>roduction and 
societal pressures which can readily skew judgment for those subjecting 
themselves to related medical procedures, and other human health and re­
lated ethical, legal, and social implications, it is irresponsible to assume the 
luxury of time when contemplating meaningful law and policy assurances 
for the safe, responsible, and thoughtful practice of medicine in assisted 
human reproduction. 21 
Part IT of this article discusses the origin of eugenics, including the rise 
of its popularity as a scientific, social, and political movement at the turn of 
the 20th century through the early 1930s.22 Part TI also explores the codifi­
cation of eugenics policies into law in both the United States and Europe 
before Nazi medicine was put on trial in Nuremberg on December 9, 
1946.23 Part ill addresses the impact of Nazi medicine and the Nuremberg 
trials on the eugenics movement and medical ethics, and Part IV chronicles 
the evolution of informed consent from a principle into law, eventually 
becoming the cornerstone ethos for medical research and the practice of 
medicine. Part V provides' an overview of ongoing genetic profiling trends 
in life science R&p. Part VI reviews trends in assisted reproduction and 
the present state of ART regulation. Part Vll sets forth proposals to intro­
duce more meaningful law and policy assurances for the safe, responsible, 
and thoughtful practice of medicine in assisted. human reproduction with­
out unduly burdening the procreative liberty of prospective parents or im­
peding innovation. 
tions). For a thoughtful, elegant account of the fundamentals of DNA and evolution of the genetics 
revolution, see JAMES D. WATSON, DNA: 'filE SECRET OF LIFE (2003). 
21 See Snake Oil, supra note 5, at 23-26 (discussing that medical community skepticism about 
biotechnology in the early 1990s has given way to a global sector and aggressive application of the 
technology in drug development, with more than 100 biotech drugs on the market by the end of the 
decade, extensive pharmaceutical industry buy-in and reliance upon biotechnology, and a rough map of 
the human genome in hand at the commencement of the new millennium). Bioinfonnatics, the tech­
nology that enabled the human genome to be mapped years ahead of schedule, continues to advance in 
jolts and could radically accelerate the development of genetic medicine. See id.; see also discussion 
infra Part V. But see Steven Pinker, Better Babies? Why Genetic Enhancement is Too Unli�ly to 
Worry About, BOSTON GLOBE, June 1, 2003, at D l ,  LEXIS, NeWs Library, Bglobe File (relying upon 
behavior genetics and observations of human nature as well as unfulfilled expectations "not long ago" 
that by the tum of the .century we would .be living in domed cities and commute by jet packs to argue 
that genetic enhancement is not inevitable nor ''particularly likely in our lifetimes" and premising this 
argument on the assumption that prospective parents will be rational when faced with genetic informa­
tion and the option to take action based on that information); David Adamson, Regulation of Assisted 
Reproductive Technologies in the United States, 78 FERTILITY AND STERILITY 932 (Nov. 2002) (ana­
lyzin� the reasons for the widespread notion that ART is not regulated in the United States). 
2 See discussion infra Part II.A. 
23 See discussion infra Part II. In July 2003, the Harvard Law School Library announced that it 
will digitalize and post original documentation via the Nuremberg Trials Project: A Disital Document 
Collection at http://www.nurcmberg.law.harvard.edu. David Mehegan, Presenting Evidence for Pos­
terity: Harvard's Nuremberg Site Counters Holocaust Deniers, N.Y. TIMES, Aug. 5, 2002, at At. 
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II. THE ORIGfN AND 20TH CENTURY POPULARITY OF EUGENICS 
Within a span of less than fifty years (the 1890s into the 1940s), 
"eugenics" shifted at the most fundamental level from a term inspiring 
praise and connotations of social patriotism to one invoking intolerance for 
human variation, state oppression, and mad science.24 As discussed below, 
in the hands of the Nazi state, eugenics was grossly soiled and stained: The 
term was used to rationalize selective breeding programs, compulsory ster­
ilization, and macabre experimentation on humans including children.25 
Consequentially, contemporary definitions of eugenics are narrower, often 
embodying a crisp distinction between eugenics and medical genetics and 
restricting the scope of "eugenics" to coerpive genetic policies.26 . 
A. Eugenics Before Nuremberg: Improving the Human Condition · 
"Eugenics" was coined in the 1880s by Francis Galton, a Victorian 
aristocrat and nephew of Charles Darwin, to mean "well-born" and to cap­
ture his concept of using knowledge about genetics to better the human 
condition.27 Galton and his contemporaries coupled centuries of success 
utilizing stockbreeding methods to improve animal species With the per­
suasive influence of the scientific rage of the time-Mendelian genetics, 
meaning the embodiment of distinguishable traits attributable to single 
genetic characteristics.28 Their work culminated in variations' of the con-
24 For a definition of"eugenics", see supra note 13 and accompanying text; PAUL, supra note 13, 
at 17. Victorian founders of the early eugenics movements sought to raise the human condition closer 
to perfection. "It is sadly ironic that this noble original objective eventually Jed to some of the most 
heinous crimes mankind has ever seen.' .' NANCY I,.. GALLAGHER, BREEDING BETTER VERMONTERS: 
THE EUGENICS PRoJEcr IN THE GREEN MOUNTAIN STATE 2 (1999) (quoting ERNST MA YR, TOWARD A 
NEW PHILOSOPHY OF BIOLOGY: OBSERVATIONS OF AN EVOLUTIONIST 80 {1988)). 
� 1 . SHADOW OFTHE REICH, supra note 14; see also PAUL, supra note 13, at 3-4, 135 (discussing 
breeding programs and compulsory sterilization). "When the Third Reich translated eugenics into a 
program of racial purification through genocide,-the .Holocaust came to epitomize, for many people, the 
purpose, character, and meaning of eugenic's.'' GALLAGHER, sup�a note 24, at 2. 
26 See PAUL supra note 13, at 3. "To spme, bre�ing'<lecisions based on genetic tests appear to be 
eugenics in modem dress. Others insist that if decisions are voluntary, the label is 'wrongly applied." 
/d. Author Francis Fukuyama has proposed alternative terminology for discussing genetic engineering: 
My own preference is to drop the use of the loaded term eugenics when referring 
to future genetic engineering and substitute the word breeding in German, ZOchtung, 
the word originally used to translate Darwin's term selection. In the future, we will 
likely be able to breed human beings much as we breed animals, only far more scien­
tifically and effectively, by selecting which genes we pass on to our children. -Breed­
ing has no necessary connotations of state sponsorship, but it is appropriately sug­
gestive of genetic engineering's dehumanizing potential. 
FUKUY AMA, supra note 6, at 88 (italics omitted). 
27 GALLAGHER, supra riote 24, at I; see also supra note 13 and accompanying text. 
28 Gregor Mendel, an Austrian monk, bred some 30,000 plants over ten years and published his 
results in 1866 in the Proceedings of the BrOnn Natural Sciences Society, a publication distributed to 
some 134 institutions in various countries. DANIEL J. KEVLES, IN THE NAME OF EUGENICS 41-42 
(1995) (1985). Although his work went unrecognized in the Nineteenth Century, it was rediscovered 
simultaneously in 1900 by three scientists-Carl Correns in Germany, Erich Tschermak in Austria, and 
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cept of controlled human breeding,29 which caught on after the turn of the 
century and inspired organized movements. 30 These movements were 
founded in Germany in 1 904, in Britain in 1907, ;ptd in the United States 
around 1910.31 In fact, eugenics prospered in approximately thirty coun­
tries.32 
The United States' eugenics movement, headed by Charles Davenport, 
was financially seeded in 1904 by a $10 million grant from the Carnegie 
Institute of Washington.33 This grant, which at the time surpassed the total 
endowment for research in United States universities, enabled Davenport to 
establish the Station for Experimental Evolution at Cold Spring Harbor, 
Hugo de Vries in Holland-working independently on problems involving hybridization and, in the 
case of de Vries, theories of evolution. !d. at 43. Soon thereafter, Mendelian genetics triggered 
international popularity within the scientific community. See id.; SHADOW OF THE REICH, supra note 
14; infra notes 41-42 and accompanying text. 
29 See generally KEVLES, supra note 28, at ix-x (discussing scientific and political programs 
based on Galton's eugenics work). As explained by author Daniel Kevles, "Human genetics as a pro­
gram of research originated with the eugenic idea that the physical, mental, and behavioral qualities of 
the human race cou Jd be improved by sui table management and manipulation of its hereditary essence." 
!d. at vii. According to Francis Galton, the forefather of the movement: 
the key to human progress would rest on a national program of better breeding, in 
which the intelligent and the accomplished, the men and women of demonstrated 
high moral character-the educated upper classes-would conceive more children, 
while the shiftless, the chronic poor, the insane and feebleminded, and the "criminal 
class" would be discouraged, preferably prevented, from breeding at all. 
GALLAGHER, supra note 24, at 1. Within and beyond eugenics, many living in the midst of the indus­
trial revolution, including Galton and other leaders in the eugenics movement, equated science with 
progress. KEVLES, supra note 28, at 3. Galton and his contemporaries placed complete faith in the 
science available at the time, which was a matter of observation of husbandry practices and social 
observation rather than any meaningful scientific understanding of human genetics: 
!d. 
Francis Galton, innocent of the future, confidently equated science with progress. 
All around him the technology of the industrial revolution confirmed man's mastery 
over inanimate nature. To be sure, in the mid-Victorian era, heredity in plants and 
animals was less a science than a body of lore based on empirical practice. . . . [l]t 
was well known that by careful selection farmers and flower fanciers could obtain 
permanent breeds of plants and animals strong in particular characters. ''Could not 
the race of men be similarly improved?" Galton wondered. "Could not the undesir· 
abies be got rid of and the desirables multiplied?" Could not man actually take 
charge of his own evolution? 
30 SHADOW OF THE REICH, supra note 14; see also PAUL, supra note 13, at 6. As discussed by 
Robert Proctor: 
Most of the 20-odd university institutes for racial hygiene were established at Ger­
man universities before the Nazi rise to power, and by 1932 racial hygiene had be· 
come an orthodox fixture in the German medical community. The major expansion 
in this occurred before Hitler came to power; most of the 15-odd journals of racial 
hygiene, for example, were established long before the rise of National Socialism. 
Robert N. Proctor, Nazi Doctors, Racial Medicine, and Human Experimentation, in THE NAZI Doc­
TORS AND THE NUREMBERG CODE, supra note 14, at 17, 19-20. 
31 
32 
PAUL, supra note 13, at 6. 
SHADOW OF THE REICH, supra note 14. 
33 KEVLES, supra note 28, at 45. 
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New York.34 In 1910, on land next to Cold Spring Harbor, Davenport also 
established the Eugenics Record Office through generous support from Ms. 
Mary Harriman, a philanthropic socialite.35 The Office's mission was to 
collect, catalogue, and eventually analyze hereditary information from 
thousands of individuals.36 "Able or not, more than two hundred and fifty 
field workers were sent out by the Eugenics Record Office between 1 9 1 1 
and 1924, when the training program ended. "37 
The "authority" gathered by the Office fueled the perceptions of le­
gitimacy and popularity of the eugenics movement, and the movement 
surged forward. Regardless of the limitations of the related science/8 the 
data gathered by the Office substantiated centuries of observation­
however tainted by prejudices. The end product was then coupled with the 
mantra of improving the human condition in a collective manner9 and fur-
34 /d. at 45, 5 1 .  
3S SHADOW OF THE REICH, supra note 1 4. Ms. Harriman gifted the Office to the Carnegie Insti-
tution in 1 9 1 8. KEVLES, supra note 28, at 55. 
36 KEVLES, supra note 28, at 56. 
37 /d. The Office proved an important center for the study of and training in human heredity for 
three decades, and it inspired a West Coast counterpart-the Human Betterment Foundation in Pasa­
dena, California. See GALLAGHER, supra note 24, at 4. 
38 See PAUL, supra note 13, at 1 1 5-16. Early in the century, "[m]ainline doctrine presumed that 
like produced like-that superior or inferior parents spawned, respectively, superior or inferior 
offspring through the transmission of traits by single Mendelian characters-unit characters as they 
were known." KEVLES, supra note 28, at 145. However, voices of scientific reason arose to argue that 
one could not predict an organism's phenotype (physical embodiment) simply from knowledge about 
its genes. These scientists-often geneticists-recognized that a given genotype may be expressed 
differently in varying environments: 
· It was here that the principal disjunction lay between mainline ideas and the advance 
of genetics. While geneticists knew that many physical characteristics were inher­
ited, and a number of them also thought there might indeed be a biological basis for 
mental and behavioral traits, they also knew that, even with the simplest version of 
Mendelism like did not necessarily produce like. 
/d. Eventually many geneticists separated themselves from eugenics and even challenged it scientifi­
cally: 
Many geneticists held that the biological strength' of the human race lay in the vast 
diversity of its genetic makeup. The diversity allowed for variety of types, and such 
variety was essential, not only for the endlessly different tasks that man asked him­
self to perform but also for the variation in environments, both present and possibly 
to come, to which he had to adapt. J. B. S. Haldane held forth on the matter in 1932, 
from the steps of a building at Cornell University, where he was attending the Third 
International Congress of Genetics. A society composed of uniformly perfect men, 
he said, would be highly imperfect. The essence of perfection among plants, ani­
mals, and most certainly man was variety. The ideal society had to have room for all 
sorts of people, each best at some one thing or other. But would it not be desirable 
to produce more Leonardo da Vincis? a reporter wondered. 
/d. at 147. 
39 See GALLAGHER, supra note 24, at 3. As stated by Nancy Gallagher, the author of a case study 
on Vermont's eugenics policies in the 20th century: 
Eugenicists promoted the idea that the human germplasm was the most important 
thing in the world, the source of all human potential in a nation or race. As such, it 
demanded cultivation and conservation. The handicapped, the mentally 
incompetent, and the chronic dependents on poor relief compromised, in the 
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thering what had become the tenets of epidemiology and public health­
individual sacrifice, and at times even government imposition of significant 
personal risk to one's health or the health of one's children, to promote the 
health and well-being of the masses.40 
In this packaging, eugenics appealed to leading scientists, health care 
providers, a range of academics, politicians, and the public, and the move­
ment's supporters persuaded others in missionary fashion.4 1 Eugenics in­
spired the founding of centers and international conferences that drew 
large, cross-disciplinary audiences: 
/d. 
Hundreds of colleges and universities in the United States 
and Europe introduced eugenics into their curricula in the ar­
eas of biology, social work, public health and medicine, and 
"sex hygiene." Eugenics societies enlisted the support of 
churches, patriotic organizations, private charities, and state 
welfare agencies to promote research and education in eugen­
ics.42 
eugenicists' view, the future of the human race by contributing their genes too 
liberally to the national germplasm through indiscriminate breeding and having too 
many "unwanted children." Likewise, the highly educated upper classes and the 
"old pioneer stocks" in particular were blamed for what Theodore Roosevelt called 
"race suicide" in their trend toward smaller families. 
4° Consider that it has become common place to administer several vaccines to all children to pro­
tect the masses, knowing that a significant number will suffer adverse effects and, recently, in the face 
of a llegations that the mercury content in many vaccines may be responsible for an increase in autiSm 
and/or other childhood ailments. See Arthur Allen, The Not-So-Crackpot Autism -Theory, N.Y. nMES, 
Nov. 1 0, 2002, §6 (Magazine) at 66; Mike Wowk, Autism Rate Up 1,500% in State, DETROIT NEWS, 
Mar. 3, 2003, at I D, LEXIS, News Library, Detnws File ("The rates of autism in children have risen 
700 percent nationally and more than 1,500 percent in Michigan since 1 992, according to a recent 
study, and no one in the medical industry or government knows why."); Two Class-Action Suits 
Launched in B.C. Over Vaccines Given to Infants, CANADIAN PRESS, Feb. 25, 2003, 2003 WL 
! 50 1 9641 (reporting on class action suits filed against Aventis Pasteur Ltd. alleging that thimerosal, an 
additive containing mercury used to preserve the vaccines, caused autism and other neurological dam­
age). The common good was Davenport's mantra: "Davenport was prepared to curtail other people's 
rights in order to promote the race-to ensure the common protoplasmic good. He remarked to a 
prospective patron that 'the most progressive revolution in history' could be achieved if somehow 
'human matings could be placed upon the same high plane as that of horse breeding."' KEVLES, supra 
note 28, at 48. 
; 
41 See KEVLES, supra note 28, at 56, 61 (discussing popular support of the eugenics movement). 
Belief in biological determinism became a unifying force that crossed fields of discipline: 
Despite its heterogeneity, the eugenics movement provided a unifying paradigm, 
common themes, and a new language of biological determinism that gained strong 
support during the first three decades of the twentieth century, as new research pro­
grams in human heredity promised to provide a more scientific approach to ensuring 
the national health, preventing crime and poverty, and preserving the national char­
acter. Eugenics provided intellectuals in many fields with an interdisciplinary forum 
to apply their research to the common goal of human bettennent. 
GALLAGHER, supra note 24, at 2-3. 
42GALLAGHER, supra note 24, at 4. See generally JAMES R. MOORE, THE POST-DARWINIAN 
CONTROVERSIES: A Sruov'oF THE PROTESTANT STRUGGLE TO COME TO TERMS WITH DARWIN IN 
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In 1 926, the American Eugenics Society ("AES") published A Eugen­
ics Catechism.43 This publication "assured readers that eugenics was not a 
plan for making supermen or for breeding human beings as if they were 
animals. The catechism did promise that eugenics would ' increase the 
number of geniuses,' foster 'more selective love-making,' and produce 
more love in marriage.',... The AES integrated its philosophy with the reli­
gious sentiment prevalent at the time, which provided assurances and ap­
pealed to the general public.45 the AES also sponsored public displays 
that integrated eugenics with family and patriotic values, such as "fitter 
families contests" at state fairs across America's heartland.46 
Without the check of natural science reality,47 the AES 's philosophy 
proved extraordinarily malleable and reali�� broad appeal .48 Ironically, 
given that the objective was to eliminate geneti� variations deemed unde-
GREAT BRITAIN AND AMERICA, 1 870-1900 253-98 (i 979) (discussing the relationship between a 
theory which taught the survival of the fittest in a brutal struggle for existence and a theology which 
taught God's designing providence in a creation that he saw was "good"). 
43 KEVLES, supra note 28, at 60. 
44 !d. at 61 . 
45 Consider this excerpt from the Eugenics Catechism: 
Q: Does eugenics contradict the Bible? 
A: The Bible has much to say for eugenics. It tells us that men ought not gather 
grapes from thorns and figs from thistles. 
Q: Does eugenics mean less sympathy for the unfortunate? 
A: It means a much bettc:r understanding of them, and a more conccitted attempt to 
alleviate their suffering, by seeing to it that everything possible is done to have fewer 
hereditary defectives. 
Q: What is the most precious thing in the world? 
A: The human germ plasm. 
AMERICAN EUGENICS SOCIETY, INC., A EUGENICS CATECHISM 2, 9 (1 926). 
46 PAUL, supra note 1 3, at 1 1 , 1 3 .  Families competed to be deemed the embodiment of the most 
desirable genetic characteristics. See id. (quoting a contest organizer's description of the contest held at 
the Kansas Free Fair). These contests were prevalent in the 1 920s. /d. 
47 Admittedly, in hindsight and with completion of a map of the human genome in hand, the 
speculative nature of the underlying science was breathtaking: 
ln the last two decades of the nineteenth century and the first three of this century, 
it was widely assumed that human mental, temperamental, and moral traits were de­
termined by heredity. Shiftlessness, religiosity, courage, patriotism, a sense of hu­
mor, love of beauty, taste for philosophy, trustful nature, and a tendency to wander 
were only a few of the traits ascribed to good or bad blood . . . .  
That society ought to foster the breeding of those who possessed favorable traits 
(''positive" or "constructive" eugenics) and discourage or prevent the breeding of 
those who did not (''negative eugenics") seemed obviously to follow. 
PAUL, supra note 13, at 1 ;  see also infra note 134 and accompanying text. 
48 See supra notes 41 -42 and accompanying text. 
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sirable,''9 the AES represented a diverse membership and headed a move­
ment that encompassed everything from patriotism to Marxism: 
In the 1920s, several Russian geneticists called for a "Bol­
shevik eugenics" baseq on Marxist principles. In their view, 
eugenics was a logicai extension of the Marxist commitment 
to the scientific organization of society. 
In the late nineteenth and early twentieth centuries, eu­
genicists were found on every side of arguments about capi­
talism, war, and especially the role of women. . . . Most de­
fended capitalism, wher�as others argue�d that only in a class­
less society woulg it be possible to separate the genetic wheat 
from the chaff. Thus eugenicists were united only in their en­
thusiasm for technocrat solutions to s,ocial ,problems.50 
Within just a few decades; the United States eugenics movement had 
grown strong enough to inspire active government involvement. The 
United States funded research in countries such as Gennany and led the 
world in enacting responsive immigration policy and forced-sterilization 
. laws.51 Indiana passed the first sterilization law in 1907,52 and fifteen addi­
tional states followed between 1907 and 1917-resulting in such legisla­
tion in every region of the co\ltltry except for the South.. Although the 
scope of the laws varied, ultimately, some form of compulsory sterilization 
was codified in twenty-seven American states:53 
49 Actually, Galton, Davenport and their contemporaries attempted to distinguish ''positive genet­
ics" from ''negative genetics," though they supported both. See KEVLES, supra note 28, at 47. The 
former consisted of encouraging the proliferation of "good [human] stock," which they identified as 
intellectuals, artists, musicians, and scientists drawn from the middle class. Jd. Charles Davenport 
"[l]ooked forward to the day 'Yhen a woman would no more accept a man 'without knowing his bi­
ologico-genealogical history' than a stockbreeder would take 'a sire for his colts or calves . . .  without 
pedigree."' /d. ; ' ' 
so PAUL, supra note 1 3 ,  at 20�21. The Victorian founders of the U.S. eugenics movement delib­
erated extensively about procreation: 
While [Davenport] preferred segregation to sterilization as a means of preventing the 
· reproduction of the unfit, he argued that any sterilization of the unfit should be ac­
complished by castratiop instead of vasectomy, Vasectomy, he knew, prevented pa­
ternity but' not lust, ahd ' he believed that physiologically divorcing the sex act from 
responsibility for its procreative consequences might well encourage rapists. Dav­
enport maintained that castration, unlike vasectomy, "cuts off the hormones and 
makes the Pl!tient-docile, tractable and without sex desire." 
KEVLES, supra note 28, at 53. 
51 Jd. at 56; SHADOW OF THE REICH, supra note 14. 
ll . KEVLES, supra note 28, at I 00 ("Dr. Sharp of the State Reformatory had mounted a campaign 
for the measure. ('Indiana is working much on sterilization,' a Johns Hopkins physician remarked in 
1910. 'Practice hurries ahead of inquiry there.')"). 
S3 SHADOW OF THE REICH, supra note 1 4. 
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Virtually all of the prewar statutes gave the states the 
power to compel the sterilization of habitual or confirmed 
criminals, or persons guilty of some particular offense, like 
rape. Also included within the scope of most of the statutes 
were epileptics, the " insane, and idi!JtS in state institutions. 
Most wide-ranging was a law passed in Iowa in 1 9 1 1 .  It 
made eligible for sterilization inmates in public institutions 
who had been incarcerated for a variety of reasons, including 
drug addiction, sexual offenses, and epilepsy. The Iowa stat­
ute compelled the sterilization of twice-convicted sexual of­
fenders, of thrice-convicted other felons, and anyone con­
victed just once of involvement in white slavery. 54 
Implementation of this legislation, however, was approached with 
more caution than its enactment. 'Although there were approXimately 
300,000 to 400,000 people deemed "feebleririnded" in the United States 
who were capable of procreation, fewer than 9,000 of these candidates 
were eugenically sterilized from 1907 to 1928.55 Still, this restraint on im­
plementation in no way reflected misgivings on the part of American eu­
genicists. "Indeed, they were confident, even enthusiastic about the pol­
icy--enthusiastic enough to make one speculate about the psychodynamics 
of their attitudes."56 Rather, implementation was tempered by legal chal­
lenges: 
In marty states, .· sterilization measures ran afoul of the 
courts, of legislative opposition, of executive refusal to en­
force, and of gubernatorial vetoes . 
. . . . 
By the outbreak of the First World War, sterilization laws 
were in such dispute as to have been de facto suspended in 
the operation in a number of states. The courts had also de­
clared unconstitutional not only the stringent Iowa statute but 
less sweeping measures in six other states. Advocates of 
eugenic sterilization, frustrated at the legal impasse, wanted 
to take the issue to the Supreme Court. 57 
The eugenicists' vehicle to break through judicial impediments was 
Buck v. Bell, sa a legal challenge to a Virginia sterilization statute passed in 
S4 KEVLES, supra note 28, at I 00. 
55 !d. at 106-07. 
56 /d. at 1 07. 
s7 !d. at 1 09-10. sa 274 u.s. 200 (1927). 
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March 1924.59 The case proved a victory for eugenicists. In the often 
quoted opinion written by Justice Oliver Wendell Holmes, the Court con­
cluded that "[t]hree generations of imbeciles are enough."60 
The fact that eugenicists in the United States were able to influence 
public education, shape public policy, and even codify eugenics theory 
through enactment of compulsory sterilization laws61 made the United 
States an epicenter for applied eugenics.62 The United States was the envy 
of many eugenicists abroad who pointed to United States law and policy as 
precedent, even paradigms, for their domestic reforms. 63 In addition to 
becoming an exporter of eugenics, the United States also directly supported 
foreign eugenics.64 For example, the Rockefeller Foundation directly 
funded a project on race variations carried out by the Berlin Institute and 
the Kaiser Wilhelm Institute that encompassed the infamous twin studies­
"one of most serious ethical violations in the history of medicine."65 Also, 
U.S. leaders lent their support. Charl�s Davenport became President of the 
International Federation of Eugenicists and an active proponent of the work 
of German eugenicists, as did Harry Laughlin, the Assistant Director of 
Cold Spring Harbor Laboratory.66 In fact, as late as 1938, Laughlin pro-
59 /d. at 205. The Supreme Court has yet to expressly overturn this decision. 
60 /d. at 207. 
61 Before practice, in principle and theory eugenics was closely linked with procreation: "In both 
England and the United States such studies fed anxieties that the population was deteriorating physi­
cally and mentally due to the unrestricted reproduction of genetically inferior persons." GALLAGHER, 
supra note 24, at 3. Giving into the temptation to improve society at such personal costs to individuals 
was tantamount to succumbing to and condoning prejudices. "Marriage restrictions, segregation in 
institutions, and sterilization laws (negative eugenics measures) dramatically affected the lives of the 
people who were investigated eugenically. Less tangible, but more powerful perhaps, was the rhetoric 
of degeneracy that the eugenics studies introduced, which validated long-held prejudices and encour­
aged discrimination." /d. This temptation proved even more persuasive in the 1920s and 1930s: 
"Aided and abetted by the Depression, steiilization drew diverse support in the United States and Brit­
ain which went far beyond eugenicists. . . . Governments in Sweden, Denmark, Finland, and even a 
canton of Switzerland also enacted eugenic sterilization measures." . KEVLES, supra note 28, at 115. 
By 1933, sterilization laws in effect reached perhaps 150 million people. /d. 
62 See KEvLES, supra note 28, at 56, 118 (highlighting the success of American field workers and 
the "Anglo-American eugenics movement"); SHADoW OF THE REICH, supra note 14. In fact, some 
eugenics leaders in the U.S. became international celebrities. For example: 
In 1936, the University of Heidelberg voted an honorary doctorate of medicine to 
Harry Laughlin, still a sterilization enthusiast and in charge of the Eugenics Record 
Office, at Cold Spring Harbor, Long Island. Laughlin, who accepted the degree at 
the German consulate in downtown Manhattan, wrote to the Heidelberg authorities 
that he took the award not only as a personal honor, but also as "evidence of the 
common understanding of German and American scientists of the nature of eugen­
ics." 
KEVLES, supra note 28, at 118. 
63 See KEVLES, supra note 28, at 56, 118 ("German eugenicists, flattering to their American coun­
terparts, said that they owed a great debt to American precedent . . . .  "). 
64 SHADOW OF THE REICH, supra note J4. 
65 /d.; see also infra notes 97-98 and accompanying text. 
66 SHADOW OF THE REICH, supra note 14. 
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moted and distributed a Nazi propaganda film attacking Jews entitled "The 
Genetically Diseased" to church groups and clubs.67 
B. Eugenics Under German Law 
Germany readily imported United States' eugenics.68 ht fact, Ameri­
can programs served as precedent and models for German initiatives to 
apply eugenics at home: 
As early as 1 9 1 3, a member of the Berlin eugenics soci­
ety published a glowing report on the American eugenics 
movement. Geza von Hoffman's Racial Hygiene in the 
United States of North America-· made many Germans (and 
Scandinavians, who closely followed German sources) envi­
ous of their American counterparts, who apparently enjoyed 
much greater popular and legis1ative support as well as suc­
cess in attracting financial patrons. 
In the aftermath of the First World War, close links were 
forged between German and American eugenicists . . . .  
These relationships were not disturbed by the Nazi sei­
zure of power . . . . 
The Nazis regularly quoted · American geneticists who 
expressed support for their sterilization policies. They also 
frequently invoked the large-scale California experience with 
sterilization. 69 
Within just a few years, German caution about eugenics gave way to 
state-mandated sterilization. 70 During this time, sweeping scientific con­
clusions were drawn based upon observations, general theories, and some 
splinters of solid science.71 . When introduced in 1925, Hitler's proclama­
tion in Mein Kampf that the state "must declare unfit for propagation all 
67 /d. 
68 /d. "[l)t was the United States that provided the most important model for German Steriliza­
tion laws. By the late 1 920s, some 1 5,000 individuals had been sterilized in the United States-most 
while incarcerated in prisons or homes for the mentally ill." Proctor, supra note 30, at 2 1 .  
69 PAUL, supra note 1 3 ,  at 84-86 (citations omitted) . 
. 70 See DANIEL JONAH GOLDHAGEN, HITLER'S WILLING EXECUTIONERS 456 (Vintage Books 
1 997) ( 1 996) (explaining that the German people "willingly acquiesced" to the Nazi German revolu­
tion). 
71 See id. In essence, science was used to justify a social agenda: "The revolution was primarily 
the transformation of consciousness-the inculcation in the Germans of a new ethos. By and large, it 
was a peaceful revolution willingly acquiesced to by the German people. Domestically, the Nazi Ger­
man revolution was, on the whole, consensual." /d. 
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who are in any way visibly sick or who have inherited a disease and can 
therefore pass it on, and put this into actual practice . . . . Those who are 
physically and mentally unhealthy and unworthy must not perpetuate their 
suffering in the body of their children"72 had been received with skepticism 
even from ardent eugeniCists.73 However, "most of the 20-odd university 
institutes for racial hygiene were established at German universities before 
the Nazi rise to power, and by 1932 racial hygiene had become an orthodox 
fixture in the German medical community."74 By the time Hitler came to 
power, there was support to codify coerced sterilization into German law: 
Before 1933, most German eugenicists had actually been 
dubious about proposals for compulsory sterilization, regard­
ing them as politically unreaiistic and scientifically prema­
ture. However, a draft law permitting sterilization with the 
consent of the person concerned or that person's guardian had 
been prepared in 1932, during the last days of the Weimar 
Republic. Before it could be approved, the government was 
in the hands of Adolf Hitler . . . .  
The Law for the Prevention of Genetically Diseased 
Progeny, issued two months after the Nazis came to power, 
allowed for compulsory sterilization, extended the range of 
"hereditarily determined" conditions, and required doctors to 
register cases of genetic disease (except in women past re­
productive age). Sterilization was mandated, whether or not 
the person was institutionalized, in cases of congenital fee­
blemindedness, schizophrenia, manic-depression, severe 
physical deformity, hereditary epilepsy, Huntington's chorea, 
hereditary blindness and deafness, and severe alcoholism. 75 
Implementation of forced sterilization was achieved through a collabo­
rative effort by the science and medical communities, the judiciary, and the 
72 ADOLF HITLER, MEIN KAMPF 404 (Ralph Manheim trans., Houghton Miffiin 1 971)  (1 925). 
73 PAUL, supra note 1 3, at 86 ("Before 1 933, most German eugenicists had actually been dubious 
about proposals for compulsory sterilization, regarding them as politically unrealistic and scientifically 
premature.") (citations omitted). 
74 Proctor, supra note 30, at 1 9-20. "[M)ost of the 1 5-odd journals of racial hygiene, for example, 
were established long before the rise of Nationai Socialism." ld. 
that: 
75 PAUL, supra note 13, at 86 (citations omitted) (emphasis added). Nancy L. Gallagher notes 
German eugenics was not a Nazi invention; the rationale, procedures, and medical 
and psychiatric research institutions for such a program had developed concurrently 
with the American and British research. The Nazi legislation, however, removed le­
gal impediments to sterilization that had existed in the Weimar Republic and framed 
its purpose in terms of an urgent fight for survival of the German nation and the 
"Aryan race." 
GALLAGHER, supra note 24, at 1 39. 
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Nazi regime: 76 
[F]ar from being passive pawns or a small minority in the 
Nazi effort, physicians were instrumental in formulating, and 
took the lead in carrying out, the Nazi racial hygiene pro­
gram. The Nazi theory, based on a social Darwinist view of 
genetics and racial purity, meshed perfectly with the Nazi 
ideology:n 
Physicians referred cases to "genetic health courts" established to evaluate 
cases.78 The role of physicians was expanded in 1 935 to encompass cases 
beyond preventive sterilization: German law was amended to allow women 
deemed "hereditarily ill" to undergo abortion within the first six months of 
pregnancy�79 
· · 
·within three years, German authorities had sterilized some 
two hundred and twenty-five thousand people, almost ten 
times the number so treated in the previou:5 thirty years in 
America. About half were reported to be "feebleminded." 
76 "[M]edical scientists were the ones who invented racial hygiene in the first place . . . .  Scien­
tists, in other w_ords, were not simply pawns in the hands of Nazi officials. But without a strong state to 
back them, racial hygiene was relatively impotent. It was not until 1933 that the programs of the pre­
Nazi era gained the support of officials willing to move aggressively in this area." Proctor, supra note 
30, at 19-20; see also SHADOW OF THE REICH, supra note 14. 
77 THE NAZI DocTORS AND THE NU�MBERG CODE, supra note 14, at 15 .  Robert Proctor points 
out that: 
The Nazis, in tum, were able to exploit both the intimacy and the authority of the 
traditional physician-patient relationship. Crudely stated, they could do things with 
doctors that would have been much harder without them . . . .  Medicine also served 
as a disguise. In Buchenwald 7,000 Russian prisoners of war were executed in the 
course of supposed ''medical exams," using a device disguised as an instrument to 
measure height. 
Proctor, supra note 30, at 27. 
71 PAUL, supra note 1 3, at 87. As of 1 934, Germany had established 1 8 1  Genetic Health Courts 
and Af�llate Genetic Health Courts to adjudicate the Sterilization Law. Proctor, supra note 30, at 21.  
PAUL, supra note 13, at 87. It is  important to note that many state laws in the United States that 
prohibit abortion at viability of the fetus also make exceptions where the health of the fetus is in ques­
tion based upon medical diagnosis and the health of the mother. See, e.g. , KAN. STAT. ANN § 65-
6709(aX4) (2002) (stating that a viable fetus may be aborted if necessary to preserve the life of the 
pregnant woman "or . . .  the fetus is affected by a severe or life-threatening deformity or abnormality"); 
MD. CODE ANN. HEALTH-GEN. § 20-209(bXii) (2003) (explaining that the state may not interfere with 
a woman's decision to terminate any time during her pregnancy if "[t]he fetus is affected by genetic 
defect or serious deformity or abnormality'') (2002); TEX. HEALTH & SAFETY CODE ANN. § 1 70.002 
(Vernon 2001} (stating that an abortion may be performed at any time provided that ''the fetus has a 
severe and irreversible abnormality, identified by reliable diagnostic procedures" ); VA. CODE ANN. § 
32.1 -92.2 (Michie 2001) (funding abortions if a physician "believes the fetus will be born with a gross 
and totally incapacitating physical deformity or with a gross and totally incapacitating mental defi­
ciency"). But see President George W. Bush, Statement on Banning Partial-Birth Abortion (June 2003) 
(expressing support for legislation banning partial-birth abortions), available at 
http://www. hitchouse.gov/news/releases/2003/06/20030604-4.htrnl. (last visited Sept. 23. 2003) (on 
file with the Connecticut Law Review). 
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For a time, the Nazi sterilization program ran independ-
ently of the regime's anti-Semitic policies.80 
Ultimately, the Germans sterilized 350,000-400,000 persons, with some 
racial hygienists dissatisfied and arguing that 10-15 percent of the entire 
population should be sterilized.8 1 
Familiarity with forced-sterilization made euthanas�a acceptable to 
many-even palatable as a logical policy progression. ''The German ster­
ilization program was followed in 1 939 by a euthanasia program designed 
to rid the nation of its mental patients, now characterized as ' useless eat­
ers. "'82 Specifically, Hitler issued orders to commission doctors to grant 
Gnadentod (mercy death) · to patients judged "incurably sick by medical 
examination" and, by August 1 941 ,  more than 70,000 patients from Ger­
man mental hospitals had been killed.83 This program inspired the devel­
opment of the infamous Nazi gas chamber technology. 84 In fact, German 
implementation of cOerced sterilization and then euthanasia of the "geneti­
cally infirm" based upon health conditions paralleled and then blended into 
the broader eugenics agenda of the German government-''racial purifica­
tion" via genocide.85 The two agendas-eugenics and genocide of the Jew­
ish race-were implemented in unison. On April 1 ,  1 933, in conjunction 
with codifying forced sterilization, the Nazi regime decreed an anti-Jewish 
80 KEVLES, supra note 28, at 1 1 7  (citation omitted). 
8 1 Proctor, supra note 30, at 2 1 .  
82 . ,  PAUL, supra note. l3, at 90. 
83 
. 
Proctor, supra note 30, at 23. 
84 PAUL, supra note 13, at 90; Proctor, supra note 30, at 25 ("The ultimate decision to gas the 
Jews emerged from the Jact that the technical apparatus already existed for the destruction of the men-
tally ill."). . 
. 
85 The term "genocide" was ''coined by the Polish refugee Raphael Lemlcin toward the end of 
World War II and enshrined for the United Nations Genocide Convention . . . .  " Christopher Shea, 
Critical Faculties, BOSTON GLOBE, June 15, 2003, at H5, LEXIS, News Library, Bglobe File. For an 
insightful case study analysis of early 20th-century genocide beyond the geography of Europe, see UWE 
TIMM, MORENGA (Breon Mitchell trans., New Directions 2003) (1 978) (addressing the 20th-century 
German presence in South West Africa as an ipustration of brutal European colonialism and genocide). 
A review of the novel explain!> that: . . . ; . 
Doctors in [the South West African colony] formulated theories of racial superiority 
that anticipated Nazism and the Holocaust. German administrators took the lesson 
of "concentration camps" (the Britis� general Kitchener's policy for containing Boer 
noncombatants) and applied if with more terrible vigor to the Herero. Out of some 
80,000 people, only about 1 5,000 survived. 
Giles Foden, Rehearsal for Genocide, N.Y. nMES, Apr. 20, 2003 (book review), at 15.  Moreover, 
dozens of cases of genocide have been identified since 1 945, ranging from the Sudan in the 1 960s to 
Kosovo in 1 999. Shea, supra at H5; cf. Nicholas D. Kristof, What Did You Do During the African 
Holocaust?, N.Y. TIMES, May 27, 2003, at A25 (commenting on Eritrea and Afiica's tailspin). 
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boycott of  Jewish-owned businesses and passed the Enabling Act.86 
Through the Act, the government established restrictive quotas for Jews 
serving in government positions, professions, and universities and effec­
tively terminated the employment of all state employees and other civil 
servants half or more Jewish. 87 In 1935, Germany enacted the first Nurem­
berg law; this law defined who was a Jew; stripped Jews of their citizen­
ship, and forbade them from marrying "citi�s of German or related 
blood."88 A flurry of similarly-intentioned laws followed: "Oth�r laws and 
extralegal actions directed against Jews, Gypsies, the offspring of German 
mothers and black French soldiers, homosexuals, and other social and po­
litical 'deviants' ,followed, culminating in the program of mass extermina-
tion known as the Holocaust. "89 
· 
The Third Reich persecuted political dissidents, Communists, Jeho­
vah's Witnesses, and Catholics, but used biology to draw a macabre line 
between persecution and execution.90 . The Thircl Reich distinguished and 
undertook "race hygiene" measures against those. deemed biologically infe­
rior by Aryan race theorists. This latter group included Jews, Gypsies, and 
persons declared genetically diseased-people with . visible disabilities and 
people tagged "asocials", meaning homosexuals, se� offenders, and crimi­
nals.91 By the time Hitler assumed power, the mantra of the German revo-
86 GALLAGHER; supra note 24, at 138. The Enabling Act 'is addressed in WHITNEY R. HARRIS, 
TYRANNY ON TRJAL: THE EVIDENCE AT NUREMBERG 47-48 {1954). . .. 87 KEVLES, supra note 28, at 1 1 7-18 (citation omitted); GALLAOHE,R. supra note 24, at 138. 
88 PAUL, supra note 13, at 90 (citations omitted); Proctor, supra note �0, at'23. "These measures 
began the formal, government-sanctioned process of exclusion, publi� �umiliatiQn, and peTsecution of 
German Jews-policies against groups deemed alien by the · German · state, ·which trlggere4 the first 
wave of Jewish refugees seeking asylum." GALLAGHER, supra note 24, at 138. As observed by histo-
rian Robert ProCtor: · · · · · · · · '' · 
Sadly, there is yet another area where Nazi physicians were able to draw support 
from their American colleagues. In 1 939, Germany's leading racial hygiene journal 
reported the refusal of the American Medical Association to adtllit black physicians 
to it$ membership; 5,000 black physicians nad petitioned . ,to . joiq the . all-white 
Americ� body were turned down. ' .· German physi�,;i�ns . only one. Year f?efore, in 't938, had barred Je)VS frorq practicing medicine (ei(Cept oti other Jews); Nazi racial 
theorjsl$ were thereby able to argUe that Germany was "not alone" in ·its effort$ to 
preserve racial purity. ' · ·· 
· Proctor, s�pra note 30, at 23. Today,' some Holocaust survivors and their heirs are bringing legal 
actions against those who benefited financiaUy from and participated m these actions, For example, an 
action has been brought against the Frerich National Railroad for delivering more than 75,000 Jews and 
others to Nazi death camps in W()rld War II . . French Rqil'road }{�locaust Suit Relnstated, N.Y. TIMES, 
June 19, 2003, at ,A4 (reporting on the reinstatement of this. three� year law suit. by the federal Second 
Circuit Court of Appeals). · ·
. 
· 
· . · 
89 PAUL, supra note 13, at 90-91 .  
90 GALLAGHER, supra note 24, at 138. 
91/d. As observed by author Daniel Goldhagen: 
'the notion, for example, that an individual's defining 'C:haracteristics were derived 
from his race and that the world was divided into distinct races-whose respective 
capacities and moral worth were biologically determined and widely variable-was, 
if not quite an axiom of German society during the Nazi .period, then an extremely 
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lution was no less than to: 
reconstitute and reshape the European social landscape ac­
cording to its racial biological principles, by killing millions 
of people deemed, according to its racial fantasies, dangerous 
or expendable, and thereby ·to increase the proportion · of the 
"superior races" and strengthen the overall biological stock of 
humanity and, complementing this, to reduce the danger to 
the "superior races" by the more numerous "inferior" 
ones. . . . Eastern Europe would become a German colony 
populated by German settlers and Slavic slaves.92 
147 
Germany would build itself into a biological super-state through ge­
netic perfectionism and gqvem a Brave New .:World.93 However, as this 
extreme position actually was implemented, seams appeared in the broader 
eugenics science community and those gave way to �ivisions: 
The shift in the meaning of eugenics was brought into 
sharper relief with the publication of scientific commentaries 
on eugenic sterilization and racial biology in the 
mid-1 930s . . . .  
Political developments in Europe also forced eugenicists 
to take a position on the issue of race. In 1 935, several influ­
ential and widely publicized scientific critiques of eugenics 
race research were published in response to Nazi implemen­
tation of their race hygiene policies. Repeated citation to 
these works as evidence of the scientific defeat of eugenics 
has fostered a myth that lmowledgeable biologists in the 
1 930s had abandoned any serious consideration of reproduc­
tive selection for the purpose of population improvement.94 
. • 
' c 
Scientific critiques certainly did not temper German policy. Rather, 
the Gennari science and medical communities engaged in unchecked hu­
man experimentation to perfect their sterilization procedures and to build a 
widespread belief. That the world ought to be organized and reorganized according 
to this conception of an immutable hierarch of races was an accepted norm. 
GOLDHAGEN, supra note 70, at 460. 
92 GoLDHAGEN, :rupra note 7 1 ,  at 458. 
93 Cf Charles J. Rolo, lntroduction to ALDOUS HUXLEY, BRAVE NEW WORLD & BRAVE NEW 
WORLD REVISITED, at vii, xiii (Harper & Row 1 960) (1 932) (describing Huxley's novels as books 
depicting a world in which "mass production has been applied even to biology."). See generally 
SHADOW OF THE REICH, supra note 14. 
94 GALLAGHER, supra note 24, at 142-43. See generally discussion infra Part Ili.B. 
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stronger scientific base for their positions.95 Experimentation to improve 
sterilization procedures gave way to so-called w� studies to measure hu­
man endurance, including germ warfare studies, ·and crude attempts at ge- · 
netic manipulation.96. Some of the more notorious of these involved 1,500 
pairs of twins culled . from the masses on their way to concentration 
camps.97 The common pattern was for one twin to be injected with a germ, 
get sick, and die, and then to inunediately execute the healthy twin to per­
form an �utopsy to compare their organs.98 The range of studies included 
some to measure human endurance in water conditions inflicting hypo­
thermia and manipulation of l;ltmospheric pressure, death being the target 
endpoint, and gruesome genetics experiments. The genetic experiments 
included attempts to change eye color through the injection of chemicals, 
generally resulting in blindness,99 to change sex.100 In the words of eye 
95 The Nazis supported but also gn)ssly skewed the course of research. They commingled excel­
lent, innovative science with result-oriented experimentation. As_ c,xplained by historian Robert Proc­
tor: 
'fh�' Nazis suppressed some areas and encouraged others. They supported extensive 
research on ecology, public health, cancer, behavioral aenetics, and (of course) race and so­
ciobiology. The Nazi government funded research on the effects of exposure to X-rays and 
heavy metals; some of the first reliable studies on the health effects of asbestos were done in 
this period. The Nazis were among the first to initiate bans on smoking in public buildings; 
Nazi leaders organized unprecedented support for midwifery, homeopathy, and a number of 
other areas of heterodox medicine. Nazi physicians recognized the importance of a diet high 
in fruit and fiber, and in the early war years manaaed to have. en"cted a. law requiring every 
Gennan bakery to produce whole-grain �read. Nui physidans restricted the use of DDT 
and denied women tobacco rationing coupons on the grounds that nicotine could harm the 
fetus. Racial hygiene itself was supposed to provide "long-run," preventive care for the 
German germ plasm, complementing shorter-term social and individual hygiene. 
Proctor, supra note 30, at 28. 
96 . ·  • . . 
. . .  ·• '. . .· .' "'· . 
See Eva Mozes-Kor, The Menge/e Twins and Human Experimentation: A Personal Account, in 
llfE NAZI DocTORS AND THE NUREMBERG CODE, supra note 14, at 55 ("One set of [Mengele's) ex-
periments dealt with genetics and the other with aenn warfare."). . 
97 See generally SHADOW OF THE REICH, siqJra note 14 ("(T]he most notopous experiments were 
the twin studies."). 
98 . ' See Mozes-Kor, supra note 96, at 53, 55 ("To look back on my childhood is to remember my 
experience as a hunwt guinea pig . . . .  [W]e were there . . .  to be used as experimental objects and then 
to b e  killed."); SHADOW OF THE REICH, supra note 14 (giving Eva Mozes-Kor's personal account of the 
twin experimentations). . . 
·· · ' . · · 
99 SHADOW OF THE REICH, supra note 14 (describing experiments that were conducted to convert 
brown :zes to blue eyes). 
1 Telford Taylor, Opening Statement of the Prosecution December 9, 1946, in llfE NAZI Doc­
TORS AND THE NUREMBERG CODE, supra note 14, at 71 -84 (discussing the following: high-altitude 
experiments; freezing experiments; malaria experiments; mustafd gas experiments; Ravensbrueck 
experiments concerning sulfanilamide and other drugs; bone, muscle, and nerve regeneration and bone 
transplantation; sea-water experiments; epidemic jaundice; sterilization experiments; typhus and related 
experiments; poison experiments; and incendiary bomb experiments); Proctor, supra note 30, at 25-26 
(documenting experiments including: forcing people to drink seawater to assess longevity without fresh 
water; immersing prisoners of war in ice water to test gear and treatment techniques; vacuum chamber 
experiments to assess the impact of high-illtitude bailouts; infecting prisoners with pathogens to test 
homeopathic preparations and to cope with exotic diseases; exposure to · phosgene gas to test possible 
antidotes; sterilization and castration experiments;_ limb and bone transplants in the absence of medical 
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witness and survivor Eva Mozes-Kor: 
One of the twins, who was 19 years old, told of experi­
ments involving a set of teenage boys and a set of teenage 
girls. Cross-transfusions were carried out in an attempt to 
"make boys into girls and girls into boys." Some of the boys 
were castrated. Transfusion reactions were similarly studied 
in the adolescent twins. 
A set of Gypsy twins was brought back from Mengele's 
lab after they were sewn back to back. Mengele had at­
tempted to create a Siamese twin by connecting blood vessels 
and organs. The twins screamed day and night until gangrene 
set in, and after 3 days they died. Mengele also attempted to 
connect the urinary tract of a 7 -year-old girl to her own co­
lon. Many experiments were performed on the male and fe­
male genitals. 10 1 
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Ill. THE IMPACT OF NAZI MEDICINE ON EUGENICS, RESEARCH, AND 
MEDICAL ETHICS PRIOR TO NUREMBERG 
Close to fifty percent of German physicians were members of the Nazi 
Party, and thousands of doctors, nurses and other health care providers 
were directly involved in the genocide and human experimentation prac­
tices put on trial at Nuremberg. 102 Many more witnessed these actions and 
the resulting suffering and did nothing. Confrontation of Nazi medicine 
through the Nuremberg doctor trials (the "Doctors' trial") had a fundamen­
tal impact on the eugenics movement, research on human subjects, and, 
ultimately, general medical ethics. 103 Most notably, informed ,consent 
need; and, attempts to permanently change eye color); SHADOW OF THE REICH, supra note 14 (describ­
ing various types of human experimentation). 101 Mozes-Kor, supra note 96, at 57. 102 Proctor, supra note 30, at 1 9  ("By 1 942, more than 38,000 doctors had joined the Nazi Party, 
representing about half of all doctors in the country."); SHADOW OF THE REICH, supra note 14 (thou­
sands of healthcare providers helped conduct experiments on humans); see also infra notes 1 08-09 and 
accompanying text. See generally LIFTON, supra note 14, at 5 ("Part I examines the sequence from 
forcible sterilization to direct medical killing . . .  made possible by the Nazification of the German 
medical profession . . . .  "). 
· 
. , 103 See Proctor, supra note 30, at 29 ("Today one hopes that . . .  professional honor will always 
be understood to include a requirement that professionals act in an ethical and socially responsible 
manner. Elaborating on this ethic has become the painful taSk of physicians ever since 
Nuremberg . . . .  "); lJFTON, supra note 1 4, at xii ("[N]azi doctors are distinguishable from . . .  other 
['doctors in evil'], not so much in their human experimentation but in their central role in genocidal 
projects-projects based on . . .  genocide as a means of national and racial healing. . . . For this, Nazi 
doctors require a study of their own . . . .  "). Lifton also concludes that "[d]octors in general, it would 
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evolved from a principle into law, eventually becoming the cornerstone 
ethos for contemporary medical research and the practice of medicine. 104 
A. The Role and Prosecution of German Physicians 
In the early 20th century through post-WWI, the Weimar Republic's 
medical profession was revered by the world and often cited as the absolute 
pinnacle of medicine.105 Germans routinely captured global attention for 
their pioneer contributions in science and technology, and the German 
medical profession was renowned for its scientific sophistication and ea­
gerness to incorporate the latest advances into practice. Some American 
medical scholars who went to Germany for training were later accepted for 
admission at schools such as Harvard and John Hopkins. 106 
Serious consideration must be given to the fact that German doctors, 
though medical professionals, also were citizens of a proud nation rich in 
culture that had been humbled in WWI and thereafter, as a means of recov­
ery, prioritized the status of the nation state over all else. 107 They were a 
politically conservative and active group. 108 As explained by historian 
Robert Proctor: 
seem, can all too readily take part in the efforts of fanatical, demagogic, or surreptitious groups to 
control matters of thought and feeling, and of living and dying." !d. Lifton cites the following exam­
ples in support of this conclusion: 
One . need only look at the role of Soviet psychiatrists in diagnosing dissenters as 
mentally ill and incarcerating them in mental hospitals; of doctors in Chile (as 
documented by Amnesty International) serving as torturers; of Japanese doctors per­
fanning medical experiments and vivisection on prisoners during the Second World 
War; of white South African doctors falsifying medical reports of blacks tortured or 
killed in prison; of American physicians and psychologists employed by the Central 
Intelligence Agency in the recent past for unethical medical and psychological ex­
periments involving drugs and mind manipulation; and of the "idealistic" young 
physician-member of the People's Temple cult in Guyana preparing the poison (a 
· mixture of cyanide and Kooi-Aid) for the combined murder-suicide in 1978 of al­
most a thousand people. 
!d. See generally SHADOW OF THE REICH, supra note 1 4  (explaining that the Nuremberg trials funda­
mentally impacted medical ethics). 
104 See discussion infra Part III.B (exploring the development of eugenics after WWII). See 
KENNETH GETZ & DEBORAH BORFITZ, INFORMED CONSENT: THE CONSUMER'S GUIDE TO THE RISKS 
AND BENEFITS OF VOLUNTEERING FOR CLINICAL TRIALS 17  (2002) (providing a pragmatic treatment of 
informed consent written for
. 
the general public). 
105 SHADClW OF THE REICH, supra note 1 4  (explaining that the medical profession of the Weimar 
Republic was "of an f?Xtremely high quality"). 106 !d. 
107 See LIFTON, supra note 1 4, at 30-44 ("[nhe physician could carry out what Gerhard Wagner 
identified as the task of his Public Health Office: 'the promotion and perfection of the health of the 
German people . . .  to ensure that the people realize the full potential of their racial and genetic endow­
ment.'"); SHADOW OF THE REICH, supra note 14 (explaining that many German doctors, like other 
German citizens, prioritized the status of their nation state over all else). 108 See generally LIFTON, supra note 1 4, at I I  0 (discussing how one member of the medical fac­
ulty of the University of Berlin "favored abandoning the old 'liberal-materialistic spirit' . . .  and acquir­
ing instead 'the idealistic Weltanschauung of National Socialism"'). 
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Before 1933, the leadership of the profession was dominated 
by the Deutschnationa/en-a German nationalist party that 
subsequently threw its support to Hitler . . . .  The profession 
was politicized and polarized after the economic collapse in 
the late 1 920s and early 1930s . . . .  By the end of 1 932, the 
National Socialist Physicians' League was twice as large as 
the Association of Socialist Physicians (3 ,000 vs. 1 ,500 
members). In the Reichstag elections leading to the Nazi sei­
zure of power, nine physicians were elected to represent the 
Nazi Party; only one physician was elected to represent the 
socialists. 109 
1 5 1  
Germany's stumble as a nation in WWI fit well within the lifetimes of 
a generation of active, senior medical professionals post-WWI who until 
that point had relished in both the esteem of their international peers and 
the position of global leadership their nation enjoyed. 1 10 In fact, for these 
individuals, the two were largely intertwined: Membership in the German 
medical and science professions innately encompassed striving to become 
recipients of the prestige and government support enjoyed by the nation's 
top research-scientists who, again, generally were recognized by competing 
nations as among the best in the world. I l l  Post World War I, as citizens 
and participants in German politics and culture, doctors and scientists read­
ily embraced the spirit of reborn nationalism that invigorated the life of 
their deflated nation. 
The Third Reich was able to ready members of the German medical 
profession by effectively combining the roles of patriotic citizen and medi­
cal professional. 1 12 Foreign eugenics movements and the support they em­
bodied enabled the Third Reich to package their political, social and eco­
nomic agenda in recognized science and to present the medical and scien­
tific communities with a national mission encompassing notions of health, 
welfare, service, and acceptance of individual sacrifice as a necessary 
means to realize the former. 1 13 Medicine, science and nationalism were 
integrated in social Darwinism-the promise of achieving a vibrant Ger­
man society through a rising population of full-blooded Aryans, the cui-
109 Proctor, supra note 30, at 26-27. 
1 10 Jd. at 1 7-29; see supra notes 105-06 and accompanying text. 
1 1 1 SHADOW OF THE REICH, supra note 14 (explaining that many German doctors wanted gov­
ernment support to help their professional reputation). 
1 12 See Proctor, supra note 30, at 27 ("(l]t is possible to argue that there was a certain ideological 
affinity between medicine and Nazism at this time. Many physicians were attracted by the importance 
given to race in the Nazi view of the world . . . .  "). 
1 13 See id. at 2 1 -22 ("German racial hygienists throughout the Weimar period expressed their 
envy of American achievements in this area [of sterilization], warning that unless Germans made pro­
gress in this field, America would become the world's racial leader."); SHADOW OF THE REICH, supra 
note 14. 
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ture-based "fitter family"1 14 ideal shared by the majority of the German 
population. The principles were familiar and fundamental: achieve sound 
health and other desirable qualities in the German population through prac­
tices developed, tried, and proven . true through centuries of animal and 
plant husbandry. The objective of sound health and a reinvigorated Ger­
many resonated well; and, · after all, social Darwinism simply was a Ger­
man national application of prevalent theories in eugenics-theories that 
already had shaped policy and law and had been implemented in nations 
such as the United States. 1 15 • The link between medicine and anti-Semitism 
then became a matter of extending this philosophy: "The most important 
theoretical link was what might be called the 'medicalization of anti­
Semitism,' part of a broader effort to reduce a host of social problems­
unemployment, homosexuality, crime, 'antisocial behavior,' and others­
to medical or, ideally, surgical problems."1 16 
So the Third Reich called upon those responsible for Germany's re­
nowned international strengths in technology, science, and medicine to 
enable their nation to "treat" societal ills deemed causative of overwhelm­
- ing social, political and economic burdens. 1 17 Those called upon re­
sponded: 1 18 
Contrary to postwar apologies, doctors were never forced 
to perform [medical] experiments. Physicians volunteered­
and in several cases, Nazi officials actually had to restrain 
overzealous physicians from pursuing even more ambitious 
experiments. . . . Doctors acting in this situation were not 
without values. Their values were clear (Nordic supremacy, 
total war demands extreme measures, Jews are vermin, etc.), 
and they acted in accordance with those values. 1 19 
1 14 See supra note 48 and accompanying text. See generally SHADOW OF THE REICH, supra note 
1 4  (explaining that medicine was used to eliminate "inferior" traits). 1 15 As stated by author Nancy Gattagher: 
After World War II the Nazi radicalization of eugenics into genocide would dem­
onstrate the potential for evil in eugenics ideology and would make prophets of its 
early critics, but the implications of the German sterilization program were not so 
obvious in 1 934. Some found the German program enviable; campaigns for sterili­
zation laws were launched in the United States and many nations abroad, including 
the Scandinavian countries, the Baltic states, Japan, and the Netherlands. 
· GALLAGHER, supra note 24, at 1 39-40. 1 16 Proctor, supra note 30, at 25. 
1 17 SHADOW OF THE REICH, supra note 14 (explaining that doctors were catted upon to "treat" or 
''heal" societal ills). 1 18 LIFTON, supra note 14, at 43-44 ("[W]hile a few doctors resisted [committing medical 
crimes], and large numbers had little sympathy for the Nazis, as a profession German physicians of­
fered themselves to the regime."); SHADOW OF THE REICH, supra note 1 4  (explaining that doctors were. 
"ready and willing to offer their assistance"); su also supra note 72 and accompanying text. 1 19 Proctor, supra note 30, at 26 (internal citation omitted). 
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Commitment to healing and strengthening the Gennan state and belief 
in social Darwinism certainly were not the only inspirations for medical 
community participation .in Nazi medicine. A much more sober and per­
�ps decisive influence was professional self-interest and advancement.120 
Another related influence was government coercion and surviva�, which 
later became the primary defense of Nazi doctors put on trial at Nurem­
berg. 12i So, how influential was professional self-interest and advancement 
relative to these other influences? First, within the professions of medicine 
and science, ardent eugenicists had an especially strong incentive to col­
laborate, for the Nazis were the only party to wholly support their proposed 
sterilization policies and vice versa.122 Ultimately, the research commu­
nity supportive of eugenics was given virtually carte blanche discretion to 
experiment on human beings and state support for doing so.123 The end 
result, in addition · to immense human suffering and murder, was ''nothing 
which civilized medicine can use": 124 
Even if [Nazi clinical researchers] had merely been forced to 
pay as little as two dollars for human experimental subjects, 
. such as American investigators may have to pay for a cat, 
they might have thought twice before wasting unnecessary 
numbers, and thought of simpler and better ways to solve 
their problems. Th� fact that these investigators had free and 
unrestricted access to human beings to be experimented upon 
misled them to the dangerous and fallacious cpncJusion that 
the results would thus be better and more quickl� obtainable 
120 SHADOW OF THE REICH, supra note 14 (explaining that many German doctors conducted ex· 
periments to gain professional advancement); see also Proctor, supra note 30, at 27 ("[l]n a certain 
sense, the medical profession might even be said to have prospered under the Nazis . . . .  It may even be 
true that physicians achieved a higher status in the Nazi period than at any time before or since."); 
GOLDHAGEN, supra note 70, at 384 (stating that ''the perpetrators [of the Holocaust] . . .  pursued their 
self-interest (conceptualized of as career advancement or personal enrichment) in total disregard of 
other considerations"). . , 
_ 121 SHADOW OF THE REICH, supra note 14 (explaining that many doctors, nurses, and other 
healthcare providers defended their actions by alleging government coercion); see infra notes 149-50 
and accompanying text. · 
122 SHADOW OF THE REICH, supra note 14 (stating that involvement of doctors legitimized im· 
plementation of racial theories). 
123 See Proctor, supra note 30, at 25 ("Given the effort to destroy entire peoples, and given the 
medical complicity in Nazi racial crime, it is hardly surprising that physicians attempted to exploit 
concentration camp inmates as subjects in human experimentation."); SHADOW OF THE REICH, supra 
note 14; supra note 100 and accompanying text (identifying documented Nazi experiments); LIFTON, 
supra note 14, at 5..6 ("Part I examines . . .  the Nazification of the German medical profession . . . .  Part 
II . . .  [examines) the socialization ofNazi doctors to the killing project . . . .  [P]art Ill [examines] more 
general principles of Nazi genocide . . . .  "). 
12 Taylor, supra note 100, at 91;  see also id. at 70·85 (referring to ghastly experiments including, 
inter alia, administering poison to prisoners of war, forcing subjects to drink seawater, and performing 
medicinal sterilizations on persons imprisoned in concentration camps). 
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than if they had gone through the labor of preparation, think­
ing, and meticulous preinvestigation. 125 
Second, in accordance with Nazi eugenics, Jewish doctors were gradu­
ally barred from participating in the medical system. The immediate prac­
tical effect of pushing Jews out of the practice of medicine was to make 
room for other German doctors whose careers had been impeded during the 
Great Depression. 126 Therefore, for non-Jewish doctors struggling to estab­
lish themselves in a zero-sum profession during difficult economic times, 
nationalism and bolstering the health of the German people certainly were 
convenient rationales for personal advancement, and personal advancement 
proved a powerful influence from the outset with this group. In fact: 
The medical community grew substantially under the Nazis 
despite the banishment of the Jews and Communists. It may 
even be true that physicians achieved a higher status in the 
Nazi period than at any time before or since. During the 12 
years of Nazi rule, for example, the office of Rektor (presi­
dent) at German universities was occupied by physicians 59 
percent of the time; this contrasts with 36 percent for the dec­
ade prior to the rise of the Nazis and 18 percent for the two 
decades following the Nazi period. Doctors also prospered 
financially under the Nazis. In 1926, lawyers earned an aver­
age annual salary of 1 8,000 RM compared with only 12,000 
RM for physicians. · By 1 936 doctors had reversed this trend 
and were earning 2,000 RM more than lawyers. 127 
Third, once the Third Reich put Nazi medicine into motion, presuma­
bly professional self-interest grew much more persuasive and more of a 
pervasive influence on the medical profession. Medicine and party politics 
became interchangeable; there was no viable opportunity to succeed in the 
German medical profession without actively participating in Nazi medi­
cine. Ultimately, as Nazi medicine spread from forced sterilization of tar­
geted groups to genocide and experimentation on those destined for geno­
cide, 128 the entire German medical profession-thousands of nurses and 
orderlies as well as doctors-participated. 129 Under these circumstances 
(terminating rather than saving lives), nurses were shown heightened pro-
125 /d. at 91-92. 126 
. 
Proctor, supra note 30, at 27-28; SHADOW OF THE REICH, supra note 14. 127 Proctor, supra note 30, at 27-28; see also SHAOOW OF THE REICH, supra note 1 4. 128 See supra notes 82-86 and accompanying text. 
129 See generally SHADOW OF THE REICH, supra note 14. The few doctors with some Jewish heri­
tage who were allowed to practice were placed in the worst of all situations. /d. They often were 
assigned to assist in carrying out the mass executions, which they did with the knowledge that resis­
tance would result in their own executions. See id. One rationale was that, occasionally, some good 
could be done. /d. 
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fessional discretion that included administering thousands of lethal injec­
tions. 130 However, the Third Reich issued rules to ensure that doctors as­
sisted in every step of the process, especially gassing. 131 The rules of the 
Third Reich mandated that at least one doctor be present when executing 
by gas, and doctors were recruited expressly to supervise mass extermina­
tion. After gassing, these doctors were responsible for certifying death.132 
Beyond the context of genetics-premised forced sterilization and exe­
cution, the conduct of members of the German medical profession raises an 
additional dimension of considerations. In the Third Reich, complying 
physicians assumed the ultimate position of power over life and death; 
those engaged in eugenics and war-driven research enjoyed unprecedented 
freedom. Members of the medical profession actually decided who among 
those destined to die at their hands-concentration ·camp inmates and those 
destined for the camps-should first be subjected to experimentation for 
the benefit of science in the name of the German government, meaning to 
advance a German war effort so intertwined with German science. 133 Typi­
cally, death was the target endpoint of these studies, and in fact, surviving 
research subjects were sent to gas chambers as soon as studies were 
deemed complete-meaning there was absolutely no medical benefit 
earned by people for haVing been subj ected to experimentation on behalf of 
the German goveminent.134 
Much of the most controversial experimentation began with the objec­
tive of perfecting sterilization techniques-for example, sterilization ex­
perimentation in Barracks Ten at Auschwitz to eliminate hereditary blind­
ness.13s In fact, "[a]s a consequence of the Sterilization Law, sterilization 
research and engineering rapidly became one of the largest medical indus­
tries. Medical supply companies designed new and improved sterilization 
equipment; medical students wrote more than 1 80 doctoral theses explor-
130 Jd. 
131  SHADOW OF THE REICH, supra note 1 4. 
132/d. 
133 See supra notes 95·96 and accompanying text; SHADOW OF THE REICH, supra note 1 4. 
134 SHADOW OF THE REtCH, supra note 14; see also supra note 98 and accompanying text; 
Mozes-Kor, supra note 96, at 53·59. 
13s SHADOW OF THE RErcH, supra note 1 4. As relayed by historian Daniel Kevles: 
During the war, news reports trickling back to the United States indicated that the 
Nazis were deploying eugenic sterilization on an even broader scale. When the full 
horrors of the death camps were revealed at the Nuremberg trials just after the war, 
witnesses testified that Nazi doctors had established centers for experimental sterili­
zation. Men were used to test castration procedures; women, to assess sterilization 
by X rays, injections, and electrical destruction of their reproductive organs. Marie 
Claude Valliant-Couturier, a former inmate at Auschwitz, reported: "The Gennans 
said they were looking for the best method of sterilization so they could repopulate 
all westem European countries with Germans within one generation after the war." 
KEVLES, supra note 28, at 169 (citations omitted). 
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ing new methods and consequences of sterilization."136 But then a range of 
studies were introduced, the very nature of which typically involved uni­
maginable human suffering. For example, studies were undertaken on 
starvation and on high altitude to benefit German aviation (subjects were 
"tested" in pressure chambers).137 Physicians also conducted "sea water 
tests" (subjects were to struggle to stay afloat in a tank of frigid water until 
death) to determine how long a downed pilot could endure the frigid North 
Atlantic.138 Children, rather than being spared, were sought out. For ex­
ample, Dr. Mengele engaged in research on some 1 ,500 pairs of twins at 
Auschwitz from 1942-1 944. These experiments, which generally were not 
based on any meaningful scientific foundation and contributed Jittle scien­
tific knowledge, encompassed a gruesome range of applications including 
attempts to convert brown eyes to blue by injecting methalyn blue139 and 
exposing children to a range of toxic injections.140 Dr. Mengele also had 
contemporaries, including Dr. Kurt Heissmeyer who conducted a study on 
tuberculosis in which he and his· associates removed the lymph glands from 
twenty Jewish children ages five through twelve and then infected them 
with the disease.141 
Nazi medicine was put on trial on December 9, 1 946 at the Doctors' 
trial following a major international trial of the political .leaders.142 Ulti­
mately twenty-four defendants were charged with performing medical ex­
periments on concentration camp inmates and other living human sub­
jects. 143 Twenty-three defendants were brought before an American mili­
tary tribunal; fifteen were found guilty, seven were acquitted, and one was 
convicted of other crimes. 144 Of those convicted, seven were executed by 
hanging and five were sentenced to life imprisonment. The remaining four 
136 
. 30 2 Proctor, supra note , at 1 .  
137 /d. at 25-26; SHADOW OF THE REICH, supra note 14. 
138 Proctor, supra note 30, at 25; SHADOW OF THE REICH, supra note 14. 
139 SHADOW OF THE REICH, supra note 14. Similar eye color experiments were performed on 
adult Jews and gypsies. See id. ; Proctor, supra note 30, at 26. 
140 Proctor, supra note 30, at 26; Mozes-Kor, supra note 96, at 53-59. 
141 S!iADOW OF THE REICH, supra note 14. In order to eliminate all witnesses, Dr. Heissmeyer 
ordered the execution of these children, along with two French doctors, two Dutch orderlies, and 
twenty-four Russian prisoners of war. LIFTON, supra note 14, at 457. "After the war, Heissmeyer 
returned to his home in Magdeburg, now in East Germany, where he was highly regarded as a lung and 
tuberculosis specialist." /d. 142 George J. Annas & Michael A. Grodin, Judgment and Aftermath, in THE NAZI DocTORS AND 
THE NUREMBERG CODE, supra note 14, at 94, 94 [hereinafter Judgment and Aftermath]; SHADOW OF 
THE REICH, supra note 14. For a list of the twenty-three trial defendants with identification summaries, 
see George J. Annas & Michael A. Grodin, The Doctor 's Trial and the Nuremberg Code, in THE NAZI 
DocTORS AND THE NUREMBERG CODE, supra note 14, at 63, 63-65. 
143 Judgment and Aftermath, supra note 142, at 120; SHADOW OF THE REICH, supra note 14. 
144 SHADOW OF rnE REICH, supra note 14; Alexander Mitscherlich & Fred Mielke, Epilogue: 
Seven Were Hanged, in THE NAZI DOCTORS AND THE NUREMBERG CODE, supra note 14, at 105. 
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were sentenced to extended prison terms, and all were free by 1967.145 
Some of the most notorious Nazi doctors, including Dr. Mengele, escaped 
capture and prosecution. 146 In fact, "[ e ]ven Na� doctors who had been 
directly involved in murder could initiate or resume medical practice in 
their home areas and become conscientious, much-admired physicians. 
Hence, the strange three-part odyssey from pre-Nazi physician-healer, to 
Nazi-physician-killer, to post-Nazi physician-healer."147 The United States 
directly contributed to this outcome via a program called "Paperclip," 
which encompassed employing 765 German and Austrian scientists, engi­
neers, and technicians with the objective of exploiting their expertise and 
preventing remilitarization of post-war Germany. 148 
It is important to note that, given the thousands of doctors and many 
more thousands of medical professionals who engaged in the intentional · 
mutilation and infliction of grave harm, refusal to treat, and murder of 
thousands of human beings under the auspices of research, 149 the defenses 
raised proved highly persuasive. The gist of these defenses was that in­
volved medical professionals were simply following government orders 
during a time of war and at the hand of direct government coercion. Many 
of the medical professionals actually left the experience expressing belief 
that, on the whole, they were apolitical and simply did their jobs. 150 How­
ever, there remains much evidence to the contrary: 
Among physicians, there were as many volunteers as victims; 
no one had to force physicians to support the regime. Hans 
Hefelmann testified to this effect in the euthanasia trial at 
Limburg in 1946: "no doctor was ever ordered to participate 
in the euthanasia program; they came of their own voli­
tion."JS J 
145 Mitscherlich & Mielke, supra note 144, at 105-07; SHADOW OFTHE REICH, supra note 14. 
146 SHADOW OF THE REICH, supra note 14. 
147 LIFTON, supra note 14, at 457; see also supra note 141 and accompanying text (discussing Dr. 
Kurt Heissmeyer). 
148 Mitscherlich & Mielke, supra note 1 44, at 106-07; LINDA HUNT, SECRET AGENDA: THE. 
UNITED STATES GOVERNMENT, AND THE PROJECT f APERCLIP, 1945-1 990 78-93 (1991 ). See generally 
TOM BOWER, THE PAPERCLIP CONSPIRACY: THE HUNT FOR NAZI SCIENTISTS ( 1 987) (exploring the 
history and consequences of the Paperclip Conspiracy). Some participants in this program subse­
quently were prosecuted for war crimes. Mitscherlich & Mielke, supra note 144, at I 06-07. 
149 See Proctor, supra note 30, at 27-29. ISO SHADOW OF THE REICH, supra note 14. 
15 1 Proctor, supra note 30, at 28. Nevertheless, presumably the circumstances caused some to be­
lieve that the choice they faced was, rather than a professional one, a choice of life or death-especially 
for Jewish health care providers. Although readily distinguishable, consider the story of Dr. Gisella 
Perl, a Jewish gynecologist who performed more than 1 ,000 abortions in Auschwitz in order to save the 
lives of women, many of whom were destined for the gas chamber because guards impregnated them. 
GISELLA PERL, I WAS A DoCTOR IN AUSCHWITZ (1 948); 0uJ of '!he Ashes (Showtime television broad-
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Although the number of prosecutions and convictions was small� the 
tone and implications of the doctors' trial extended far beyond prosecution 
of the culprits charged. The world's medical profession, largely via foun­
ders of the World Medical Association which came into being during the 
process, was asked how doctors, recognized as healers, could have engaged 
in some of the most immoral antihuman crimes ever imagined. There was 
strong international consensus that measures had to be taken to ensure that 
these pages from history were never duplicated. 152 The trial put in motion 
codification of basic principles that, over the following decades, became 
codified as international professional standards, then domestic professional 
standards and, ultimately, the domestic rule of law in countries such as the 
United States,153 
B. Post-WWII "New Eugenics " 
In the aftermath of WWII, German geneticists like their medical pro­
fession counterparts claimed that they were victims of the regime, not will­
ing participants in Nazi medicine. "They knew nothing of the mass mur­
ders of mental patients and Jews. ' Even if they had joined the party, none 
had been Nazis 'at heart. ' They found Nazi racism abhorrent. There were 
no traces of anti-Semitism in their work. Some of their best friends were 
Jews. "154 However, they were not able to erase memories of their actions 
through denial, for those were too plentiful, public, and recent: 
Most of Germany's leading geneticists-including those who 
prior to 1933 had criticized anti-Semitism-actively helped 
construct the racial state. They served on important commis­
sions, provided opinions on individuals' racial ancestry, gave 
courses on genetics for SS doctors, participated in the draft­
ing of racial laws. More than half of all academic biologists 
joined the Nazi Party, the highest membership rate of any 
professional group. That so many joined the Party (and also 
the SS and SA) is not explained by pressure; in fact, there 
was remarkably little. For example, party members and 
nonmembers had equal success in obtaining grants for their 
research. It rather reflects their enthusiasm for a regime that 
finally gave biologists, and geneticists in particular, the sup­
port they thought was their due. Far from being repressed, 
genetics-which was considered to be of grea� ideological, 
cast, Apr. 1 3 ,  2003); Robin Pogrebin, Entering the Gray Areas of Survivalist Moralil)l, N.Y. TIMES, 
Apr. 1 3 ,  2003 § 13 (Television), at 4. 
152 SHADOW,OF THE REICH, supra note 14. 
153 See discussion infra Part IV (examining the effect of the Nuremberg trials on the evolution of 
medical ethical standards). 
154 PAUL, supra note 13,  at 91 (citations omitted). 
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military, and economic importance to the regime-flourished 
in the Third Reich. Basic research was generously funded, 
career chances were expanded, and restrictions on experi-
mental work were minimized.155 
· 
1 59 
Given the Germans' reliance on eugenics as a "scientific" rationale for 
genocide, the eugenics movement was immediately criticized sharply (both 
externally and internally) in reaction to dissemination about the details of 
Nazi medicine and the Holocaust.156 Even prior to the full Nuremberg dis­
closure, the movement had swelled and had begun to show fraying seams, 
especially between geneticists who valued biodiversity and eugenicists 
who sought to direct human evolution.157 Growth of the movement during 
tl1e 1920s encompassed differences of opinion that tested unity, as was 
readily apparent by the 1930s, and from the fray arose a smaller, contained, 
and more scientifically sound movement known as "new eugenics": 
The 1930s represent a period of dissension and reform within 
the eugenics movement in Britain and the United States. Ad­
vances in genetics and medicine, criticism of eugenics re­
search and propagandist campaigns, and a sensitivity to the 
race and class prejudices, heightened by Hitler's translation 
of eugenics into a national race hygiene program, all contrib­
uted to reforms within the tllOVement. Proponents . of the 
"new eugenics" o( the 1930s stressed the role of environment 
in shaping intellect and behavior, eliminated the rhetoric .of 
racial inequality, condemned
. 
anti-Semitism, and abandoned 
analogies between animal breeding and human betterment. 
While some eugenicists adhered to the old, or "mainline," 
eugenics, the new eugenics enjoyed the support of scientists 
and maintained a notable constituency after World War TI. m 
Geneticists worked .to draw an even darker delineation between genet­
ics and eugenics, equating the latter with soft social science. 159 The new 
ISS Jd. (Citations omitted). 
1 56 GALLAGHER, supra note 24, at 4-6; see also infra note 1 59. "After World War II, however, 
biologists in the United States and Britain fought-by and large successfully-to emancipate human 
genetics from such biases in order to establish it as a solid field of science that would explain the com­
plexities of human hereditary and assist medicine by illuminating the relationship of genetics to dis­
ease." KEVLES, supra note 28, at vii. 
151 "The eugenics movement was international, politically diverse, and wrought with internal ten­
sions as its moral and scientific ambiguities became apparent.:' GALLAGHER, supra note 24, at 2. 
158 Jd. at 4-6. 
. 
159 See generally KEVLES, supra note 28 (stating that criticisms of the "science" underlying 
eugenics were valid). See discussion supra notes 38, 47 and accompanying text. As explained by 
author Daniel Kevles: 
During the heyday of eugenics-much of the first half of the twentieth century­
social prejudice often overwhelmed scientific objectivity in the investigation of hu-
160 CONNECTICUT LA W  REVIEW [Vol. 36: 1 25 
eugenics movement had a difficult time recapturing a meaningful concen­
tration of its pre-Nuremberg popularity: 
The American Eugenics Society continued to revise its 
eugenic mission in response to scientific and political devel­
opments through the 1960s, as it supported research on world 
population problems, birthrates, and birth control; genetics 
counseling; and "social biology." Still, the ','old eugenics" 
cast a long shadow on enterprises concerning the quality of 
the human gene pool, and the term was fmally abandoned af­
ter 1970!60 
In addition to the searing wounds associated with the release of details 
of Nazi medicine and the lingering stigma on eugenics, the movement was 
been hampered by another trend that the Holocaust and Nuremberg put into 
motion-a fundamental shift in medical ethos · from provider to patient­
determined decision-making, culminating with the present emphasis placed 
on infonned consent and patient autonomy . 161 
IV. NUREMBERG TO THE PRESENT: EVOLUTION OF REGULATIONS TO 
.PROTECT HUMAN SUJ3JECTS AND MEDICAL ETHICS 
Although the prosecutions and convictions of Nazi doctors were 
largely symbolic, Nuremberg has had . a penetrating sociological; profes­
sional, and legal impact during the decades that have followed. The facts 
disclosed leading into and during the Doctors' trial shocked civilized soci­
ety.162 Even more shocking was the realization that, before the trial, deter­
minative, fundamental bioethical and medical standards were not enforced 
by the authorities and, rather, were largely entrusted to the practice of the 
medical profession. 163 Prior to and at the time of Nuremburg, the medical 
. . 
.man genetics. Social distinctions of race and class were commonly attributed to dif-
. ferences in biological merit. After World War II, however, biologists in the United 
States and Britain fought-by and large successfully-to emancipate human genet­
ics from such biases in order to establish it as a solid field of science that would ex­
plain the complexities of human hereditary and assist medicine by illuminating the 
relationship of genetics to disease. 
KEVLES, supra note 28, at vii. 
160 . . GALLAGHER, supra note 24, at 6. 
161  See infra Part IV. 
162 PRICEWATERHOUSECOOPERS LLP, PROTECTING THE PEOPLE WHO VOLUNTEER TO PARTICI­
PATE IN RESEARCH 1 1  (Thomas Publisi & Michele K. Russeii-Einhom eds., 2001) [hereinafter PRO­
TECTING THE PEOPLE); see also THE NAZI DoCTORS AND THE NUREMBERG CODE, supra note 14, at 61-
120 (providing a summary of the aftermath of the trial ; a discussion of the origin of the Nuremberg 
Code; and photographs of the judges, the courtroom, counsel, defendants, and exhibits). 
I� . SHADOW OF THE REICH, supra note 1 4; see also Sharon Perley et at., The Nuremberg Code: 
An International Overview, in THE NAZI DoCTORS AND THE NUREMBERG CODE, supra note 1 4, at 1 5 1 -
52. "[T]he Nuremberg Code was enumerated as part of the judgment against Karl Brandt and his co­
defendants. The Code was based on the testimony of two U.S. physicians, Drs. Leo Alexander and 
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profession throughout the world generally was left to self-regulate, 164 and 
one of the challenges of the Nuremberg Doctors' trial was to develop and 
articulate guiding, objective principles against which the actions of the 
medical profession could be judged objectively. 165 The medical profes­
sion's embarrassment and threatened loss of trust and authority prompted a 
strong reaction, primarily through founding the World Medical Association 
("WMA") in 194 7. 166 Many principals of the WMA were actively involved 
in the Nuremberg proceedings, and the founding of the WMA may be in­
terpreted as a self-d�claration by the international medical commtll1ity that 
measures had to be taken to ensure that Nazi medicine would never be re­
peated. 167 
The immediate work product of the Doctors' trial was the Nuremberg 
Code-ten principles developed to judge the actions of the Nazi doctors in 
the absence of preexisting codified guidance. 168 The Code emphasized that 
there must be no research on human subjects without their voluntary, in­
formed consent. 169 Under the Code, the advancement of knowledge for the 
Andrew Ivy, who served as expert medical witnesses for the. prosecution." ld. at 1 5 1 -52. At its core; 
the Code constitutes criteria formulated during the course of a trial for war crimes to be used to judge 
the acts of physicians. /d. at 1 52 (internal citations omitted). 
164 See PAUL STARR, THE SOCIAL TRANSFORMATION OF AMERICAN MEDICINE 79-144 (1982) 
("The Consolidation of Professional Authority, 1 850-1 920"). ntustrative of this point, consider that 
Rudolf Ramm, a Nazi medical ethicist, ''noted in his 1942 book on medical ethics that phy5icians will 
often encounter patients who complain of the treatment they have received from another doctor. Ramm 
advised that physicians·should always tau the side of the other doctor, turning a blind eye to whatever 
incompetence or malpractice their colleagues may be accused of." Proctor, supra note 30, at 29 
(citation omitted). 
16$ See PAUL CARRICK, MEDICAL ETHICS IN THE ANCIENT WORLD 214-15 {2001 ); Michael A.  
Grodin, Historical Origins of the Nuremberg Code, in THE NAZI DocTORS AND THE NUREMBERG 
.CODE, supra note 14, at 137 (concluding that "[i]t is not surprising that, in the context of criminal 
judgment, the judges found the need to ao beyond the guilty verdict and to speak to the broader norms 
of medical ethics. The Nuremberg Code is an attempt to provide a natural law based universal set of 
ethical�rinciples."). 
1 See CARRICK, supra note 165, at 217; Perley et al., supra note 1 63, at 1 54 (stating in an article 
in the first issue of WMA 's journal, "that among the most important of the actions taken by the WMA 
in its assembly in Geneva in September 1948 was the adoption of a form of dedication by the physician 
to his Rrofession of medicine'') (internal citations omitted). 67 See CARRICK, supra note 165, at 219 (''Nor need we consider in detail all the possible per­
sonal injuries or deaths that would be visited on innocent persons if individual doctors, or the societies 
to which they belonged, ever lost their moral footing. The medical agenda of Nazi Germany immedi­
ately comes to mind . . . .  "); PROTECTING THE PEOPLE, supra note 162, at I I .  
168 . See Grodin, supra note 165, at 137; PROTECTING THE PEOPLE, supra note 162, at 1 1 . 
169 2 TRIALS OF WAR CRIMINALS BEFORE THE NUREMBERG MILITARY TRmUNALS UNDER CON· 
TROL COUNCIL LAW No. 1 0, 1 81 {William S. Hein & Co., Inc. 1997) {1949). The first principle of the 
Nuremberg Code, which underscores that the psychological integrity of research subjects must be 
protected absolutely, provides: 
The voluntary consent of the human subject is absolutely essential. This means that 
the person involved should have lc�gal capacity to give consent, should be so situated 
as to be able to exercise free power of choice, without the intervention of any ele­
ment of force, fraud, deceit, duress, overr�ching or other ulterior form of constraint 
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benefit of mankind always must be secondary to the well-being of human 
subjects.170 As explained by humanities professor Elie Wiesel: 
I once read a dissertation-from the University of Cali­
fornia, I think-by a psychiatrist who maintains that the 
sense of morality was not impaired . in these killers. They 
lmew how to differentiate between good . and evil. Their sense of reality was impaired. Human �eings were not hu­
mat1 beings in their eyes. They were abstractions. This is the 
legacy of the Nuremberg Tribunal and the Nuremberg- Code. 
The respect for human rights in human experimentation de­
mat1ds that we see persons as unique, as ends in them-
selves.171 
· 
The Code put into motion efforts by the globaland then national medi­
cal societies to interpret and codify the principles recognized into profes• 
sional standards. tn This effort started with establishment of the WMA in 
1947 and the WMA's Declaration of Helsinki in 1964,173 which in tum 
inspired the American Medical Association (''AMA") and sister organiza­
tions in other nations to take similar measures domt:stically. m Ultimately, 
/d. 
· or coercion; and should have sufficient knowledge and comprehension of the ele­
ments of the subject matter involved as to enable him to make an unden;tan�ing and 
enlightened decision . . ·. 
. 170 See id. at 181-82; Jay Katz, The Conse,t Principle of th.e Nuremberg Cqde: Its Significance 
Then and Now, in THE NAZI DocTORS AND THE NUREMBERG CODE, supra note 14, at 236 (explaining 
that the code "commanded that the principle of the advancement of sciepce bow to a hi&Jler principle: 
protection of individual inviolability"). . ·· 
17l  Elie Wiesel, Foreword to THE NAZI OOCI'ORS AND THE NUREMBERG CoDE, supra note 14, at 
ix. 
172 See Perley et at., supra note 163, at 154 (explaining that Nurembera and the resulting Nurem­
beriJ Code were an impetus for the founding of the WMA, which was established in 1947); PROTECT· 
lNG THE PEOPLE, supra note 1 62, at 1 1 . 
173 See Figure 2; World Medical Association, Declaration of Helsinki: Ethical Principles for 
Medical Research Involving Human Subjects (1964, revised 1975, 1983, 1989, 1996, 2000, 2002), 
available at http://www.wma.net/e/policy/pdf/17c/.pdf (last visited Aug. 25, 2003) (on file with the 
Connecticut Law Review); COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAl. SCU;!NCES, 
INTERNATIONAl. ETHICAl. GUIDELINES FOR BIOMEDICAl. RESEARCH INVOLVING HUMAN SUBJECTS 8 
(1993) (''The purpose of the Guidelines was to indicate how the fundamental ethical principles that 
guide the conduct of biomedical research involving human subjects, as set forth in the World Medical 
Association's Declaration of Helsinki, could be applied effectively, particularly in developing coun­
tries, taking into account culture, socioeconomic circumstances, national laws, and . executive and ad­
ministrative arrangements."); Perley et al., supra note 163, at 157-60 ("The draft code went through a 
number of revisions and was finally adopted by the 18th World Medical Assembly in Helsinki in 
1964."�· . .  . .. . . . . .. 
1 4 See AMERICAN MEDICAl. ASSOCATION, COUNCIL ON ETHICAl. AND JUDICIAL AFFMRS CODE 
OF MEDICAl. ETHICS (2000-01 ed.) x-xi; Michael J. Malinowski & Eric Rose, Regulation of Human 
Subjects Research, in MICHAEL J. MALINOWSKI ET AJ.., BIOTECHNOLOGY; LAW, BUSINESS AND REGU­
LATION 9-16 (1 999) (explaining that the AMA's code has been increasingly supplemented to com­
plement related government initiatives and actions). 
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the governments of the United States and many other nations codified in­
terpretations of the fundamental principles and standards into their rules of 
law. 175 
FIGURE 1 :  HUMAN SUBJECTS ' PROTECTION TIMELINE-FROM 
PRINCIPLES TO LAW 
1949 . . . . . . . . . . .  Nuremberg Code 
1964 . . . . . . . . . .. Dec/aration of Helsinki (World Medical Association) 
1966 . . . . . . . . ... U.S. Public Health Service Order 129 (precursor to IRBs) 
19:32-72 . . . .. . U.S. Public Health Service Syphilis Study at Tuskegee 
1 974 . . . . . . . . . .. National Research Act (establishes the National Commis­
sionfor the Protection of Human Subjects). The Office 
for Protection from Research Risks ("OPRR ''), also es­
tablished under the Act and situated in · NIH, oversees 
compliance with human subject protection regulations 
1 979 . . . . . . . . . . .  The Belmont Report (issued by the National Commission) 
1 98 1 .  . . . . . . . . . .  DHHS (45 C.F'.R. Part 46) and FDA (21 C.F.R. pts. 50 
and 56} issue parallel regulations on informed consent 
and IRB review 
199 1 . . . . . . . . . . .  Subpart A of the DHHS Regulations (45 C.P.R. pt. 46) 
are adopted by 15 other federal agencies as "The Com-
mon Rule " 
· ·  
2000 . . . . . . . . . .. 1he Office for Human Research Protections ("OHRP"), 
situated .in the Office of the Secretary, DHHS, replaces 
OPRR 
. Domestic interpretation, meaning the weaving of these principles into 
domestic R&D funding, regulatory 'schemes, and health care systemS, has 
proven somewhat idiosyncratic and reactive to ugly controversies that cap­
ture public and political attention.176 For example, through the early 1970s, 
115 See Malinowski & Rose, supra note 1 74, at 9·16 to 9-17 ("Many of the Belmont Report rec­
ommendations have been implemented by federal agencies, including the FDA and HHS."). 
176 See George J. Annas, The Nuremberg Code in U.S. Courts: Ethics versus Expediency, in THE 
NAZI DOCTORS AND THE NUREMBERG CODE, supra note 14, at 217-19 {explaining that, after Nurem· 
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the United States government continued with a research agenda, that 
grinded against the Nuremberg Code and Declaration of Helsinki. 117 Most 
notably, during the 1950s and 1 960s, disclosure of a string of incidents 
raised public concern: radiation and other experimentation on enlisted mili­
tary men and patients, ·· including children, institutionalized for mental 
health, "the dubious transplantation of an animal kidney into a human pa­
tient, the 'bugging' by social scientists of jury deliberations in Kansas, the 
injection of live cancer cells into patients at the Jewish Chronic Disease 
Hospital, and scientist Henry Beecher's publications (1959, 1 966) discuss­
ing examples of ethically questionable research."178 
For the United States, public disclosure of the Tuskegee study, a syphi­
lis study funded by the Public Health Service ("PHS") over four decades, 
captured the attention of the American public and became a profound turn-
ing point: · 
· 
. The infamous "Tuskegee Study of Untreated Syphilis in 
the Negro Male" was a 40-year research study conducted in 
Macon County, Alabama, by PHS physicians. Initiated in 
1932, the research targeted poor African-American share­
croppers suffering from syphilis, but was presented to sub­
jects as a study of "bad blood." The study continued until a 
July 26, 1972 New York Times story, "Syphilis Victims in 
U.S. Study Went Untreated for 40 Years" exposed it as "the 
longest non-therapeutic experiment on human . beings in 
medical history."179 
Details of the study, which decades later compelled an apology from 
the United States government under the Clinton Administration, 180 consti­
tute textbook violations of the fundamental requirements of bioethics. The 
study encompassed 600 men, 399 men with latent syphilis and a control 
group of 20 1 men without the disease,181 who were "encouraged" to par­
ticipate through free meals, free medical examinations, and free burial in-
berg, human experimentation became a mainstream and valued activity, but the courts have fumbled 
with the Code, troubling experimentation has taken place in the U.S. post-Nazi era, and promise of the 
Nuremberg Code has not been fulfilled in the United States); FuKIJYAMA, supra note 6, at 201 (domes­
tically, "[r]ules reprding human experimentation evolved in tandem with regulation of the drug indus­
try in the United States, and were driven fo!Wilfl:) in each instance by the revelation of scandal or atroc-
ity."). . 
.. ,  177 See PROTECTING THE PEOPLE, supra note 1 62, at 12-13. 
1 78 /d. at 1 2; see also Henry K. Beecher, ETHICS AND CLINICAL REsEARCH, 274 NEW ENG. J. 
MED. 1 354, 1 354 (1966) (discussing troubling practices in medicine involving human experiments); 
FUKUY AMA, supra note 6, at 201 (detailing medical experiments that raised public unease). 
179 PROTECTING THE PEOPLE, supra note 162, at 12. 
1 80 /d. at 13 .  
1 8 1 /d. at 12 .  
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surance. 182 "In a reprehensible breach of ethics, investigators took specific 
steps to ensure that subjects were denied access to effective treatment, even 
after penicillin became widely available, to preserve the integrity of the 
research. "183 
Tuskegee inspired Senate hearings and legislation, Title II of the Na­
tional Research Act of 1974,184 which mandated regulation to protect hu­
man subjects and the formation of the National Commission for the Protec­
tion of Human Subjects of Biomedical and Behavioral Research ("National 
Commission"). 185 This Commission issued The Belmont Report: Ethical 
Principles and Guidelines for the Protection of Human Subjects of Re­
search, 186 a guideline for distinguishing biomedical research and the prac­
tice of medicine that centers on identification and elucidation of three 
touchstone ethical principles: (1)  respect for persons, implemented through 
realization of informed consent; (2) beneficence, implemented by assessing 
and comparing risks and benefits from the perspective of the person(s) 
involved in the study; and (3) justice, implemented through an objective 
assessment of the fair selection of subjects. 187 
In conjunction with the establishment and operations of the National 
Commission, in May 1974, the Department of Health Education and Wel­
fare, predecessor of the Department of Health and Human Services 
("DHHS"), codified its policy on protection of human subjects. 188 In re­
sponse to the Commission's recommendations, DHHS greatly enhanced its 
human subject regulations and implemented a significant revision in Janu­
ary 198 1 .189 Simultaneously, the Food and Drug Administration ("FDA") 
issued parallel regulations190 and additional product-specific regulations 
pertaining to the protection of human subjects.191 In 198 1 ,  another com­
mission, the President's Commission for the Study of Ethical Problems in 
Medicine and Biomedical and Behavioral Research, recommended that the 
United States adopt uniform regulations for all federally supported human 
182 Jd. 
183 /d. at 12-13 .  184 National Research Service Award Act of 1974, Pub. L. No. 93-348, § 21 1 ,  88 Stat. 342 (re­
pealed 1978). 
ISS PROTECTING THE PEOPLE, supra note 1 62, at 13 .  
186 NAT'L COMM'N FOR THE PROT. OF HUMAN SUBJECTS OF B IOMEDICAL AND BEHAVIORAL RE­
SEARCH, THE BELMONT REPORT: ETHICAL PRINCIPLES AND GUIDELINES FOR THE PROT. OF HUMAN 
SUBJECTS OF RESEARCH (1978). 187 PROTECTING THE PEOPLE, supra note 162, at 13. 188 45 C.F.R. §§ 46. 1-.22 (1 974). 
189 45 C.F.R. §§ 46. 101 , 46.109-.1 1 1  (1981). 190 See Protection of Human Subjects, 21 C.F.R. §§ 50.1-.56 (2003) (providing guidelines for in­
formed consent of human subjects); 21 C.F.R. §§ 56. 101-. 124 (2003). 19 1 See Investigational New Dru& Application, 21 C.F.R. §§ 3 12.1-. 160 (2003); Biological Prod­
ucts, 21 C.F.R. § §  600.3-;90 (2003); Investigational Device Exemptions, 21 C.F.R. §§ 812.1-. 1 50 
(2003). 
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subject research. 192 A decade later, the United States largely realized this 
recommendation through codification of the Common Rule, 1 93 which cur­
rently is implemented by seventeen federal agencies: the Department of 
Agriculture; 194 Department of Energy; 195 National Aeronautics and Space 
Administration; 196 Department of Commerce; 197 Consumer Product Safety 
Commission; 198 International Development Cooperation Agency, Agency 
for International Development; 199 Department of Housing and Urban De­
velopment;200 Department of Justice/01 Department of Defense;202 Depart­
ment of Education;203 Department of Veterans Affairs;204 Environmental 
Protection Agency/05 Department of Health and Human Services;206 Na­
tional Science Foundation;207 . Department of Transportation;208 .Central In­
telligence Agency;209 and Social Security Administration.210 The Common 
Rule and FDA regulations require institutions engaging in covered human 
subjects research to establish Institutional Review Boards ("IR.Bs") to pre­
approve and oversee human subjects research.211 In fact, all grant applica­
tions for federal funding that encompass research .on human subjects must 
include a pre-approved protocol that specifies measures to ensure that vol­
untary informed consent is obtained from subjects prior to their participa-
192 Protection of Human Subjects; First Biennial Report on the Adequacy and Uniformity of Fed­
eral Rules and Policies, and their Implementation for the Protectioil of Human Subjects in Biomedical 
and Behavioral Research; Report of the President's Commission for the Study of Ethical Problems in 
Medicine and Biomedical and Behavioral Research, 47 Fed. Reg. 1 3 ,272, 13,274 (March 29, 1 982). 
193 Federal Policy for the Protection of Human Subjects, 45 C.F.R. §§ 46. 101-.124 (2003). 
194 7 C.F.R. § §  l c. I OJ-.124 (2003). 
19S 1 0  C.F.�. § §  745. 10 1-.124 (2003). 
196 . . . . . 14 C.F.R. §§ 1230.101-. 1 24 (2003). 197 15 C.F.R. §§ 27. 101-. 1 24 (2003). 
198 . . 1 6  C.F.R. §§ 1 028.1 01-. 1 24 (2003). 
199 .. · 22 C.F.R. §§ 225.101-. 1 24 (2003). 
200 24 C.F.R. § 60. 1 0 1  (2003). 
201 28 C.F.R. § §  46. 1 01-.124 (2003). 
202 32 C.F.R. § §  2 1 9. 10 1-.124 (2002). 
203 34 C.F.R. § §  97. 1 0 1-.124 (2002). 
204 38 C.F.R. §§ 1 6. 101-. 1 24 (2002). 
205 40 C.F.R. §§ 26. 1 0 1-. 124 (2002). 
206 45 C.F.R. §§ 46.101-. 1 24 (2002). 
207 45 C.F.R. §§ 690.1 01-.124 (2002). 
208 49 C.F.R. § §  1 1 . 1 01-. 1 24 (2002). 
209 Jeffrey Cohen, Ph.D., Associate Director of Education, Office for Protection from Research 
Risks, Department of Health and Human Services National Institutes of Health, Presentation at Ford­
ham University School of Law (Feb. 1 6, 2000) (stating that FDA has regulations that are distinct from 
those adopted by all other research-oriented agencies in the United States Government). 
210 See id. 
211 See 45 C.F.R. §§ 46.1 02(g), 46. 103(b)(4), 46. 103(b)(5), 46.108(a) (2003); 21 C.F.R. 
50.3(i)(2003). See generally Malinowski & Rose, supra note 174 (explaining the general framework 
for human subject research regulation in the United States); PROTECTING THE PEOPLE, supra note 162. 
2003] OUR EUGENICS PAST-PRESENT. AND FUTURE? 1 67 
tion.212 The Office for Human Research Protections ("OHRP") within the 
Office of the Secretary of Health and Human Services ("HHS") reviews 
IRB performance and policies.213 All institutions, both domestic and inter­
national, must file an Assurance with OHRP before enrolling subjects in 
research.214 Figure 2 illustrates the resulting regulatory regime. 
FIGURE 2: HUMAN SUBJECT PROTECTION REGULATIONS-REPORTING 
AND ACCOUNTABILITY 
HHS/OHRP 
NIH FDA 
Recipient Institutions 
IRBs 
Individual Researchers 
The net effect of the Common Rule and FDA regulations is that direct 
U.S. federal jurisdiction over human subject research encompasses re­
search conducted or supported by the federal government and research 
regulated under a specific federal statute-i.e., most notably research regu-
212 See Federal Policy for the Protection of Human Subjects, 45 C.F.R.§§ 46.109(c), 46.1 16-. 1 1 7  
(20021. 
13 Office for Human Research Protection, OHRP Homepage, at http://ohrp.osophs.dhhs.gov (last 
visited Aug. 2 1 ,  2003) (on file with the Connecticut Law Review). 
214 See Malinowski & Rose, supra note 1 74, at 9-17, 9-23 {explaining that "many biomedical re­
search institutions and academic medical centers file general assurances with OPRR" and discussing 
the guidelines in place for experimental drug and genetic research); PROTECTING THE PEOPLE, supra 
note 162, at 340 ("An institution that receives funding from a Federal Policy {Common Rule) depart­
ment or agency to conduct research . . .  must ensure that all collaborating institutions file an Assurance 
before enrolling human subjects. This Assurance requirement applies to both domestic and interna­
tional institutions."). Registration information is available on OHRP's Web Office for Human Re­
search Protection's website. Office for Human Research Protection, Assurances and 1RB Registration, 
at http://ohrp.osophs.dhhs.gov (last visited Aug. 2 1 ,  2003) (on file with the Connecticut Law Review). 
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lated under the FDA's enabling legislation.m No medicinal product within 
the FDA's jurisdiction · can be introduced into the market for human use 
without pre-approval by the agency, which includes limited market access 
to engage in research on human subjects to establish safety and/or efficacy. 
The latter requires an FDA-approved investigational new drug ("IND") or 
investigational device exemption ("IDE") application.216 However, the 
U.S. protection of human subjects has its limitations: "At this time, human 
subject research neither regulated by the FDA (meaning not involving an 
investigational drug) nor supported by the federal government is not sub­
ject to direct federal oversight."217 .  Also, limitations on the FDA's ability to 
interfere with the practice of medicine has left the delivery of clinical ser­
vices, including many arguably experimental services, largely to the discre­
tion of the medical profession218-even though the contemporary physi­
cian' s objective discretion has been pruned immensely by managed care 
and other · financial influences.21 9 Even when the regulations are applied, 
their reliability has been called into question.220 Moreover, there are in-
215 Most notable are the Federar Food, Drug, and Cosmetic Act, as amended by the Safe Medical 
Devices Act of 1990, Pub. L. No. 101-629, 104 Stat. 45 1 1  (codified in scattered sections of 21 U.S.C.); 
the Medical Device Amendments of 1992, Pub. L. No. 102-300, 106 Stat. 238; and the Public Health 
Services Act, 42 U.S.C. § 262 (2000). 
2 16 See 21 C.F.R. §§ 312.3(b), 312.20 (2003) (outlining the requirement for an Investigational 
New Drug Application); 21 C.F.R. §§ 50.3(b)(l 5), 50.24(d), 56.1 02(b)(l2)  (2003) (outlining the re­
quirement for an Investigational Device Exemption). 
2 17 Instilutional Conflicts, supra note 19, at 60. 
2 18 See discussion infra Part V. 
2 19 See Timothy S. Hall, Bargaining with Hippocrates: Managed Care and the Doctor-Patient 
Re/atlonship, 54 S.C. L. REv. 689, 740 (2003) ("One of the most telling criticisms of managed care is 
that it has allowed its cost-control function to override, at least in some ways and for some consumers, 
the fundamental truth of the physician-patient relati9nship-that the physician 's ultimate responsibility 
must be to the individual patient."); Aaron Seth Kesselheim, Comment, What 's the Appeal? Trying to 
Control Managed Care Medical Necessity Decisionmalcing Through a System of External Appeals, 149 
U. PA. L. REV. 873, 880-81 (2000) (discussing how in the late eighties managed care organizations 
began restraining the way physicians provide care "either directly through rules and organizational 
controls limiting the options available to health care providers or indirectly by modifying health care 
providers' behavior through financial incentives"); Michael J. Malinowski, Capitation, Advances in 
Medical Technology, and the Advent of a New Era in Medical Ethics, 22 AM. J. L. & MED. 331,  338 
(1 996) [hereinafter New Era] (stating that "care managers are assuming direct control over patient care 
decision�making, thereby shrinking the discretion to which physicians have grown accustomed"). 
22° For example, in June 2003 a task force of the Association of American Medical Colleges in­
troduced a set of guidelines for research using human subjects that proposed more intensive review 
before trials begin and monitoring where researchers hold more than a minimal financial interest. Draft 
"Financial Relationships and Interests in Research Involving Human Subjects: Guidance for Human 
Subject Protection," 68 Fed. Reg. 15456 (March 3 1 ,  2003); see also Editorial, Keeping Research Clean, 
BOSTON GLOBE, June 1 5, 2003 at H l O; LEXIS, News Library, Bglobe file ("[A] task force of the 
Association of American Medical Colleges has come up with a set of guidelines for research using 
human subjects, calling for more intensive review before trials begin and monitoring of any studies in 
which a researcher has more than a minimal financial interest"); Protecting Subjects, Preserving Trust, 
Promoting Progress /1-Po/icy and Guidelines for the Oversight of Individual Financial Interests in 
Human Subjects Research, TASK FORCE ON FINANCIAL CONFUCTS OF INTEREST IN CLINICAL RE· 
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stances in which the FDA has demonstrated regulatory passivity­
including its regulation of human tissue products, which was the focus of a 
Senate Investigative Committee inquiry and public testimony in May 2003 
following the death of a young man who received contaminated carti­
lage.221 
Whether consistently realized in practice, informed consent has 
evolved from the guiding principle recognized at Nuremberg to a codified 
standard that constitutes the cornerstone of the United States' human sub­
ject protections regime. 222 Legally sound informed consent must be ob­
tained from subjects before they are exposed to experimentation,223 mean­
ing consent under conditions that provide "sufficient opportunity to con­
sider whether or not to participate �nd that minimize the possibility of co­
ercion or undue influence."224 Moreover, federal regulations constitute a 
floor, not a ceiling, for they expressly provide that "[t]he informed consent 
requirements in these regulations are not intended to preempt any applica­
ble Federal, State, or local laws which require additional information to be 
SEARCH 2 (Association of American Medical Colleges, Oct. 2002) ("[T]he report offers a conceptual 
framework for assessing institutional conflicts of interest and a set of specific recommendations for the 
oversight of certain financial interests in human subjects research that, in the view of the AAM's Task 
,Force, are especially problematic and must therefore receive close scrutiny), available at 
http://www.aamc.org/members/coitf/2002coireport.pdf (last visited on Aug. 21 ,  2003) (on file with the 
Connecticut Law Review); Protecting Subjects, Preserving Trust, Promoting Progress - Policy and 
Guidelines for the Oversight of Individual Financial Interests in Humaiz' Subjects Research, TASK 
FORCE ON FINANCIAL CONFLICTS OF INTEREST IN CLINICAL REsEARCH (Association of American 
Medical Colleges, Dec. 2001) (offering "guidance to institutions in their efforts to provide responsible 
and effective oversight of financial interests in human subject research"), available at 
http://www.aamc.org/members/coitf/firstrepott.pdf (last visited on Aug. 2 1 ,  2003) (on file with the 
Connecticut Law Review). 
221 See infra note 486 and accompanying text. But see Adamson, supra note 2 1 ,  at 936-37 (an· 
ticipating FDA assertion of regulatory authority and enforcement with reliance on instances of FDA 
cease and desist letters to six ART programs engaging in cytoplasmic transfer on a research basis and a 
statement that lympohocyte immune therapy for recurrent pregnancy loss cannot be performed without 
an IND). 
222 See Malinowski & Rose, supra note 174, at 9-18 (describing "[t]he doctrine of informed con­
sent [as] the bedrock of international and domestic codified standards that address the protection of 
human subjects in research"). ·· 
· 
223. 21 C,F.R. § 50.20 (2003); 45 C .F.R. § 46.1 1 6  (2002). 
224 ' 21 C.F.R .§ 50.20 (2003); 45 C.P.R . . § 46.! 1 6  (2002). Some commentators argue that: 
The use of human subjects for medical research without their informed consent­
forbidden by the Nuremberg Code almost fifty years ago-is an instance of a misuse 
of medicine for goals otherwise acceptable. The ban against such research is almost 
absolute, applicable even if the research would save Jives or provide other great 
benefits. Only in the case of children and the incompetent can exceptions be made, 
and then only for the direct benefit of the patient. 
THE GOALS OF MEDICINE: THE FORGOTTEN ISSUE IN HEALTH CARE REFORM 3 1  (Mark J. Hanson & 
Daniel Callahan eds., 1999) (hereinafter GOALS]; see also Malinowski & Rose, supra note 1 74, at 9-33, 
Fig. 9-5 (identifying the fundamental elements of informed consent). See generally KENNETH GETZ & 
DEBORAH 80RFI'fZ, INFORMED CONSENT: A GUIDE TO THE RISKS AND BENEFITS OF VOLUNTEERING 
FOR CLINICAL TRIALS (2002) (hereinafter INFORMED CONSENT) (analyzing informed consent from a 
poiential subject's perspective). 
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disclosed for informed consent to be legally effective.'t22s The federal 
regulations also identify and further protect vulnerable populations, includ­
ing pregnant women,226 fetuses, and children, and these regulations apply 
to psychological as well .as pharmaceutical research.227 
The trilogy of informed consent, patient self-determination, and patient 
autonomy also has become the cornerstone ethos for the practice of medi­
cine in the United States and many other countries.228 · Over the last several 
decades, the reasonable physician standard (applied from the provider's 
perspective and resting on medical community judgment) has given way to 
the material-risks/informed patient standard (the boundaries of disclosure 
are e stablished by the patient's need to know).229 The roles of physician 
and patient have realigned to assure greater patient access to and control 
over information about their health care options. Perhaps most notably, the 
prevalence of managed care restrictions on physician discretion230 and a 
22S 21 C.F.R.§ 50.20 (2003); 45 C.F.R. § 46.1 16  (2002). 
226 45 C.F.R. pt. 46, subparts B, D (2002) (Common Rule); 21 C.F.R § 56.l l l (b) (FDA regula-
tions). 
227 45 C.F.R. pt. 46, subparts B, D (2002) . . 
228 "An important development in contemporary medicine in many countries, articulated in most 
international declarations, is increased recognition of the respect due persons. This has been most 
commonly understood most broadly to entail a ri&ht of self-determination, sometimes called auton­
omy, in medicine and health care;'' GOALS, supra note 224, at 34. 
229 Malinowski & Rose, .supra note 1 74, at 9-35. "Physicians are obligated to disclose the risks 
of the treatment and the risks of foregoing it. . . .  The ultimate decision rests on an assessment of what a 
reasonable patient in the same particular circumstances as the individual patient would consider mate­
rial in formulating a decision." · /d. at 9-21 . This shift is very visible in professional standards for self­
regulation, including those of the American Hospital Association. The American Hospital Associa­
tion's original 1 973 version of A Patient's Bill of Rights was open to withholding medical information 
from the patient to avoid harm over cof11)1ete disclosure when the two were in conflict However, the 
revised 1 992 version promotes full disclosure-presumably a reflection of influences such as height· 
ened appreciation of patient self-determination, the infusion of managed care, a deluge of medical 
innovation and care options, liability considerations, and economic influences. GOALS, supra note 224, 
at 34. 
230 See STARR, supra note 1 64, at 420-49 (indicating competitive pressures in medicine may in­
crease patient access to health care professionals); Markel Implications, supra note 5, at 42 ("The 
research community, medical community, and even tlt.e general public should anticipate access to more 
pharmacogenomic testing capabilities in the foreseeable future."); KENNETH M. LUDMERER, TIME TO 
HEAL: AMERICAN MEDICAL EDUCATION FROM THE TURN OF THE CENTURY TO THE ERA OF MANAGED 
CARE 349-69 ( 1999) (discussing the rise of managed care in the context of the development of Ameri­
can medical education); New Era, supra note 219, at 335 (1996). The United States' shift from small 
practices affiliated with hospitals to consolidation and the domination of large J'!l&naged care organiza­
tions has forced out considerable long-standing inefficiencies and reaped some short-term windfalls. 
Robin Toner & Sheryl Gay Stolberg, Decade After Health Care Crisis, Soaring Costs Bring New 
Strains, N.Y. TIMES, Aug. 1 1 , 2002, at A I .  However, although managed care stabilized the cost of 
health care in the mid-90s, a new period of turmoil is in sight. The combination of economic troubles 
and rising costs arc pricing working Americans out of health care. "Health insurance premiums rose an 
average of I I  percent last year and are expected to rise an additional 1 3  percent this year after several 
years o f  very modest growth." /d. Premiums for small businesses are expected to rise even higher. /d. 
Prescription drugs rose at an average annual rate of 1 9.7 percent in the last two years, id. , and the 
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deluge of technological advances attributable to the genetics revolution 
have overwhelmed members of the medical ·profession and encouraged 
patients to demand and seek out information from their doctors, each other, 
and a range of Internet resources.231 Today, patients and their physicians 
routinely look into the drug development pipeline for health care options, 
thereby commingling clinical research and clinical care.232 In addition, the 
prevalence of academic-indus1ry collaborations and general · integration of 
academia and industry in conten1porary biomedical research and develop­
ment necessitate higher standards of disclosure to prevent alld manage con­
flicts of interest . that threatell research integrity _and patient safety.233 
Unfortunately, the majority of th�.nation's research institutions have failed 
to implement policies to meet the threshold of reaso�ble disclosure/34 and 
the reliability of the United States regulatory regime to protect human sub­
jects has fallen into question. These insufficiencies were well docUmented 
under the Clinton Administration following several national controver­
sies, 235 and now the Bush Administration too has declared enhancement of 
relative precision of the genomics revolution in drug development will trigger unprecedented drug 
costs. "Politicians in both parties are beginning to respond, but they are profoundly divided on the 
issue . . . . " /d. 
231 Clinical care and clinical .. research a� integrating through a range of sites compiling and mak­
ing available data on clinical trials, including the U.S. government's www.clinicaltrials.gov. See 
Institutional Conflicts, supra note 19, at 53-56, 66-68. "The public is seeking access, and the advent of 
information technology is helping to make access possible." /d. at 54; see also GOALS, supra note 224, 
at 42 (citing the market's role in patient access). 
232 See Institutional Conflicts, supra note 1 9, at 53-56, 66-68 (exploring the growing relationship 
between clinical research and patient care). . 
2l;3 See Janet Fleetwood, Conflicts �� Interest in Clinical Research: Advocating for Patient­
Subjects, 8 WIDENER L. SVMP. J. 105 (2001)  (indicating that disclosure may alleviate conflict of inter­
est concerns). Cj Lita Nelson, The Rise of Intellectual Property Protection in The American Univer­
sity, SCIENCE, 279, available at http://www.sciencemag.org/cgi/contentlfu1V279/5356/1460 Oast visited 
Sept., 2, 2003) (on file with the Conn�c�jcut Law Review) (citing benefits of industrial support of clini­
cal research, especially for students); Mark G. Edwards ,et al., Value Creation and Sharing Among 
Universities, Biotechnology and Pharma, 2 1  NATURE BIOTECHNOLOGY 6 1 8-24 (June 2003) (finding 
universities pl,ay a pivotal role in the biotechnology revolution through collaborations with industry). 
234 See Mildred K. Cho et al,, Policies on Faculty Conflicts of Interest at US Universities, 284 
JAMA 2203 (2000) ("Most policies on conflict of interest at major US research institutions lack speci­
ficity about the kinds of relationships with industry that are permitted or prohibited."); Patricia Baird et 
al., Clinical Trials and Industry, ScrENCE, Sept. 27, 2002, at 221 1 (addressing disputes between clinical 
researchers and pharmaceutical manufacturers, and asserting that these disputes highlight the critical 
importance of protecting the right of trial subjects to disclosure of risks and the academic freedom of 
investigators). · . ' 2� 
. 
The most notable controversy was the death of Jesse Gelsinger, an 1 8-year-old gene-therapy 
subject in a protocol approved by the University of Pennsylvania. See Univ. of Pa. Health Sys., Inst. 
For Human Gene Therapy, Preliminary Findings Reported on the Death of Jesse Gelsinger, at 
http://www.med.upenn.edu/ihgtlfindings.html (last visited Aug. 23, 2001) (on file with author); Gel­
singer v. Trustees of the Univ. ofPa., Case No. 000901 885 (Pa. Ct. Com. Pl., filed Sept. 1 8, 2000), 
http://www.sskrplaw.comllinks/healthcare2.html (last visited Aug. 23, 2001) . . For Paul Gelsinger's (the 
father of Jesse Gelsinger) thoughts about informed consent and more insight regarding this controversy, 
see Foreword to INFORMED CONSENT, supra note 224, at l l -1 2; see also Institutional Conflicts, supra 
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human subject protections and strengthening of conflicts of interest regula­
tions national priorities and has established a Secretary's Advisory Com­
mittee on Human Research Protection ("SACHRP").236 
V. CONTEMPORARY GENETICS: EXPANDING SCIENTIFIC CAPABILITIES 
Completion of a draft map of the human genome in February 2002237 
demonstrated the. potential of coupling biology and information teclmology 
("bioinformatics"); advances in this and related enabling teclmologies pro­
pelled the project to completion from 1997 through 2001 .238 The resulting 
map constitutes identification of a digital code that contains three billion 
base pairs and approximately 30,000 genes:239 This code, which is ninety 
nine point nine percent consistent among human beings, translates into a 
set of instructions that, combined with individual contributions to the tenth 
note 19, at 70-73 (addressing the Clinton Administration's response); Press Release, Department of 
Health and Huma� Services, Secretary Shalala Bolsters Protections for Human Research Subjects (May 
23, 2000), available at http://www.hhs.gov/news/press/2000presl20000523.html (last visited Sept. 2, 
2003) (on file with the Connecticut Law Review) (citing initiatives to .bolster protection of human 
reilearch subjects); Donna Shalala, Protecting Research Subjects-What Must Be Done, 343 NEW ENG. 
J. MED. 808, 809 (2000) (proposing new disclosure guidelines for the protection of human research 
subjects). 
23 See M. Alexander Otto, New Bush Research Advisory Committee Has Industry Ties, One Pa­
tient Advocate, MED. REs. LAW & POL'Y, vol. 2, no. 2, ISSN 1539-4530 (Jan. 15, 2003); W. Randy 
Kubetin, Outlook 2003: HIPM, Human Subject Protection, Fraud, Among Year 's Top Research Policy 
Concerns, MED� REs. LAW & POL'Y REP. vol. 2 no. I , ISSN 1 539-4530 (Jan. 1 .  2003) available at 
http:/�ubs.bna.com/ip/BNA/mrl.nsf/isla-a6g7d3w6. ·. • · 
37 See Market Implications, supra note 5, at 3 1  n . l  (announcing completion of a "rough draft" on 
June 26, 2000, with the release of a ''true," complete map due in 2003); Ed Regis, Other People 's 
Molecules, N.Y. TIMES, Mar. 1 6, 2003 (Book Review), at 27 (reviewing JOHN SULSTON AND GEORGIA 
PERRY, THE COMMON THREAD: A STORY OF SCIENCE, POLITICS, AND ETHICS (2003)). The Human 
Genome Project was commenced in 1 990 with an expected completion date of 2005. /d. 238 . • ., .· See The Human Genome, ECONOMIST 3-14 (July 1 ,  2000) (s"ting that exponential progress 
in biotechnology parallels' advances in computing); GoALS, supra note 224, at 7 (emphasizing advances 
in medicine and technology). In 1 997, the Human Genome Project had exhausted half of its fifteen­
year duration and ninety percent of its funding just to sequence approximately 2.68 percent of the 
human genome. Juan Enriquez & Ray Goldberg, Transforming Life, Transforming Business: The Life­
Science Revolution, HARV. Bus. REv., Mar .• Apr. 2000, at 96. Advances in enabling technologies such 
as DNA chips and other bioinformatics capabilities propelled the mapping project to completion. /d. 
See generally NOV A, Cracking the Code of Life (PBS television broadcast, Apr. 17, 2001) [hereinafter 
Cracking the Code] (tracing the decoding of the. Human Genome); Snake Oil, supra note 5 (discussing 
bioinformatics). Information about the Human Genome Project may be obtained from the National 
Human Genome Research Institute (''NHGRr'), available at www.nhgri .nih.gov (last visited Sept. 2, 
2002):Aon file with the Connecticut Law Review). · 
9 FUKUY AMA, supra note 6, at 73-74. For information about the code, visit the Internet site of 
the National Institutes of Health's National Center for Biotechnology Information at 
http://www.ncbi.nlm.nih.gov/Genbank/GenbankOverview.html Oast visited Sept. 2, 2003) (on file with 
the Connecticut Law Review). However, in June 2003, a group of scientists concluded that the genes 
in the human genome total just 2 1 ,000. See Nicholas Wade, Gene Sweepstakes Ends, But Winner May 
Well be Wrong, N.Y. TIMES, June 3, 2003, at Fl .  
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of a percent variation and environmental factors, makes each of us the per­
son that we are.240 This translation, beginning with the identification of 
genes and gene and protein function (the fields of genomics and pro­
teornics, respectively), is an ongoing effort that envelopes the forefront of 
drug research and development and the future of medicine: 
Beyond genomics lies the burgeoning :field of proteomics, 
which seeks to understand how genes code for proteins and 
how the proteins themselves fold into the exquisitely com­
plex shapes required by cells. And beyond proteomics there 
lies the unbelievably complex task of understanding how 
these molecules develop into tissues, organs, and complete 
human beings.241 
There are approximately 30,000 genes and exponentially more proteins in 
the human body.242 This composition suggests intense multitasking by 
genes, extraordinary interaction and complexity, and the need for volumi­
nous data to make medical meaning out of the r�sulting genetic informa­
tion-with the end product being mere probabilities, not medical certain­
ties, in most instances.243 
Nevertheless, the code is being translated.244 fu fact, the rate of transla-
240 See FUKUY AMA, supra note 6, at 73 (stating that a large percentage of the h�man genome 
consists of noncoding DNA, while the remainder constitutes genes that contain the actual blueprint for 
human life). For an insightful discussion of the journey humans have taken as a species and the practi­
cal influence of DNA on individuality, see SPENCER WELLS, "fifE JOURNEY OF MAN: A GENETIC OD· 
YSSEY (2002); Craclcing the Code, supra note 238 (tracing the decoding of the �uman Genome); How 
to Build a Human: Predictor (BBC television broadcast, Jan. 2, 2002) (exploring gene connection to 
human behavior). Moving from base pairs to the level of genes and genetic expression, differences are 
multiplied however. For example, according to a discovery reported on June 16, 2003, the genomes of 
men and women differ by a full one to two percent-a difference equivalent to that between a man and 
a mate chimpanzee, and between a woman and a female chimpanzee. Nicholas Wade, Y Chromosome 
Depends on Itself to Survive, N.Y. TIMES, June 1 9, .2003, at A20; see also Helen Skaletslcy et !ll., The 
Male-Specific Region of the Human Y Chromosome is a Mosaic ofDiscrele Sequence Classes, 423 
NATURE 825-837 (June 19, 2003) (presenting data regarding genetic differences betWeen mates and 
females and other mammals). 
241 FUKUY AMA, supra note 6, at 74 (internal citations omitted); see also The Human Genome, su­
pra note 238, at 4 ("Proteins are the workhorses of �iology. Almost _ every molecule in the body is 
either a protein or the result of a protein's activity."). James Watson refers to DNA as "the script" and 
proteins as ''the actorS." See Editorial, A Cast of Thousands, 2l NATURE BroTECHNOL<)GY 2 1 3  (Mar. 
2003) (describing proteins as actors). See generally Supplement: Proteomics, 422 NATURE INSIGHT 
191 , 191-237 (Mar. 1 3, 2003) (discussing the forefront ofproteomics research). 
242 See Nancy Gibbs, The Secret of Life, TtME, Feb. 1 7, 2003, at 42-45 (explaining that the typical 
gene may yield 20,500 different proteins). 
243 FuKUYAMA, supra note 6, at 73 (describing scientists' partial understanding and uncertainty 
about the number of genes in the Human Genome). 
244 For a thoughtful, elegant account of the fundamentals of DNA and evolution of the genetics 
revolution, see WATSON, supra note 20; see also GENOMICS AND WORLD HEALTH: REPORT OF THE 
ADVISORY COMMITTEE ON HEALTH RESEARCH, supra note 20 (reporting on health care developments 
since the completion of the Human Genome Project). 
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tion is escalating with the ongoing advancement of bioinformatics and 
other enabling technologies attributable largely to the pharmaceutical and 
biotechnology sectors' aggressive investment in the advancement and ap­
plication of these tools.245 This nexus between biology and information 
technology also is meaningful enough to work in the inverse, meaning that 
researchers are turning living cells into computers.246 The pharmaceutical 
sector, confronted by a plethora of domestic and international market chal­
lenges juxtaposed against investor expectations inflated by decades of ex­
traordinary profitability, 247 has embraced biotechnology in drug develop­
ment. 248 The drug development industry has been dramatically increasing 
the percentage ofrevenue .allocated to R&D in an attempt to replenish its 
pipeline and future revenue streams.249 "The overall revenue allocated to 
R&D h�s risen from 1 1 % to 1 8.5% over the last twenty years, and overall 
pharmaceutical investment in R&D has risen · from approximately $2 bil­
lion . in 1 991  to $30.5 billion in 2001 ."250 Through several fields that bridge 
· 245 See Market Implications, supra note 5, at 3 1  ("Completion of a map of the human genome and 
the explosive emergence of a multitude of complementary technologies ranging from DNA chips . . .  to 
sophisticllted software have transformed great expectations for genetic . medicine into goals potentially 
obtainable' in the foreseeable future."); Snake Oil, supra riote 5, at 28�33 (describing the accomplish­
ments in the field of genetic research and health care);  The Human Genome, supra note 238, at 4 (citing 
computers' contribution to the advancemet of genomics). See generally Robertson et al., Pharmacoge­
netic Challenges for the Health Care System, 21 HEALTH AFF. 155-67 (July-Aug. 2002) (defining and 
analyzing the development of pharmacogenetics). • 
246 Jascha Hoffman, Microbe-Processors, BOSTON GLOBE, July 1, 2003, at C l ,  LEXIS, News Li­
brary, Bglobe File. S�ielltists are ·. using knowledge of biology and information technology to actually program cells. These applications include using proteins and DNA within cells to create living circuits 
(the work of Ron Weiss at Princeton University), creating a working toggle (on/oft) switch in which 
exposure to a particuhi.r protein makes a cell glow arid heat makes it stop (Prof. Timothy Gardner, 
Boston · University), and designing a bacterium that :Slowly glows red and green, "like Christmas lights 
in a Petri dish" (Professors Michael Elowitz and St.anislas Liebler, Rockefeller Univer5ity). /d. ;247 ·. . • . . ·  .
. . · .  . . .  · .· . · · . .  ' " ' .··· . . See Michllel l Malinowski, FDA Regulation of Biotechnology Products for Human Use, in 1 
ENCYCLOPEDIA OF ETHICAL, LEGAL, AND POLICY ISSUES IN BIOTECHNOLOGY 2 15, 224-25 (Thomas J. 
Murray & Maxwell J. Mehlman eds., 2000) (citing· JT1arket challenges idler decades of high revenues); 
Market Implications, · supra note 5, at 34-3.5' (''After decades of solid profitability, pharrllaceutical 
business plans to meet shareholder expectations based upon traditional rates or retum have become 
uncertain 'if not wltolly'unrealistic."). • · · · · · ·
.
· 
· 
248 Market lmpli(:ations. supra note 5, at 39-43 (stating that advances in biotechnology are fuel­
ing R&D for patet1t applications). See genefal/y R9bertson et al., supra note 245 (describing advances 
in biotechnology as decreasing health costs and Sparking new drug development). 
249 . 
. 
• 
. . • .  . . ·•(. · . , . . . .,, 
See generally Robertson et al., supra note 248; . PHRMA, PHARMACEUTICAL INDUSTRY PRO-
FILE 2003 : NEW MEDICINES. NEW HOPE. (2003) (hereinafter PROFILE 2003), available at 
http://www.phrma.org/publicationslpublicationslprofileo2/index.cfrn; PHRMA, PHARMACEUTICAL 
INDUSTRY PROFILE 2001 : A CENTURY OF PROGRESS 14 (200 I )  (hereinafter PROFILE 2001 ), available at 
ww\v.phrrna.org; PHRMA, PHARMACEUTICAL INDUSTRY PROFILE 2000 (2000) (hereinafter PROFILE 
2000] available at www.phrma.org. .· ·  
· 
250 Market Implications, supra note 5, at 38 (citing PROFILE 200 1 ,  supra note 249, at ch. 2). Ac­
cording to the latest data from the Tufts Center for the Study of Drug Development, an industry-funded 
Center, developing an innovative drug, including studies required after regulatory approval, costs $897 
million-a significant jump from the $802 million estimated in November 2001 . Joseph A. DiMasi et 
2003] OUR EUGENICS PAST-PRESENT. AND FUTURE? 1 75 
science and information technology, the industry anticipates identifying as 
many as 10,000 drug targets over the next several years-a jolting shift 
from decades of dependence on approximately 3 ,000 commercial pharma­
ceuticals derived from just 483 drug targets.251 
The alliance-based nature of biotechnology R&D, reflected in the ex­
traordinary integration of biotechnology and pharmaceutical companies, 
and industry and academia through entanglements of alliance and collabo­
ration agreements, has contributed to the pace · of collective advancement in 
the field of biotechnology and its progeny fields-e.g., bioinformatics, 
genomics, and proteomics.252 Although DNA chip253 and other bioinfor­
matics capabilities have been internalized by major pharmaceuticals such 
as AstraZeneca, that technology was pioneered by biotech companies such 
as Affymetrix which sold access to their capabilities as a service available 
to an array of paying customers.254 Moreover, HGP and biotechnology 
collaboration experiences have led commercial players to recognize the 
shared benefits of creating "biomedical R&D commons."255 The most no­
table example to date is the SNP Consortium-a consortium among phar­
maceutical, biotech, and academic participants to identify connections be­
tween variations of single letters in the genetic code and human health 
characteristics, such as adverse drug reactions.256 Other notable examples 
al., The Price of Innovation: New Estimates of Drog Development Costs, 22 J. HEALTH ECON. 1 5 1 ,  1 80 
(Mar. 2003); Jeffrey Krasner, Study by Tufts Group Says Average Cost of a Drog's Development is 
$897m, BOSTON GLOBE, May 14, 2003, at C4, LEXIS, News Library, Bglobe File. 
251 Market Implications, supra note 5, at 33; see also PROFILE 2001 , supra note 249, at 5, 1 4; 
Ronald Rosenberg, Data Bottleneck Slowing Drug Discovery, BOSTON GLOBE, June 20, 2001 ,  at 04, 
LEXIS, News Library, Bglobe FtJe (implying future drug development based on the expanding number 
of targeted genes). See generally ERNST & YOUNG, CONVERGENCE: THE BIOTECHNOLOGY INDUSTRY 
REPORT (2000) [hereinafter CONVERGENCE] (exploring the emergence of biotechnological tools and the 
increase in targets and drugs in the pipeline). 
252 See generally Snake Oil, supra note 5 (providing relevant definitions and a discussion of these 
terms). On September 30, 2003, NIH announced a $2.1 billion, five-year plan to help researchers, 
physicians, and drug conipanies apply scientific findings and develop new therapies. M. Alexander 
Otto, NIH Streamlining Plan Stresses Cooperation Between Scientists, Others in Research Areas, MED. 
RES. LAW & POL'Y, vol. 8, no. 1 90, ISSN 1 091-4021 (Oct. I ,  2003) available at 
http://healthcenter. bna.comlpic2/hc.nsf/id/BNAP-5 RXRS5?0pen Document. 
253 Market Implications, supra note 5, at 40 ("Utilization of DNA chips, which are silicon chips 
embedded with multiple, distinguishable bits of DNA, has made large-scale screening possible."); see 
also David Stipp, Gene Chip Breakthrough, FORTIJNE, Mar. 3 1 ,  1 997, at 56 ("Taking shape there are 
biochips whose impact witt far outreach that of any clone, helping to transform the practice of medicine 
and the quality of our lives."). In October 2003, Commercial Suppliers announced the market avail­
ability of DNA chips containing the entire human genome. See Pottack, supra note 5, at C l .  
254 CYNTHIA ROBBINS-ROTH, FROM ALCHEMY TO IPO: THE BUSINESS OF BIOTECHNOLOGY 76-
8 1  (2000); Snake Oil, supra note 5, at 32; Market Implications, supra note 5, at 40-41 n.59; Stipp, 
supra note 253, at 56. 
2S5 S 5 d . ee supra note an accompanymg text. 
256 See The SNP Consortium Ltd., Single Nucleotide Polymorphisms for Biomedical Research, at 
http://snp.cshl.org (last visited Sept. 24, 2003) (on file with the Connecticut Law Review). See also 
supra note 5. The entity at the center of the SNP Consortium is Orchid Biosciences, Inc., and inforrna-
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are the ongoing initiative to establish a collaboration to develop cancer 
drugs257 and a proposed international stem cell project.258 Historically ruth­
less academic competitors also are collaborating. The most notable exam­
ple to date is  the collaboration reported on June 20, 2003 between Harvard 
University and the Massachusetts Institute of Technology to apply lmowl­
edge of the human genome to the practice of medicine through the estab­
lishment of a $300 million Genome Institute.259 Other examples include 
collaborations among various compilations of governments, commercial 
entities, and academic institutions around sometimes voluminous reposito­
ries of human biological samples and medical histories. Following the 
country of Iceland, whose citizenry's DNA and medical records are being 
made commercially available through deCODE genetics, Inc./60 at least 
eight other countries have announced or launched similar initiatives­
including an ambitious effort announced in 2003 by the United King­
dom.261 Commercial entities have emerged and continue to emerge to ere-
tion about the effort is available at http://www.orchid.com (last visited Sept 24, 2003) (on file with the 
Connecticut Law Review). Correlations already have been made between variations in genes and 
enzymes that metabolize drugs, including liver enzymes, and impact the· pharmacokinetics (drug ab­
sorbtion, metabolization, and excretion) of some commercial pharmaceuticals in identified ways. See 
Noah, supra note 5, at 7-8; Market lmplicaiions, supra note 5, at 41 (discussing the compilation of data 
on the impact of variations of single nucleotide polymorphism on susceptibilities to disease and respon­
siveness to prescription drugs). As explained by Lars Noah: 
For each gene, individuals have a pair of copies called alleles, and one o� both of 
these may vary from the norm. Over numerous generations, certain variant alleles 
may become relatively common, and they are designated as "polymorphisms" when 
they occur in at least one percent of the population. In many instances, only one in 
the thousands of base-pairs that make up a gene differs from the norm, resulting in a 
single nucleotide polymorphism (SNP). For some genes, scjentists have identified 
more than half a dozen such variations. 
Noah, supra note 5, at 7 (internal citation omitted). "The companies involved considered [such varia­
tions] important basic information that they wanted placed in the public domain, so that others could 
not patent them." Andrew Pollack, An Early Step on Collaboration on Cancer Drugs, N.Y. TIMES, 
May 13,  2003, at A l . . 
257 Pollack, supra note 256, at AI ("Pharmaceutical companies are beginning to contemplate new 
collaborative efforts to lower the cost and speed the development of drugs for cancer, according to 
executives involved in the effort."). A task force has been culled from within industry to put this col­
laboration together. ld. 
258 Business and Regulatory News: International Stem Cell Project, 2 1  NATURE BIOTECHNOL­
OGY 220 (Mar. 2003). 
259 Andrew Pollack, $/00 Million Donation Helps to Establish a Genome Institute, N.Y. TIMES, 
June 20, 2003, at A2 1 .  
260 Information about this company and its endeavor is available at http://www.decode.com (de­
scribing deCODE also as having established deCODE to commercialize diagnostics and therapeutics) 
(last visited Sept. 24, 2003) (on file with the Connecticut Law Review). · 
261 Bertha Maria Knoppers, Presentation to the LSU Law Faculty on Populations, DNA Banking, 
and Ethics (Mar. 13, 2003) (discussing deCODE, DNA Sciences, Uman Genomics AB, RMGA, Sig­
naiGene, Eesti Geenikeskus: Estonian Genome Foundation, and Newfound Genomics). See deCODE 
and IBM Form Strategic Alliance, M2 PRESSWIRE, Jan. 23, 2003, LEXIS, News Library, M2pw file 
(reporting collaboration between deCODE and IBM Global Services to offer joint consulting, imple­
mentation and integrations services); Simon King, Genome Project in Estonia Shows Rapid Progress, 
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ate and manage such biocommons, meaning collective accomplishments 
that make broad contributions to science, sometimes through the public 
domain and other times through licenses.262 Academic institutions, such as 
Howard University, also are participating.263 
Working on such an intricate level with such multitudes of data would 
be impossible without DNA chip and other bioinformatics capabilities.264 
The enonnity of the information being processed has even necessitated 
invention of new numbers to measure it.265 Nevertheless in spite of the 
enormity of the task, bioinformatics has made fields such as genomics and 
proteomics at least theoretically feasible, and the genetic code is being 
translated into human health meaning. For example, "DNA chips can be 
used to test the samples of · individuals for the presence · of thousands of 
identified genetic variations and, alternatively, to screen hundreds of thou­
sands of individuals with a shared phenotype characteristic to isolate and 
identify shared genetic expressions."266 In fact, .this technology already has 
been used to engage in voluminous gene expression comparisons with 
' ' ·
. 
. 
. 
WMRC DAILY ANALYSIS, Dec. 20, 2002, available at 2002 WL 104096346 (reporting that the project 
is expeeted to encompass 700A. of th� Estonian popuiation, take five year$ to complete, and be used to 
develop a number of targeted treatments, including anti-depressant drugs). The U.K. project's backers 
have pledged $65.6 million (45 million British Pounds) to build a biobank with samples from 500,000 
Britons, thereby establishing the world's laiJest genetic database. Genetic Database Receives Funding, 
WALL. ST. J., Apr. 30, 2002, 2002 WL-WSJ 3393326 (stating that samples are to be gathered from 
volunteers age 45 to 69 and held in public ownership); UK Genetic Database to Rival Iceland's Set Up, 
MARKETLETTER; May 6, 2002, 2002 WL 7 179539. A related scientific endeavor is to engage in haplo­
type mapping, the Iritemational HapMap Project, which involves identifying genetic variations that 
travel with populations. See Paul Recer, lnternational Project to Map Genome Called a Step Toward 
Finding Genes that Trigger Diseases, ToRONTO STAR, Nov. 3, 2002, LEXIS, News Library, Tstar File 
(explaining that the project is premised on the observation that SNPs arc organized into DNA neighbor­
hoods called haplotype blocks comprising about 10,000 or mare base pairs, and that many people share 
the same haplotype blocks and common variations). 
262 Knoppers, supra note 261 (identifying major commercial efforts). See generally supra note 
261 . An emerging leader in the field is the First Genetic Trust, information about which is available at 
http://www.firstgenetic.net (last visited Sept. 24, 2003) (on file with the Connecticut Law Review). 
The author is working on a series of articles that explore biocommons and collaborations among com­
petitors as fundamental to biotechnology, and address biobanking as the latest extension of this phe­
nomenon. 
263 On May 27, 2003, Howard University announced plans to create the nation's largest reposi­
tory of DNA from African-Americans, "[s]aying black people are in danger of being left behind at the 
newest frontier of medical research." Andrew Pollack, DNA of Blacks to Be Gathered to Fight Illness. 
N.Y. TIMES, May 27, 2003, at AI . This plan consists of gathering DNA samples from 25,000 people 
over fi ve years by drawing mainly from patients at hospitals affiliated with Howard College of Medi­
cine and to also use alumni to solicit donors globally. /d. 
264 See Marlcet lmp/ications, supra note 5, at 40-4 1 .  
26s Beyond terabYtes (a trillion bits of genetic data}, these measurements include "petabytes 
(equivalent to half the contents of all the academic libraries in America}, exabytes, yottabytes and 
zettabytes. All the words ever uttered by everyone who ever lived would amount to five exabytes." 
Gibbs, supra note 242, at 42, 45. 
266 Market Implications, supra note 5, at 40-43 (identifying corporate examples) (citations pro­
vided). 
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meaningful results.267 "What will be possible in the future will depend 
heavily on the ability of computers to interpret the mind-boggling amounts 
of data generated by genomics and proteomics and to build reliable models 
of phenomena such as protein folding. "268 
These advances in biotechnology "have transformed great expectations 
for genetic medicine into goals potentially obtainable in the foreseeable 
future. "269 As acknowledged recently by the World Health Organization in 
an ambitious report, Genomics and World Health, increased understanding 
of gene and protein function will revolutionize the practice of medicine.270 
In fact, that revolution already is underway. Clinical trials are being de­
signed with genetic precision . ("pharmacog�nomics," also known as 
"PGx") and those are resulting in pharmace1,1ticals tied to genetic character­
istics.271 Some of these drugs are entering the market with genetic profiling 
as an accompaniment, and there are . instances · of genetic profiling being 
utilized by physicians to make -prescription and other treatment choices for 
individual patients. An illustration of the former is Herceptin, a drug to 
treat an aggressive form of breast cancer associated with over-expression 
of Her-2 .neu/72 and an example of the latter is HN genotyping.273 The 
ability to decode an individuai:s genome and then screen for a condition or 
susceptibility for a few hundred dollars has become a realistic and foresee-
267 Consider the following disease .case study, as reported through interviews with scientists 
working at the new joint Harvard�MIT genome institute: 
"[N)ew research into the cause of diabetes exemplifies how the new style of research 
will probably unfold . . . .  [A] group of genes involved in producing energy for cells 
are less active in diabetic patients. If this effect can be counteracted, then it may of­
fer a new way to treat the disease . . .  " 
Gareth Cook, $300m Genome Institute Launched; Harvard, MIT Join in Medical Effort, BOSTON 
GLOBE;· June 20, 2003, LEXIS, News Library, Bglobe File. 
268 FUKUY AMA, supra note 6, at 74. 
269 Market Implications, supra note 5, at 3 1 .  See generally Robertson et al., supra note 245. 
270 Genomics and World Health, supra note 20. "The trend, as the WHO has noted, is toward 
more exrensive treatment for diseases affecting fewer people." GoALS, supra note 224, at 7 . 
. 27 See generally Market Implications, supra note 5; Noah, supra note 5; Robertson et al, supra 
note 245. See also Jim Kling, US FDA Contemplates Collection of Pharmticogenomic Data, 2 1  NA­
TURE BIOTECHNOLOGY 590 (June 2003) (reporting FDA contemplation of a draft proposal to incorpo­
rate pharmacogenomic data into the regulatory process). For more information, sec FORETELLING OUR 
PHARMACOOENOMIC FUTURE (Mark A. Rothstein ed., 2003) (anthology addressing the science but 
with a focus on law, ethics, and other policy issues). 
272 Similarly, Gleevec, a drug for the treatment of a form of leukemia, blocks a chemical that sig­
nals cancer cells to grow. See Gibbs, supra note 242, at 42, 44. 
273 See Market Implications, supra note 5, at 42. Herceptin is manufactured by Genentech, Inc. 
(South San Francisco, CA), and HIV genotyping services are provided by Visible Genetics Inc. (To­
ronto, CA) and Virologic (South San Francisco, CA). See id. See also Andrew Pollack, When Gene 
Sequencing Becomes a Fact of Life: Test Helps Doctors Find Best AIDS Drugs, N.Y. nMES, Jan. 1 7, 
2001 ,  at Cl (discussing the development ofHIV genotyping and noting that it will help doctors choose 
which ofthe available drugs will work best with particular patients). 
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able possibility.274 Recent history dictates that we not assume the luxury of 
time when gauging the evolution from science fiction to fact. 
In the late 1 980s there was a finn consensus among geneticists that it 
was impossible to clone a mammal from adult somatic cells, a view that 
came to an end with Dolly in 1 997.275 As recently as the mid-1990s, ge­
neticists were predicting that the HGP would be completed sometime be­
tween 2010 and 2020; the actual date by which the new, highly automated 
sequencing machines completed the work was July 2000. "There is no 
way of predicting what kinds of shortcuts may appear in future years to 
reduce the complexity of the task ahead."276 
· 
VI. REGULATION OF AND TRENDS IN ASSISTED REPRODUCTION 
TECHNOLOGY ("ART") 
George Annas, a noted bioethicist and law professor at the Boston 
University School of Public Health who serves on the . Ethics Advisory 
Board of the Society for Assisted Reproductive Technology ("SART") and 
the American Society for Reproductive Medicine ("ASRM"), refers to as­
sisted reproduction as "the wild West" of American medicine.277 ART is 
poised at the intersection of a highly vulnerable and growing patient group 
willing to pay directly and expend considerable personal wealth for these 
services,271 and a sophisticated, highly competitive commercial sector en­
gaged in aggressive DTC marketing.279 ART also provides an opportunity 
for medical professionals to enjoyprofessiollal autonomy and reap signifi-
274 See 60 Minutes (CBS television broadcast, Apr. 17, 2002) (providing an overview of HGP and 
stating that hundreds of companies are making tests available so, ultimately, persons will be able to 
decode and screen their entire genome for a few thousand dollars) (tape on file with author). 
215 The Start of SomeJhing Big? Dolly Has Become a New Icon for Science, SCI. AM., May 1997, 
at 15. 
276 FUKUY AMA, supra note 6, at 79. See also Snake Oil, supra note 5, at 23-26 (discussing how 
the medical community underestimated the promise ofbiotechnology during the early 1990s). In May 
2003, scientists announced that they had cloned a mule, meaning the first clone of an equine animal, 
and that typically sterile animals now may be able to reproduce. Andrew Pollack, Another Milestone of 
Clanin� is Reached as a Mule is Born in Idaho, N.Y. TIMES, May 30, 2003, at A21 .  
2 7 Making Babies, supra note 6. But see generally Adamson, supra note 21  (arguing that there 
exists meaningful, comprehensive, and largely sufficient regulation and placing great trust in patients 
and the medical profession). See generally Lars Noah, Assisted Reproductive Technologies and the 
Pitfalls of Unregulated Biomedical Innovation, 55 FLA. L. REv. 603 (2003). . 278 See, e.g. , Maggie Jones, The Mystery of My Eggs, N.Y. TIMES, Mar. 16, 2003, § 6 (Magazine), 
at 44-46. Demographic trends in the U.S. include delaying reproduction and, consequentially, in­
creased difficulty with reproduction. Making Babies, supra note 6; 18 Ways to Malee a Baby, supra 
note 6; see also CDC, Final Report, supra note 1 1 ; Press Release, supra note 1 1 ;  Kolata, supra note I 0 
(addressing marketing ·practices of clinics, including money-back guarantees that pressure clinics to 
transfer more embryos and otherwise be . more aggressive in practice). For more information, visit the 
Internet site of RESOLVE at http://www.resolve.org/main/national/index.jsp?name=home (consumer 
organization that assists people considering ART treatment) (last visited Sept. 24, 2003) (on file with 
the Connecticut Law Review). 
219 Kalata, supra note 10; Making Babies, supra note 6. 
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cant financial retums2110 at a time when physician income and discretion are 
generally being checked by managed care.28 1 In spite of this tension, the 
sector is subject to insufficient mandatory, consistently enforced, and reli-
able regulation and oversight.2112 
· 
A Regulation of ART 
The practice of assisted reproduction generally is performed as a medi­
cal service in a clinical laboratory setting, and in recent years, hundreds of 
independent ART clinics have. been established across the country.283 His­
torically, the jurisdiction of the FDA, shaped largely by enabling legisla­
tion consisting of the Federal Food Drug and Cosmetic Act ("FDCA")284 
and the Public Health Services Act ("PHSA"), 285 has been checked to 
minimize interference with the practice of medicine.286 For example, the 
280 See generally pi'QCcedings, American Bar Association, Administrative Law Section, New 
Frontiers: Policy Considerations . and Options for Regulation of Assisted Reproduction Technology 
(ART), Feb. 7, 2003 (Seattle, WA) [hereinafter New Frontiers). But see generally Jeffrey R. Botkin, 
Prenatal Diagnosis and the Selection of Children, 30 FLA. Sr. U. L, REV. 265, 287-92 (2003) (propos-
ing professional standards as a desired alternative to regulation or other law). . .. 
281 A contemporary phenomenon is a strong (�rv�e) financial incentive to refuse treatment to 
the very sick. See S�deep Jauhar, When Dociors Slam the Door, N.Y. TIMES, Mar. 1 6, 2003, § 6 
{Magazine), at 32-33. ,;For the past 30 years, the profession has been in economic and social decline. 
Doctors' incomes and professional judgment have beert squeezed by managed care." James M. Hirsch­
hom, The Doctors ' Strike in Context, 1 7 1  N.J.L.J . . 589, Feb, 1 7, 2003; see also Jennifer Silverman, 
Medicare Pay (;uts Lilcely to Crimp Salaries, 510)162 INTERNAL MED. NEWS 461 May 1 ,  2002, .avail­
able at 2002 WL 14305793 ("The Medicare pay cuts expected over the next 3 years could h�ve a 
whopping impact on internists' yearly salaries."). Therefore, today, we should be even less inclined to 
entrust medical ethics to the medical profession. "To paraphrase the famous proverb concerning the 
responsibility for decisions about war, health care ethics . is too important to be left. in the hands of 
scientists and health care professionals." PRIMER, supra note 2, at xi. 
282 Admittedly, there are several professional initiatives and regulatory measures worth noting, 
which are summarized in Figures 3 and 4. See generally Adamson, supra note 21 .  However, the 
insufficiency of professional self-regulation is discussed infra at Part VI. 
283 See Final Report, supra note 1 1 . But see Adamson, supra note 2 1 ,  at 933 (asserting that regu­
lations for clinical research and ethics .at the university level constitute a reli.able regulatory check on 
ART). 
284 See Federal Food, Drug, and Cosmetic Act, 2 1  U.S.C. §§ 301-397 (2000); Safe Medical De­
vices Act of 1990, Pub. L. No. 101-629, 104 Stat. 451 1  (codified in scattered sections of 2 1  U.S.C. and 
42 U.S.C.), and Medical Device Amendments of 1992, Pub . . L. No. I 02-300, I 06 Stat. 239 (codified in 
scattered sections of 21 U.S.C.). 
285 Public Health Service Act, 42 U.S.C. § 262 (2000). 
286 See 21 U.S.C. § 396 (2000)"(medical device regulation); 42 U.S.C. § .1 395 (2000) (''Nothing 
in [Medicare) shall be construed to authorize any Federal officer or employee to exercise any supervi­
sion or control over the practice of medicine or the manner in which medical services are provided."); 
Legal Status of Approved Labeling for Prescription Drugs: Prescribing Uses Unapproved by the Food 
and Drug Administration, 37 Fed. Reg. 1 6,503, 16,504 (Aug. 15, 1972) (to be codified at 21 CFR pt. 
1 30) ("[l]t is clear that Congress did not intend the [FDA] to regulate or interfere with the practice of 
medicine . . . .  "). These limitations reflect the fact that the FDA was introduced and its authority ex­
panded during a time when the medical profession was organized, politically influential, and enjoyed 
significant professional autonomy. See generally STARR, supra note 1 64  (discussing the evolution of 
the structure of the American medical profession). 
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FDA regulates the market entry of drugs and devices and scrutinizes all 
label details, but the medical profession engages in considerable off-label 
use of these products and the pharmaceutical sector promotes such use 
through aggressive marketing.287 Much reliance has been placed on self-
287 See Thompson v. W. States Med. Ctr., 535 U.S. 357, 359 (2002) (striking down a FDAMA 
provision that prohibited pharmacies from advertising compounded products); Wash. Legal Found. v. 
Henney, 202 F.3d 33 1 ,  333-34 (D.C. Cir. 2000) (discussing the hands otT approach that Congress and 
the FDA have taken in regard to off-label use); Pearson v. Shalala, 164 F.3d. 650, 655 (D.C. Cir. 1999) 
(recognizing the marketing of dietary supplements as commercial free speech and checking restrictions; 
FDA may not require disclaimers for misleading health claims on dietary supplement labels). This is 
highly evident in physicians' discretion to prescribe pharmaceuticals otT-label. "In fact, Congress 
recognized the realities of off-label prescribing when it authorized Medicaid reimbursement of pharma­
ceuticals for uses that appear in certain medical compendia, even if the FDA has not approved that use 
for inclusion in labeling." Lars Noah, Informed Consent and the Elusive Dichotomy Between Standard 
and Experimental Therapy, 28 AM. J. L. & Men. 361, 398 (2002) (citing 42 U.S.C. § 1396r-8(kX6) 
(2000)); 42 U.S.C. § 1 395x(t)(2)(B) (authorizing Medicare reimbursement for off-label uses of oncol­
ogy drugs if consistent with medical compendia or the peer-reviewed literature). Nevertheless, direct 
promotion of off-label use is illegal. Wash. Legal Found., 202 F.3d at 332-33. Recently, the govern­
ment has prosecuted numerous alleged violations and many pharmaceutical companies accused of 
marketing improprieties have been settling. See, e.g., Alice Dembner, Drug Firm Agrees to Big Pen­
alty Astrazeneca Will Pay $355M to Settle Drug Fraud Charges, BOSTON GLOBE, June 2 1 ,  2003, at C l ,  
LEXIS, News Library, Bglobe File; Milt Freudenheim, U.S. Accuses Merck Unit of Cheating Health 
Plan, N.Y. TIMES, June 24, 2003, at C5 (reporting that the Justice Dept. accused Medco Health Solu­
tions, a pharmacy benefit manager ("PBM"), of cheating the federal employees' health plan); Gardiner 
Harris, Abbott to Pay $622 Million to End Inquiry into Marketing, N.Y. TIMES, June 27, 2003, at C l  
(reporting that Abbott Laboratories agreed to pay $622 million to settle investigation into sales prac­
tices for liquids used to feed the seriously ill); Liz Kowalczyk, Hospital. Drug Firm Relations Probed, 
BOSTON SUNDAY GLOBE, at A I ,  June 29, 2003, LEXIS, News Library, Bglobe File ("Federal 
investigators are sending subpoenas to top academic medical centers in Boston and elsewhere in the 
country for records about their relationships with drug makers as part of a widespread crackdown on 
pharmaceutical company marketing practices . . . .  "); Liz Kowalczyk, U.S. Filing Baclcs Suit Against 
Drug Firm Federal Prosecutors: EpilepSy Medication was l/legal/y Marked, BOSTON GLOBE, May 28, 
2003, at D l ,  LEXIS, News Library, Bglobe File (reporting accusations that Pfizer engaged in a 
fraudulent scheme to persuade doctors to prescribe the country's top-selling anticonvulsant, Neurontin); 
Melody Petersen, Court Papers Suggest Scale of Drug's Use, N.Y. TIMES, May 30, 2003, at Cl 
("Documents released yesterday in the case of a drug co!l1)any whistle-blower shed light on how 
extensively doctors were involved in promoting unapproved uses of a Warner-Lambert drug, 
Neuron tin."); Melody Petersen, Indictment Seen by Drug Maker Over Marlceting, N.Y. TIMES, May 3 1 ,  
2003, at A 1 ("The Schering-Piough Corporation said yesterday that i t  could soon be indicted in a 
federal investigation into its prescription drug marketing practices . . . .  "); Melody Petersen, U.S. Warns 
Botox Maker About Its Ads, N.Y. TIMES, June 24, 2003, at C2 (reporting that FDA warned 
manufacturer that its ads promoted uses beyond those government approved and, therefore, were 
illegal); Christopher Rowland, U.S. Widens Drug Firm Inquiry: Schering-P/ough Faces Criminal 
Investigation, BOSTON GLOBE, May 3 1 , 2003, at Cl,  LEXlS, News Library, Bglobe File (reporting that 
the Boston U.S. attorney is investigating a "broad array of allegedly illegal sales and marketing 
practices by drug companies across the country,'' including a criminal investigation of Schering­
Plough). But see Melody Peterson, Who 's Minding the Drugstore, N.Y. TIMES, June 29, 2003, § 3, at 1 
[hereinafter Drugstore] (reporting that FDA's issuance of warning letters for overly-aggressive 
marketing is down considerably). According to a Harvard University-MIT study released February 14, 
2002, drug companies tripled their advertising budgets in recent years to directly reach consumers. See 
Press Release, Harvard. Sch. Pub. Health, Direct-to-Consumer Advertising of Prescription Drugs 
Grows Rapidly (Feb. 13, 2002), available at 
http://www.hsph.harvard.edu/pressreleaseslpress021 32002.html (last visited Sept. 24, 2003) (on file 
with the Connecticut Law Review). "Overall, direct-to-consumer advertising spending by the drug 
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regulation by the medical profession-for example via licensing and board 
certification requirements-to ensure good medical practice.288 Tort liabil­
ity, including medical malpractice, offers another assurance.289 
The United States federal regulatory scheme for ART clinics can be 
summarized as voluntary certification. This program was established in 
accordance with the Fertility Clinic Success Rate and Certification Act of 
1992 ("Fertility Act").290 In accordance with this Act, the CDC developed 
a model certification program for ART laboratories.291 The end result is a 
template program which states have the option of implementing, either 
directly or by certifying independent accrediting organizations. No state 
has fully adopted the model program, 292 and the CDC has contractually 
outsourced implementation to SART, meaning that the sector has been left 
to self-police.293 
Although ART at times encompasses aggressive integration of emerg­
ing technology with the delivery of care, the field also largely circumvents 
industry rose to $2.7 billion in 2001 from $800 million in 1 996 . . . .  For every $ 1  spent on direct-to­
consumer ads, they reaped $4.20 in sales." Christopher Rowland, Drug Ads Deliver a Few Side Effects 
Firms Reap Rewards, but so Do Their Rivals, and Patients Take Data to the Doc, Study Finds, BOSTON 
GLOBE, June 12 ,  2003, at E 1 ,  LEX IS, News Library, Bglobe File. 
288 See STARR, supra note 1 64, at 1 02-1 2; Drugstore, supra note 287, at 1 (reporting that FDA 
under the Bush Administration has relaxed enforcement of prohibitions on direct promotion of off-label 
use and other advertising practices: "[F]rom 1 999 to 200 1 ,  the F.D.A. sent one warning letter for every 
2.8 complaints about false advertising. But in the first six months of 2002 . . .  it sent one letter for 
every 1 3.5  complaints"). But see Adamson, supra note 2 1 ,  at 932-33 (suggesting that marketing by 
ART providers is sufficiently regulated by FTC and FDA and referring to anecdotal incidents of FTC 
investif:tions of ART programs for exaggerated claims of pregnancy success rates). 
2 9 See Larry I. Palmer, Genetic Health and Eugenics Precedents: A Voice of Caution, 30 FLA. 
ST. U. L. REv. 237, 263 (2003) (proposing reliance on the judiciary and theories of liability rather than 
regulation). 
290 Pub. L. 1 02-493, 106 Stal3 146 (1992). 
291 See CDC, Notice, Implementation of the Fertility Clinic Success Rate and Certification Act of 
1 992-A Model Program for the Certification of Embryo Laboratories, 64 Fed. Reg. 39373 (July 2 1 ,  
1 999); CDC Final Report, supra note 1 1 . 
292 See generally Final Report, supra note 1 1 . But see Adamson, supra note 2 1 ,  at 937 (discuss­
ing the atypical initiative taken by a New York State task force, which recommended medical ad­
vancement policies). 
293 But see Adamson, supra note 2 1 ,  at 933. This proponent of self-regulation asserts that "[t)he 
law has been enacted and over 95% of ART programs in the country annually report their results to the 
CDC through [SAR11, which has a contract with CDC to collect these data." /d. However, this state­
ment is based upon practices in 1 997, and the highly commercial (private companies with patients 
usually paying directly) and explosive nature of the sector make the reliability of this self-reported data 
suspect, as addressed infra in Part VI. See id. The author also places great importance on the observa­
tion that "[t]hirty clinics of the approximately 370 in the United States had an on-site validation inspec­
tion," meaning 340 of the identified clinics were not inspected. /d. The lax enforcement of CLIA for 
commercial laboratories due to lack of CDC resources for the endeavor even prior to 9/1 1 ,  the anthrax 
murders, and recent epidemiological outbreaks such as West Nile Virus, SARS and monkeypox is well 
established. See Snake Oil, supra note 5, at 42. See also infra note 491 and accompanying text (de­
scribing questions about CLIA). 
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United States regulations to protect human subjects.294 The applicability of 
these human subject regulations presently is limited to instances where 
research is supported at least in part with federal funding, 295 is carried out 
at least in part by institutions that receive federal funding/96 or is con­
ducted pursuant to FDA oversighf97-including research conducted in 
conjunction with an IND298 or IDE application.299 As a clinical service, 
ART escapes the FDA's product groupings,300 and the federal government 
294 See supra Part IV. See generally Malinowski & Rose, supra note 174; PROTECTING THE PEO­
PLE, supra note 162. The failure to appreciate this gap in human subject protection regulations has led 
to instances offalse assurance, such as the following: 
[T]he United States government has also required that Institutional Review Boards 
(IRBs) be impaneled to monitor any organizations receiving federal funds for ge­
netic research. Nonscientists, including lawyers and philosophers, as we11 as citizens 
from other professions, serve on these boards. These nonscientist members will help 
ensure even-handed scrutiny, candor, and fairness in the administration of this cut­
ting-edge technology. 
CARRICK, supra note 165, at 2 1 0. 
295 Federal funding triggers Common Rule regulations, 45 C.F.R. § §  46. 1 0 1 -. 1 24 (2002). See 
discussion supra Part IV; supra note 217 and accompanying text; see also Malinowski & Rose, supra 
note 1 7  4;  PROTECTING THE PEOPLE, supra note 162. 
296 Such institutions _ must file assurances of compliance with human subject protection regula­
tions with the Office for Hui118Jl Research Protections {"OHRP") in the Office of the Secretary of 
Health and Human Services. See www.hhs.gov (general HHS) (last visited Sept. 24, 2003) (on file with 
the Connecticut Law Review); http://ohrp.osophs.dhhs.gov (general OHRP) (last visited · Sept. 24, 
2003) (on file with the Connecticut Law Review); Memorandum from Director, OHRP, to OHRP Staff, 
Compliance Oversight Procedures (Dec. 4, 2000), available at http://www.ohrp.osc)phs.dhhs.gov/ 
compovr.htm (last visited Sept. 24, 2003) (on file with the Connecticut Law Review). Many of these 
institutions must adopt policies 1111d procedures for compliance-i.e. establish IRBs and operational 
procedures-that they apply uniformly to all of their research activities, including research that is 
conducted without federal funding. 45 C.F.R. §46.103 (2002). See Malinowski & Rose, supra note 
174, at 9-9 to 9-10. 
297 ' 
. . , 
·
. ,  '". 
2 1  C.F.R. § 56.101 (2003); see also 2 1  C.F;R. § 56.1 02(e) (2003) (definition of "hurnan sub-
ject"). The FDA's human subject protection regulations complement the Common Rule, but the defi­
nition of human subject �at triggers their applicability rests on FDA's control over market access 
rather than federal funding. s� Malinowski & Rose, supra note 174, at 9-1 1 to 9-12. 
298 . . .  . • 21 C.F.R. § 50.23 (2003). 
299 2 1  C.F.R. §§ 50,25, 50.3, 56. 1 02 (2003). 
300 See supra notes 277, 282 and accompanying text. Although the FDA arguably has authority 
to regulate agents used in genetic testing, to date the agency has not exercised and tested that authority. 
See Genetic Testing Under the Clinical Laboratory Improvement Amendments, 65 Fed. Reg. 25,928 
(May 4, 2000); NAT'L INST. HEALTH, SECRETARY'S ADVISORY COMMITTEE ON GENETIC TESTING 
(SACGT), ENHANCING OVERSIGHT OF GENETIC TESTS: RECOMMENDATIONS OF THE SACGT {2000), 
[hereinafter SAGCT RECOMMENDATIONS] available at http://www4.od.nih.gov/obalsacgt.htm (last 
visited Sept. 24, 2003) (on file with the Connecticut Law Review); PROMOTING SAFE AND EFFECTIVE 
GENETIC TEsTING IN THE UNITED STATES: FINAL REPORT OF THE TASK FORCE ON GENETIC TESTING, 
29 n.f (Neil A. Holtzman & Michael S. Watson, eds. 1988); Anny Huang, FDA Regulation of Genetic 
Testing: Institutional Reluctance and Public Guardianship, 53 FOOD & DRUG L.J. $55, 557 n. 15 
(1 998). But see Andrew PolJack, F.D.A. Asks if a Genetic Test Is Sold Without Approval, N.Y. nMES, 
July 1 8 ,  2003, at C2. Also, the U.S. regime to protect human subjects has been called into question by 
both the Clinton and Bush Administrations and many others . See supra notes 235-36 and accompany­
ing text. But s� Adamson, supra note 21,  at 935 (suggesting that regulations to protect human subjects 
and university oversight are reliable regulatory mechanisms for ART). 
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has long abstained from funding embryonic research-thereby further cas­
tigating ART to the private sector.301 
Additional regulation is provided under the Clinical Laboratory Im­
provement Amendments of 1988 ("CLIA") to the FDCA,302 which gener­
ally apply to clinical laboratories.303 However, these regulations set stan­
dards for laboratory proficiency, personnel, and so forth (assurances that 
laboratory test results are accurate and reliable), but they do not provide 
any assurance of utility or clinical soundness from a medical point of 
view.304 CLIA also is marred by reporting and enforcement deficiencies:305 
CLIA regulations encompass monitoring more than 150,000 laboratory 
facilities on an ongoing basis.306 In order to satisfy this responsibility, the 
CDC has delegated considerable certification authority and responsibility 
to several professional societies including the Joint Commission on Ac­
creditation .of Health Organizations ("JACHO") and the College of Ameri­
can Pathologists ("CAP").307 
SART-ASRM dominates self-regulation of ART, but its regulation is 
not exclusive.308 The professional societies most influential in ART and 
301 "President Clinton barred federal funding for research on embryos. Yet he allowed federal 
funding for research on embryos 'left over' from IVF procedures. COngress has refused to allow funds 
to be allotted by the NIH for research on living fetuses." PRIMER, supra note 2, at 198. This ban on 
federal funding of stem cell research was enacted in 2000 in an amendment to the 1999 Labor, Health 
& Human Services Appropriations Act. Consolidated Appropriations Act, 2001, Pub. L. No. 1 06-554, 
1 14 Stat. 2763 (2000). · In response · to tremendous biomedical advances attributable to · research on 
human stem cells, President Bush has. permitted federal funding for research involving stem cells al­
ready extracted from human embryos as of August 9, 2001.  The White House, President George Bush, 
Fact Sheet-Embryonic Stem Cell Research, available at http://www. whitehouse.gov/news/ 
releases/2001/08/2001 0809-I.htrnl (last visited Sept. 24, 2003) (on file with the Connecticut Law 
Review); Sheryl Gay Stolberg, Ruling by U.S. Widens Study of Stem Cells, N.Y. nMES, Aug. 7, 2002, 
at A 1 .  Subsequently, researchers have claimed that many of these existing lines are of poor quality, the 
collectioh lacks necessary genetic diversity, and· the availability of the lines is seriously checked by 
intellectual property rights in the harids of commercial entities. /d. In March 2002, the Administration 
clarified this position, stating that researchers receiving federal funding may study new stem cell lines­
and even derive them from embryos-in their university laboratories, provided that they do not com­
mingle their federal and private funds, meaning that they must engage in careful bookkeeping. /d. For 
a concise commentary on the research use of embryos that surveys science applications and ethical and 
policy aspects, see Louis M. Guenin, The Set of Embryo Subjects, 21 NATURE BIOTECHNOLOGY 482-
483 (May 2003). . 
302 Pub. L. No. 100-578, 102 Stat 2903 (1 994). 
303 Michael J. Malinowski & Erica Rose, Clinical Laboratory Regulations, in BIOTECHNOLOGY: 
LAW, BUSINESS AND REGULATION, supra note 174, at 10-4 (1999). 
304 See id. See also Snake Oil, supra note 5, at 42. 
305 Snake Oil, supra note 5, at 42. 
306 /d. (citations omitted). 
307 Malinowski & Rose, supra note 303, at 1 0-i . See also id. at 10-1 1 to 1 0-12 (addressing 
JACHO and CAP accreditation). 
301 Visit the Internet sites for SART, at http://www.sart.org (last visited Sept 24, 2003) (on file 
with the Connecticut Law Review) and ASRM at http://www.infertilityprofessionals.com 
/clinical/asrm.htrnl (last visited Sept. 24, 2003) (on file with the Connecticut Law Review). SART has 
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their major guidelines are suriunarized iri Figure 3. ASRM and SART 
guidelines and practice standards are identified in Figure 4. 
FIGURE 3:  PROFESSIONAL SOCIETY ETIIICAL GUIDELINES309 
ASRM and SART: Ethical considerations of the assisted reproductive 
technologies (1986, 1 988, 1 990, 1 994, 1 997) 
• 1 994 report with complete statements on over 29 topics 
• 1 997 report with statements on: 
o disposition of abandoned embryos 
o oocyte' donations to postmenopausal women 
o embryo splitting for infertility treatment 
o the use of fetal oocytes in assisted reproduction 
o posthumous reproduction 
o ASRM and SART: Ethical issues with respect to spe­
cific ART practices including IVF, GIFT, ZIFT, gam­
ete donation, surrogacy, cryopreservation of embryos, 
and research 
ASRM and SART: Guidelines addressing quality assurance and forma-
tion of public policy 
· 
• Definition of 'experimental' ( 1 993) 
• Definition of ' infertility' (1993) 
American College of Obstetricians and Gynecologists (ACOG ) com­
mittee on ethics and opinions on NF (1 986), surrogacy (1990) and re­
search on preirnplantation embryos ( 1 993) 
The National Advisory Board on Ethics in Reproduction (NABER) 
[Originally organized through the cooperative efforts of ACOG and 
ASRM in 1 99 1 ,  then became independently incorporated and funded 
and had broad representation before disbanding in 1998 because of 
lack of funding] : Infonried consent and the use of gametes and em-
established a National Coalition for Oversight of the Assisted Reproductive Technologies ("NCO­
ART''). In its 1994 edition of its Ethical Considerations, ASRM adopted the position that the 
preembryo deserves greater respect than other human tissue because of its potential to become a person, 
but not the respect we give human persons because "the preembryo does not have differentiated organs, 
much less the developed brain, nervous system, and capacity for sentience that legal subjects ordinarily 
have." THE ETHICS COMMITTEE OF THE AMERICAN FERTILITY SOCIETY, ETHICAL CONSIDERATIONS 
OF �SSISTED REPRODUCTIVE TECHNOLOGIES 33S (Nov. 1 994); see also Richard A. McCormick, S.J., 
Reproductive Technologies: Where Are We Headed?, in THE HEALTH CARE PROFESSIONAL AS FRIEND 
AND HEALER 1 65, 1 68 (David C. Thomasma & Judith Lee Kissell eds., 2000). 309 Adamson, supra note 21 ,  at 937. 
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bryos for research (1997) 
• ASRM and SAR T: Shared-risk or refund programs in assisted 
reproduction (1 998) 
• Guidelines for advertising by ART programs (1998, 1 999) 
• Sex selection and preimplantation genetic diagnosis (1999) 
• Financial incentives in recruitment of oocyte donors (2000) 
• Human somatic cell nuclear transfer-cloning (2000) 
• Preconception gender selection for nonmedical reasons (200 1) 
FIGURE 4: ASRM AND SART GUIDELINES AND PRACTICE 
ST ANDARDS310 
• Minimum standards for NF ( 1984) 
• Minimum standards for GIFT (1988) 
• Revised minimum standards for IVF, GIFT, and related proce­
dures (1990) 
• Guidelines for human embryology and andrology laboratories 
( 1992) 
• Guidelines for practice, including gamete donation (1993) 
• Statement of intracytoplasmic sperm injection (1994) 
• Guidelines for the provision of infertility services ( 1 996) 
• Elements to be considered in obtaining informed consent for 
ART (1997) 
• Introduction of ovarian follicle development and ovulation 
with exogenous gonadotropins (1998) 
• Guidelines for number of embryos transferred (1998) 
• Guidelines for gamete and embryo donation (1998) 
• Revised minimum standards for in vitro fertilization, game in­
trafallopian transfer, and related procedures (( 1998) 
• Position statement on nurses performing limited ultrasound in 
a gynecology/infertility setting (1997) 
• Intravenous immunoglobulin (IVIG) and recurrent spontane-
ous pregnancy loss (1998) 
• Guidelines on number of embryos to transfer (1999) 
• Antiphospholipid antibodies do not affect IVF success (1 999) 
• Who is to report ART cycles (1999) 
• Optimal evaluation of the infertile female (2000) 
• The role of assisted hatching in IVF: a review of the literature 
(2000) 
• Repetitive oocyte donation (2000) 
• Does intracytoplasmic sperm injection (ICSI) carry inherent 
310 Id. at 936. 
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genetic risks? (2000) 
• Blastocyst production and transfer in clinical assisted repro­
duction (200 1) 
• Salpingectomy for hydrosalpinx prior to IVF (200 1) 
• Preimplantation genetic diagnosis (200 1) 
However, these efforts at self-policing are undermined by several con­
siderations3 1 1-the most fundamental of which is that participation in these 
organizations is voluntary, and certification/licensing by them generally is 
not required to practice ART in the United States. To summarize, "the 
reproductive technology industry is completely unregulated at present. 
True, we do have the ASRM's Ethical Considerations of Assisted Repro­
ductive Technologies. , Th�se <;lirectives have no legal clout, however; 
compliance is voluntary."3 12 Moreover, ART is further s)lielded from legis­
lative interference through Roe v. Wade and its progeny, which prohibit 
legislatures from unduly burdening a woman's choice to terminate a preg­
nancy.313 Meaningful regulation of ART that impacts its accessibility pre­
sumably could be construed as an und11e burden on a woman's right to 
make procreative choices and challenged as such legally.314 
In February 1998, at a conference co-sponsored by CDC, RESOLVE, 
.and NABER, fundamental questions about the regulation of ART were 
defmed and answered,3 15 as summarized in Figure 5. 
FIGURE 5: HIGHLIGHTS�DC-RESOLVE-NABER Q&A ON 
. REGULATION OF ART316 
"What are the critical gaps in approaches to ART oversight 
in the United States? " 
"The answers were a lack of sanctions. in the current system, 
problems with lack of funding for embryo research, incom­
pl�e and non-unifo11ll documentation and reporting, inade­
quate quality assurance requirements, , incomplete and non,. 
uniform informed consent, lack of mandatory availability of 
counseling, lack of consumer input, inadequate donor 
31 1 See generally discussion infra Part VII. . .. . 
312 McCormick, supra note 308, �t 165 (citing ASRM, Ethics Committee, Ethical Considerations 
of Assisted Reproductive Medicine (American Fertility Society, 1 994)). Bul see Adamson, supra note 
2 1 ,  at 932-33 (describing the meclical regulations affecting ARD. 
3 13 ' . ·  ' , , ' ,  ',, ' See supra note 8; infra notes 413-14 and accompanying text. 
3 14 See supra note 8. Bul.see infra notes 435-38 and accompanying text. 
31S See Adamson, supra note 2 1 ,  at 939-40. 
316 This dialogue has been rearranged for purposes of this Article. The dialogue is taken from 
Adamson, supra note 2 1 ,  at 939-40. 
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screening and standards, lack of insurance, and lack of 
mandatory universal standards or a code of practice." 
"Does the current system protect the consumers, and if not, 
what should be done? " 
"[T]he current approach to ART oversight in the United 
States is inadequate." 
"Does the current system protect providers, and if not, what 
could be done? " 
· "It was also concluded that the current ·system had inade­
quate protection for providers and that it is important to 
identify a recognized body that can set standards, provide 
better coverage and cooperation from insurance companies, 
provide medical-legal protection for physicians practicing 
ART, better availability of research institutional review 
boards, and a code of practice to protect against unreason- · 
able requests." 
"Is there fair and equitable access to ART in the United 
States, and if not, what [are] the barriers to access? " 
"It was felt that there is not fair and. equitable access be­
cause of individual financial constrain� and insurance com­
panies' failure to provide adequate coverage for ART, exac­
erbated by the lack of education and information regarding 
ART; lack of counseling especially with respect to moral, 
religious, and cultural views; misperceptions and unin­
formed social attitudes that are negative toward ART; media 
sensationalization of ART both good and bad; state man­
dates; lack of oversight of vendors in the industry; the Em­
ployee Retirement Income Security Act ("ERISA"), which 
places limitations on health insurance liability for employ­
ers; nonaccomrilodating employers and provider attitudes; 
and geography, race, and quality of care." 
"How could new technical issues and [other] new issues be 
addressed by additional oversight? " 
"The following were identified: an oversight committee, 
SART research committee, local institutional review boards, 
national funding, nongovernmental committees, and im­
proved guidelines for· research innovations and standards of 
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care." 
"How should the increased oversight be financed? " 
"It was felt that a number of possibilities existed, including 
through insurance coverage, through a combination . of pub­
lic and private funding, or a combination of patients, infer­
tility centers, and insurance and the public." 
"Is there an international model or attributes of one that 
could be adopted in the United States? " 
"It was concluded by all that the U.S. situation is unique, 
and that none of the international models are entirely adapt­
able to this coUiltry. However, in general, those at the meet­
ing felt that accreditation [is] superior to licensing, that 
oversight should show a flexibility of language so that the 
oversight authority will not be unduly constrained as future 
unknown developments occur, and that there should be sig­
nificant consumer participation." 
"Are there other forms of oversight in the United States that 
might be applied to ART? " 
"[I]t was felt that none of these organizational models 
would be able to provide, by themselves, the appropriate 
oversight of ART in the United States." 
B. Trends in ART 
1 89 
The field of ART often literally is measured in human lives-those of 
Louise Brown and Elizabeth Carr, the first IVF child and the first IVF child 
born in the United States, respectively.317 Louise Brown now is a twenty­
five-year-old woman, and she is leading the first generation of IVF chil­
dren into adulthood. Tens of thousands of children have been conceived 
and delivered through IVF and embryo transfer ("ET"),318 with more than 
35,000 ART babies in 2000 alone.319 
The announcements of these first IVF-ET births caused animated re­
sponses from medical professionals and the general public with an intensity 
• 317 Louise Brown was born on July 25, 1 978 in Oldham, England. McCormick, supra note 308, 
at 1 65; KEVLES, supra note 28, at 297. Elizabeth Jordan Carr was born three years later in the United 
States. 18 Ways to Make a Baby, supra note 6. On July 26, 2003, I 000 IVF children gathered to cele� 
brate Louise Brown's twenty�fifth birthday. Patricia Reaney, ln�Vitro Children Celebrate Milestone, 
BOSTON GLOBE, Mar. 20, 2003, at A7, LEXIS, News Library, Bglobe File. 
318 McCormick, supra note 308, at 165. 
3 19 Technology Report, supra note I I , at I I .  
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echoed by reaction to claims of successful human cloning. 32° Concerns 
raised about IVF and ET when introduced included the possibility that 
these processes would endanger the health of resulting pregnancies, per­
haps not in readily ascertainable ways. 321 There also were concerns that 
these procedures would negatively impact the family and society-for ex­
ample, by encouraging abortions and the delay of childrearing through 
perhaps inflated promises of opportunities later. Most of these concerns 
were put to rest over time in conjunction with the healthy development of 
Louise, Elizabeth, and the many thousands of NF children who fol­
lowed.322 Consequentially, the commercial ART sector developed slowly 
at first but then grew and matured immensely during the 1 990s, especially 
with the introduction of intracytoplasmic sperm injection ("ICSI").323 This 
NF method, which consists of injecting a single sperm cell directly into an 
egg cell with a pipette (an extremely thin glass needle), alleviates the stan­
dard need for 50,000 to 1 00,000 sperm cells to achieve conception, thereby 
making conception a possibility for perhaps nine out of ten men previously 
320 See Symposium, Conceiving a Code for Creation: The Legal Debate Surrounding Human 
Cloning, 53 HASTINGS L.J. 987, 987-1 204 (2001 -02); Carolyn Wilson, Statement in the Ad Hoc Com­
mittee on the International Convention Against the Reproductive Cloning of Human Beings, Feb. 26, 
2002, in ISSUES L. & MEO., Fall 2002, at 1 87-90; President George W. Bush, Remarks on Human 
Cloning Legislation (Apr. 1 0, 2002), available at http://www.whitehouse.gov/news/releases 
/2002/04/2002041 0-4.html (last visited Sept. 24, 2003) (on file with the Connecticut Law Review); 
THE PRESIDENT'S COUNCIL ON BIOETHICS, HUMAN CLONING AND HUMAN DIGNITY (2002), available 
at http://www.bioethics.gov/cloningieportlfullreport.html (last visited Sept. 24, 2003) (on file with the 
Connecticut Law Review); Fox News, House Passes Cloning Ban (Feb. 28, 2003) ("The bill, spon­
sored by Reps. Bart Stupak, D-Mich., and Dave Weldon, R-Fia., and backed by President Bush, passed 
241-255. The measure prohibits any form of cloning, including therapeutic cloning used for research 
of Alzheimer's, Parkinson's, diabetes and other diseases."), available at 
http://www.foxnews.com/story/0,2933,79770,00.html (last visited Sept. 24, 2003) (on file with the 
Connecticut Law Review). In contrast with the House, the U.S. Senate has proposed banning cloning 
for reproduction but allowing therapeutic cloning to continue. See Human Cloning Prohibition Act of 
2002, S. 2439, J 07th Cong. (2002); Human Cloning Prohibition Act, S. 2076, 107th Cong. (2002); 
Human Cloning Prohibition Act of 200 1 ,  S. 1 899, 1 07th Cong. (2002); see also Jonathan S. Swartz, 
The Human Cloning Prohibition Act of 2001: Vagueness and Federalism, 43 JURIMETRICS J. 79 (2002) 
(discussing the House version of this biil); Helen Dewar, Human Cloning Ban Sidetracked, WASH. 
POST, June 1 9, 2002, at A4, LEXIS, News Library, Wpost File. Similarly, in June 2003, the American 
Medical Association endorsed cloning for 'research purposes. For information about this statement, 
visit the Internet site of the AMA at http://www.ama-assn.org/arnalpub/artic1e/8833-7788.html; see also 
Research Cloning Backed by AMA, BOSTON GLOBE, June 1 8, 2003, at A2. 32 1 See 18 Ways to Make a Baby, supra note 6. According to a report issued from the United 
Kingdom in July 2003, IVF babies are at least as healthy as babies conceived through the traditional 
method. Embryology Conference: Longest-Running Study Finds Little Evidence of Ill-Health, 
INDEPENDENT, July 3, 2003, at 10, LEXIS, News Library, lndpnt File. 322 See 18 Ways to Malee a Baby, supra note 6. 
323 ICSI was developed by Professor Andre van Steirteghem, a Belgian gynecologist, and Dr. Ng, 
a Vietnamese physician. Andrea S. Voss, The Right to Privacy & Assisted Reproductive Technologies: 
A Comparative Study of the Law of Germany and the U.S. , 21 N.Y.L. SCH. J. INT'L & COMP. L. 229, 
232 (2002); see also infra note 384 and accompanying text. 
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deemed infertile.324 
According to the most recent report issued by the CDC, based upon in­
formation submitted voluntarily by 383 fertility clinics around the country, 
more than 35 ,000 babies (25,228 live births, including many multiple 
pregnancies) were born as a result of 99,639 ART cycles carried out in 
2000.325 These numbers may be conservative. Other reports have placed 
the number of babies born with ART at 60,000 as early as 1 998.326 More­
over, the sector, already a multi-billion dollar business annually,327 is grow­
ing exponentially due to cultural trends that include delay of childbear­
ing,328 the rising popularity of medical innovation in general and interven­
tion in reproduction especially in the midst of the genetic revolution,329 and 
the placement of a premium on autonomy in medicine,330 procreation,331 
and procreative liberty.332 According to one report, as of May 2001,  one in 
six American couples experienced difficulties conceiving a child, and ART 
constituted a $4 billion industry-a somewhat astonishing number given 
the youth of the sector.333 Where limits on reimbursement are tempering 
324 Voss, supra note 323, at 232. 
325 Technology Report, supra note I I , at I I .  
326 ISLA T Working Group, ART into Science: Regulation of Fertility Techniques, SCIENCE, July 
3 1 ,  1 998, at 65 1 ,  available at http://www.sciencemag.org/cgi/content/full/281/5377 /651 (last visited 
Sept. 24, 2003) (on file with the Connecticut Law Review). 
327 See discussion supra note I 0. ART is at the extreme side of a general trend of shifting health 
care deeper into the private, for-profit market: 
There can be little doubt that the greatest economic force now sweeping through 
health care systems worldwide is that of the market. The "market" may be under­
stood in a variety of ways, but it is perhaps best interpreted in theory as a way of al­
loWing individuals, not government, to make their own choices; as a way of promot­
ing the most efficient distribution of goods, to be brought about by open and private 
competition; and as a means of devising incentives and disincentives for modifying 
supply and demand behavior. For a growing number qf countries a market orienta­
tion combines a desire on the part of patients for more choice and a desire on the part 
of governments to relieve their economic burdens and thus to force onto patients 
and/or employers a greater share of health care costs. 
GoALS, supra note 224, at 42. 
328 See 18 Ways to Make a Baby, supra note 6; discussion supra note 10. 
329 See generally The Human Genome, supra note 238; discussion supra Part V. For example, 
the public is increasingly seeking out information about and demanding access to clinical trials to meet 
health care needs. See supra notes 231-32 and accompanying text. 
330 See supra notes 1 69-70, 228-29 and accompanying text; GoALS, supra note 224, at 34 (dis­
cussin� autonomy as a medical goal). 
3 1 The "pro-choice" and "pro-life" (or "anti-abortion") movements are both strong, perhaps in­
vigorated by a challenge to the status of Roe made by a Republican-dominated government. See, e.g. , 
Marilyn Rauber, Abortion Foes Hope Vote Signals Shift, RICHMOND TIMES DISPATCH, Mar. 1 6, 2003, 
at A-6, LEXIS, News Library, Rchtmd File; Joan Vennochi, That Other War: Abortion Rights,. BOSTON 
GLOBE, Mar. 20, 2003, at Al7, LEXIS, News Library, Bglobe File. 
332 See discussion supra note 313.  
333 See 18 Ways to Maire a Baby, supra note 6; Making Babies, supra note 6. It is  very likely that 
assessments of the sector are conservative given reliance on self-reporting for available data, institu­
tional differences among the entities offering ART (according to the CDC), and the fact that most are 
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the financial profitability of most areas of medicine and reducing physician 
income, patients usually pay for ART directly and at an average cost of 
$8,000-$10,000 per NF cycle,334 even though the average rate of concep-
tion is only about twenty-five percent.335 
· 
The vast majority of ART clinics are highly competitive, for-profit 
commercial companies.336 These entities measure their success rates based 
upon live births and usually without considering the health of the chil­
dren.337 Market competition is exacerbated by the mobility of the patient 
group responsible for market demand. Given the fact that these patients 
usually are paying for ART directly and making a considerable financial 
investment in addition to subjecting themselves to invasive procedures and 
a regimen of high dosages of potent fertility drugs,338 a significant part of 
this patient population is willing to travel to obtain the best service-as 
reflected in the national and even international DTC marketing of many 
ART service providers.339 Moreover, with a meaningfully greater likeli­
hood of failure ·than success, given the cost and invasiveness factors and 
with time being of the essence,340 prospective parents usually are eager to 
maximize the likelihood of a positive outcome by implanting multiple em-
private commercial entities and profitability and demand sugest that more arc being established on an 
ongoin g  basis. See generally Kolata, supra note 10; Making Babies, supra note 6; ANALYTICAL SCI­
ENCES, INC., CDC, FINAL REPORT SURVEY OF ASSISTED REPRODUCTIVE TECHNOLOGY: EMBRYO 
LABORATORY PROCEDURES AND PRACTICES 1 ,  1 3  (1999), available at http://www.phppo.cdc.gov 
/dls/pdf/art/ARTsurvey.pdf [hereinafter EMBRYO PROCEDURES AND PRACTICES]. 
334 
335 
Jones, supra note 278, at 44-45. 
See Technology Report, supra note 1 1 ,  at 1 .  
336 See EMBRYO PROCEDURES AND PRACTICES, supra note 333, at 1 3; Making Babies, supra note 
6; 18 Ways to Malee a Baby, supra note 6. Of the clinics included in the CDC survey (which was based 
heavily on voluntary reporting through SART and ASR'D, 1 82 of the facilities identified as eligible for 
the survey were categorized "Independent ART programs." Sixty-seven were deemed "University­
based ART programs" and fifty-one were categorized as "Hospital-based ART programs." EMBRYO 
PROCEDURES AND PRACTICES, supra note 333, at 1 ,  13 .  
337 See Technology Report, supra note 1 1 ;  Making Babies, supra note 6 ;  18 Ways to Make a 
Baby, s'fra note 6. 
33 See Making Babies, supra note 6. 
339 See Kolata, supra note 10; Centres for Assisted Reproduction ("CARE"), at http://www.care­
ivf.com/welcome.htrn (last visited Sept. 24, 2003) (on file with the Connecticut Law Review); The 
Fertility Center, LLC, at http://www.thefertili�center.com (last visited Aug. 23, 2003) (on file with lhe 
Connecticut Law Review); The Law Office of Sue A. Moravec, A Family Law Practice, at 
http://www.familylawpractice.net/htrnl/assistedrcproduction.htrn (last visited Sept. 24, 2003) (on file 
wilh the Connecticut Law Review). 
340 It has been established that fertility decreases significantly with advancing age. Women ex­
perience a significant drop at 35 and men at age 40. See Technology Report, supra note 1 1 ;  Michele 
Norris, Infertile Ground Study: Fertility Chances Drop Sooner than Expected (May 1 ,  2002), at 
http://abcnews.go.com/sections/wnt/DailyNews/fertility020430.html (last visited Sept. 24, 2003) (on 
file with the Connecticut Law Review). 
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bryos.341 ART providers generally are receptive, for rises in success rates 
increase the persuasiveness of marketing.342 In fact, some ART clinics 
even offer money-back guarantees.343 Consequentially, the popularity of 
ART has coincided with a substantial increase in the number of multiple 
pregnancies, which has resulted in more premature births and more chil­
dren with often debilitating health problems.344 Also, receptiveness to ART 
by both providers and patients demonstrates a propensity for applying 
medical innovation and, in many instances, originating medical innovation 
in the context of clinical service. The invention and application of ICSI 
constitutes a noted example. 345 That technique originated as a laboratory 
mistake: the doctor mistakenly perforated the outer membrane of an egg 
cell and directly introduced a sperm cell.346 Then, �t embryo grew while 
the patient's other embryos did not.347 Without the benefit of comprehen­
sive animal studies, a staple prerequisite for human subject experimenta­
tion,348 or the oversight of an IRB and comprehensive information ex­
change to obtain informed consent, !Jlis researcher then took the liberty of 
implanting the controversial embryo-which resulted in a successful deliv­
ery.349 Consider that now some ART physicians are taking even greater 
liberties that involve genetic manipulation without the prerequisite of com­
prehensive animal studies and compliance with standard human subject 
protection mechanisms, such as cytoplasmic transfer to help women who 
conceive but cannot carry a pregnancy past a few months.350 The proce­
dure involves transferring cytoplasm from a .donor egg into a patient's egg 
in the hopes that the transferred mitochondrial DNA will give the patient's 
egg and resulting embryo a needed boost of energy.3Sl Another evolving, 
34 1 See Making Babies, supra note 6; supra note 1 1  and accompanying text. It also is common 
practice to create many more embryos than are acwaJiy used. See discussion supra note I 1 (reporting 
nearly 400,000 frozen embryos in the U.S.). · · 
342 See Kolata, supra note 1 0. 
343 /d. 
344 Preemies, supra note 1 I ;  Malcing Babies, supra note 6. 
345 See supra notes 323-24 and accompanying text. 
346 . 
' 
18 Ways to Make a Baby, supra note 6. 
347 /d. 
348 See Malinowski & Rose, supra note .1 74, at 9-4 to 9-5. 
349 See 18 Ways to Maire a Baby, supra note 6. 
350 See id. For more information about cytoplasmic transfer, visit The Reproductive Sciences 
Center at http://www.fertile.com/cytoplasmic_transfer.htm (last visited Sept. 24, 2003) (on file with the 
Connecticut Law Review), 
· 
351 18 Ways to Make a Baby, supra note 6. The premise for the technique is that the healthier cy­
toplasm has more or more vibrant mitochondria, which are analogous to batteries, and thus gives the 
recipient an energy boost. See id; see also The Reproductive Scienc� Center, supra note 350. "Mito­
chondria are the powerhouses of the ceJI, little 'organelles'-1 ,000 per cell-that, in the presence of 
oxygen, convert the energy stored in · the hydrogen bonds in fat and sugar into the kind of energy the 
body can use, a substance called adenosine triphosphate, or A TP." Judy Foreman, Diseases Can Affect 
the Power in our Cells, BOSTON GLOBE, June 17,  2003, at C3, LEXIS, News Library, Bglobe File. 
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experimental procedure is in vitro maturation, which as of July 2003 was 
estimated to create about 250 babies worldwide.352 This method consists of 
maturing ova in a laboratory dish, thereby allowing fertile women part­
nered with men who have sperm problems to avoid taking high levels of 
risk hormone injections.353 
If the future of ART remains wholly market-driven,354 companies in the 
sector will continue to apply advances in genetic medicine as soon as it is 
financially feasible to do so--for example, to increase their success rates (a 
powerful marketing factor) and to offer potential clients more options than 
the competition. From the perspective of a consumer who decides to em­
brace this technology and to make a tremendous personal and financial 
investment, having more options to influence the outcome of a pregnancy 
for marginally more money holds appeal.355 ART options, which presently 
include sperm selection to influence the sex of the child and limited genetic 
screening of embryos prior to their implantation, will expand exponentially 
in conjunction with the advancement of genetic medicine.356 While tradi­
tional prenatal genetic testing has depended upon the sometimes specula­
tive endeavor of detecting a protein associated with a gene connected to the 
subject disease,357 DNA can be analyzed directly through recombinant 
DNA technology-giving rise to a multitude of application possibilities.358 
352 Children from Eggs Matured in Lab Normal, BOSTON GLOBE, July 1 ,  2003, at A6, LEXIS, 
News Library, Bglobe File. . . 
353 /d. ("Danish researchers told scientists at a European fertility conference yesterday that a 
· study of 33 babies born using the technique . . .  indicat[ed] they are normal, at least up to age 2."). 
354 See discussion supra Part VI.A. 
355 But see Pinker, supra note 21 (stating, based largely upon observations of human nature, that 
1hc public will not embrace PGD in this manner). In fact, according to a survey of public responsive­
ness to choosing traits for offspring completed in 1 999, sixty percent of respondents indicated that they 
would do so to rule out fatal illness, thirty-three percent indicated they would to ensure greater intelli­
gence, twelve percent would to influence height or weight, and eleven percent would to determine sex. 
What People Think, TIME, Jan. 1 1 ,  1 999, at 48, LEXIS, News Library, Time File. 
356 See Jason Christopher Roberts, Customizing Conception: A Survey of Preimplantation Genetic 
Diagnosis and the Resulting Social, Ethical. and Legal Dilemmas, 2002 DUKE L. & TECH. REv. 1 2, � 
26-27 (July 23, 2002), at http://www.law.duke.edu/joumals/dltr/articlcs/2002dltT0012.html (last visited 
Sept. 24, 2003) (on file with the Connecticut Law Review). See generally discussion infra Part VI. 
PGD received much attention with the announcement that Chicago researchers used the technology to 
enable a woman with a family history of Alzheimer's to deliver a child born free of identified genetic 
susceptibility to the disease. See Roberts, supra, at 1 3; Jones, supra note 278, at 44-45 (discussing the 
PGD procedure from a patient's perspective). As stated by Leon Kass, "to produce . . .  healthy and 
well-endowed babies, let alone babies with the benefits of genetic enhancement, a new scientific obstet­
rics will be necessary, one that will come very close to turning human procreation into manufacture." 
LEON R. KAsS, LIFE LIBERTY AND THE DEFENSE OF DIGNITY: THE CHALLENGE FOR 8JOETHICS 130 
(2002�57 "The protein, however, cannot be easily or safely detected in numerous cases-notably sickle­
cell anemia. (The telltale hemoglobin can be obtained only by direct extraction of fetal blood-a pro­
cedure extremely hazardous to the fetus.)." KEVLES, supra note 28, at 294. 
358 ''The trick relies on choosing a restriction enzyme that will cut from the DNA chain a strand 
containing or adjoining the gene of interest." /d. 
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For example, in May 2003, a British woman gave birth to Jamie, a child 
genetically matched to an older brother, Charlie, suffering from a rare form 
of anemia so that stem cells from Jamie's umbilical cord could be used to 
treat Charlie.359 
Bioinformatics is making it possible to bundle thousands of genetic 
characteristics into a single and increasingly affordable test. While small 
bits o f  genetic information that amount to a cluster of probabilities may not 
hold much appeal on an individual basis, together, thousands of individual 
notes may hold the market appeal of a symphony of information, especially 
when there are embryos from which to choose.360 Also, some screening 
tests for specific genetic characteristics-for example, those associated 
with cystic fibrosis-do deliver meaningful genetic information. When 
choices must be made among embryos, certainly there is market appeal in 
testing for these and, for a slightly higher price, screening for hundreds or 
even thousands more characteristics at the same time. Depending on the 
prospective parents and their circumstances (for example, an older couple 
that approaches ART as a single opportunity to have the perfect child), 
broad genetic screening may hold market appeal even at a significantly 
higher price.361 
Arguments can be made that, at least for a number of years, the avail­
ability of broad PGD screet?-ing will be checked by control over the tech­
nology by commercial interests with a focus on drug 4evelopment rather 
than patient services and otherwise prevent access thrqugh high prices. 
There certainly are instances now where commercial entities hold patent 
rights over genetic tests and make them available only at a prohibitive price 
or not at al1.362 However, these situations reflect limited developed genetic 
359 The mother obtaine.d ART services at the Reproductive Genetics Institute in Chicago after 
Britain's regulatory body that oversees ART, the Human Fertilization and Embryology Authority, 
vetoed the treatment because Charlie did not have a hereditary illness. Warren Hoge, Britain: Baby 
Born to Couple Who Want Stem Cells, N.Y. TIMES, June 20, 2003, at AS. The same authority approved 
this technique for use by another British couple to save a terminally ill son who suffered from a heredi­
tary disease. /d. It is important to note, however, that Britain, in contrast with the United States, allows 
the creation of embryos for research purposes un.der the oversight of authorities like the Human Fertili­
zation and Embryology Authority. Nicholas Wade, Clinics Hold More 'Embryos Than Had Been 
Thought, N.Y. 'nMES, May 9, 2003, at A20. See generally John A. RobertSon et al., Conception to 
Obtain Hematopoietic Stem Cells, HASTINGS CENTER REP., May-June 2002, at 34, 40 (concluding, 
"[s]uch practices may be controversial, but they will often reflect deep concern for both children, and 
should be available for parents who have no other good therapeutic alternatives."); Robertson, supra 
note 5, at 468 (addressing case-specific uses of PGD in this context). 
360 But see Pinker, supra note 21 (measuring the basic appeal of PGD upon the predictive limita­
tions of individual genetic screens rather than the potential appeal of bundles of such genetic screens 
through bioinformatics and DNA chips). The trend in the U.S. is to create many more embryos than 
are actually used, resulting in approximately 400,000 human embryos in frozen storage. See 400,000 
Embryos and Counting, supra note 1 1 , at A24. 
361 See infra note 409 and accompanying text (competition for "Baby Ivies"). 
362 A noted example is Myriad's BRCA test, which is discussed supra note 5. See generally Al­
len C. Nunnally, Note, Commercialized Genetic Testing: The Role of Corporate Biotechnology in the 
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testing capabilities in the hands of an also limited number of commercial 
entities engaged in commercial genetic testing which, incidentally, face 
tremendous market impediments due to the legal environment surrounding 
this technology. 363 Limitations on market availability may hold true for 
genetic tests that generate big pieces of genetic information that carry in­
dependent commercial value, but the deluge of subtle genetic-medical con­
nections being made in conjunction with drug development will provide a 
means for broad PGD.364 Compilation of SNPs into massive databases is a 
prerequisite for drug development and certainly should make SNPs medi­
cally useful. 365 Even multinational competing commercial interests such as 
AstraZeneca and Merck have been collaborating to create these commons, 
and the commons are being created.366 Consider that, from a commercial 
perspective,367 use of these commons in ART constitutes a potentially 
meaningful windfall return-an additional source of revenue and also a 
means for generating yet more data to better clarify some genotype­
phenotype connections in the broad human population. We live in an age 
when the DNA and medical histories of entire populations are being organ­
ized and made commercially available.368 Ultimately, the same advances in 
bioinformatics that make this knowledge useful for drug development will 
make it useful for PGD and on a cost-effective basis: 
In the future it should be routinely possible for parents to 
have their 'embryos automatically screened for a wide variety 
of disorders, and those with the "right" genes implanted in 
the mother's womb . . . .  Geneticist Lee Silver paints a future 
scenario in which a woman produces a hundred or so em­
bryos, has them automatically analyzed for a "genetic pro­
file," and then with a few clicks of the mouse selects the one 
that not only lacks alleles for single-gene disorders like cystic 
fibrosis, but also. has enhanced characteristics, such as height, 
New Genetic Age, 8 B.U. J. SCI, & TECH. L 306, 322 (2002) (discussing the high costs of genetic tests 
for breast cancer and Canavan disease resulting from the monopoly rights awarded to the patent hold­
ers); James Donahue, Note, Patenting of Human DNA Sequences-Implicptions for Prenatal Genetic 
Testing, 36 BRANDEIS J. FAM. L. 267, 282 (1997-1998) ("Nevertheless, the patenting of human DNA 
sequences will have a profound effect on the lives of nearly every American."). 
. 363 See Nunnally, supra note 362, at 324; Snake Oil, supra note 5, at 38-39 (stating "Legal liabil-
ity is simply too crude an instrument for responsible integration of predictive genetic testing into health 
care . . . .  "). 
364 s d' · 5 d · ee JscussJon supra note an accompanymg text. 
365 See discussion supra note 5 and accompanying text. 
366 s d' · 5 d · ee JscussJon supra note an accompanymg text. 
367 It is important to note that there likely will be varying commercial interests and commercial 
controls over this information, as reflected in the interests of AstraZeneca, Merck, Orchid Pharmaceuti­
cals, and other entities in the SNP Consortium. See discussion supra note 5 and accompanying text. 
368 See supra note 261 and accompanying text (addressing biobanking). 
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hair color, and intelligence.369 
"Ultimately" may prove to be years rather than decades. The pace of 
advancement of biotechnology over the last decade and of genomics over 
the last few years loudly cautions one to not assume the luxury of time. 370 
VII. A PROPOSED ROLE FOR MORE MEANINGFUL REGULATION OF ART 
There are ample reasons to embrace ART and to rejoice at the vitality 
of this sector, especially now as technology such as bioinformatics opens 
entirely new dimensions for science-namely the orchestrated intricacies 
of gene and protein function-and introduces potential to improve human 
health.37 1 ART already must be attributed with a dramatic increase in pro­
creative liberty: Annually, thousands of children who would not otherwise 
exist are being delivered to wanting parents.372 Also, through ART, many 
miscarried pregnancies and the associated trauma have been avoided.373 
Nevertheless, there are compelling arguments that support immediate 
infusion of comprehensive regulation into the field of ART. First, experi­
mentation on human subjects must be recognized as such and regulated 
accordingly.374 Controversies reported over the last several years have 
caused many to question the soundness of the United States' regulatory 
369 FUKUYAMA, supra note 6, at 75. Professor Silver "(e]ven contemplates a scenario in which 
society splits into two camps, the 'gen-rich' and the 'gen-poor,' those with and those without a designer 
genome." Michael Lemonick, Designer Babies, TIME, Jan. 1 1 , 1 999, at 66, LEXIS, News Library, 
Time File; see also LEE SILVER, REMAKING EDEN 1 99-203 (1997) (discussing the potential for POD to 
allow parents to screen virtual childmt in order to choose desired genetic characteristics). For further 
discussion on this, see MCKIBBEN, supra note 14, at 226-227. 
370 See supra notes 1 8, 275-76 and accompanying text. 
371 See generally discussion supra Part V. Genetic disorders occur in three to five percent of all 
live births. KEVLES, supra note 28, at 291 . This technology, if mainstrcamcd and used with a focus on 
human health certainly could make a meaningful difference, especially as genetic testing capabilities 
unfold :  
!d. 
The percentages may be small, but the absolute annual numbers suggest a wrenching 
magnitude of individual afflictions-in the United States, up to one hundred and 
sixty-five thousand abnormal infants, including from six to eight thousand with neu­
ral-tube defects like spina bifida, five thousand cases of Down's syndrome, fifteen 
hundred of cystic fibrosis, at least a thousand of sickle-cell anemia. 
372 According to data reported voluntarily and processed by the CDC, more than 35,000 babies 
were born as a result of ART procedures carried out in 2000. Technology Report, supra note 1 1 .  373 See, e.g. , Goldberg, supra note 7. 
374 See generally discussion supra Part IV. Orte might argue that experimentation on humans in­
volving genetics should trigger extra scrutiny given how the quest for understanding and controlling 
genes and the mission of improving the human condition have proven intoxicating rationales for the 
science and medical communities. See generally supra Parts II and III; cf. PAUL, supra note 13, at 2 
("Some people have recently questioned whether the reaction to Nazi crimes produced more than a 
temporary hiatus in eugenic theory and practice. . . . They fear that eugenics is back-in the benevolent 
guise of medical genetics.") (citation omitted). 
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regime to protect human subjects375 and prompted first the Clinton Admini­
stration376 and then the Bush Administration to declare their intentions to 
make the regime more reliable.377 Nevertheless, a baseline of regulations 
to protect human subjects through regulatory oversight of human experi­
mentation does exist.378 Ironically, this law, which evolved over time in 
response to Nazi eugenics and subsequent domestic human subject abuses 
such as the Tuskegee experiments,379 which expressly recognizes pregnant 
women, fetuses, and children as vulnerable groups in need of added protec­
tions,380 and which expressly imposes added protections for human in vitro 
fertilization, has not been meaningfully applied to ART.381 In the absence 
of application of these baseline safeguards, experimentation such as the 
early applications of ICSI and now aggressive drug therapy, cytoplasmic 
transfer, and perhaps even attempts at human cloning for reproduction382 
are being carried out on an immensely vulnerable patient group383 and at 
their significant personal financial expense and with great profitability to 
375 One of the most publicized controversies was the death of Jesse Gelsinger. See supra note 
235 and accompanying text; Jeffrey Brainard, Could Better Reports by Researchers Have Prevented a 
Clinical-Tria/ Death?, CHRON. HIGHER Eouc., Apr. 14, 2000, available at 
http://chronicle.com/pnnlweekly/v46/i32/32a0450l .htrn. Controversies in human subjects research 
continue to arise. See, e.g. , Alexander Otto, Researchers Under Criminal Investigation for VA Drug 
Study Deaths in N. Y. , BNA, INC., available at http:/lwww.researchprotection.org/ 
infomail/0203/06.html (last visited Sept. 18, 2003) (on file with the Connecticut Law Review) (report­
ing that two medical researchers are under criminal investigation for the deaths of at least five patients 
in dru¥, studies at the Stratton Veterans Affairs Medical Center in Albany, NY). 
6 See Press Release, Department of Health and Human Services, Secretary Shalala Bolster Pro­
tections for Human Research Subjects (May 23, 2000) [hereinafter DHHS Press Release], available at 
http://www.hhs.gov/newslpress/2000pres/20000523.html (last visited Sept. 1 8 ,  2003) (on file with the 
Connecticut Law Review); Shalala, supra note 235, at 809; Erica Rose, Financial Conflicts of Interest: 
How are we managing?, 8 WIDENER L SYMP. J. 1, 8 (2001 )  (discussing the expectation that NIH and 
FDA would develop joint conflicts of interest policies). 
377 See discussion supra notes 235-36; Jeffrey Brainard, New Human Subjects Chief Will Face 
Challenges and OJntroversies; Agenda May Include Protections for Embryos, Self-Regulation, and 
Unfinished Business, CHRON. HIGHER Eouc., Nov. 22, 2002, at A25 (mentioning that the Bush admini­
stration is likely to expand human-subject protection). 
378 See generally Malinowski & Rose, supra note 174, at 9-4 (stating that "regulatory schemes . .  
. include safeguards to ensure that the rights and interests of individual patients are not sacrificed for 
the advancement of medicine."); PROTECTING THE PEOPLE, supra note 1 62, at 20 (explaining that 
federal jurisdiction over human subject research extends to research that is conducted or supported by 
the federal government, and to research that is regulated under a federal statute). 
379 See generally discussion supra Part IV. 
380 45 C.F.R. §§ 46. 1 l l {b), 46.20 1-.207 (2002); 2 1  C.F.R. 56. 1 1 1 (b) (2003). 
38 1 See generally discussion supra Part VI. 
. 
382 See Today: Panos Zavos Discusses the Controversial Cloning for the First Human Baby 
(NBC television broadcast, Aug. 13,  2002); Sunday Morning: French Chemist Claims to Have Pro­
duced the First Human Clone (CBS television broadcast, Dec. 29, 2002). See generally CLONE, supra 
note 12 ("A highly controversial effort is underway to produce children by cloning."). 
383 See supra notes 226-27 and accompanying text (added protections for pregnant women and 
embryos under the Common Rule). 
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those engaged in providing ART services.384 
Second, action must be taken to ensure good medicine practices are 
developed and adhered to especially given the vulnerability of this patient 
group,m commercial influences,386 and the temptations to overuse emerg­
ing science prematurely.387 The well-documented tre�d of multiple ART 
births-the CDC estimates thirty-five percent of ART deliveries388 and 
some estimates exceed forty percent of ART pregnancies389-and, conse­
quentially, tens of thousands of premature deliveries resulting in often seri­
ously unhealthy babies390 is ample reason to take this action. In addition, 
known experience to date with ART includes the unchecked introduction 
of techniques such as ICSI, 391 ongoing experimentation with cytoplasmic 
transfer,392 and the brazen declarations of Dr. Panos Zavos and the Raelians 
of their intentions to clone humans.393 · Moreover, ART is a field that has 
expanded explosively during the last decade, and especially in recent years. 
Its detonation synchronized with the launch of the genetics revolution and 
a jolting shift of biomedical research into commercialization and privatiza­
tion of even basic research through academic-industry collaborations and 
the proliferation of hundreds of private biotechnology companies.394 This 
384 See supra notes 278-80 and accompanying text. 
385 This vulnerability has been recognized and codified under United States Jaw. 46 C.F.R. §§ 
46.201 -.207; see also supra notes 226-27 and accompanying text. 
386 See Kolata, supra note 1 0  (discussing the competitive fertility clinic market and the strategies 
some clinics are using to attract clients). · 
387 See generally Botkin, supra note 280, at 288 (proposing professional standards, but as op­
posed.to regulation or other law). But see David Wasserman, A Choice of Evils in Prenatal Testing, 30 
FLA. ST. U. L. REv. 295, 3 1 3  (2003) (preferring unrestricted parental choice rather than making medi­
cal choices about testing options); Making Babies, supra note 6 (mentioning that the ART industry has 
consistently resisted regulation). 
· 388 This estimate is based upon data submitted voluntarily by ART clinics. See supra note 1 1  and 
acco�anying text. 
3 9 See Making Babies, supra note 6 ("In many leading fertility clinics, nearly 50 percent of all in 
vitro treatments of women under 35 result in multiple births . . . .  ") 
390 Jd.; see also Preemies, supra note 1 1  (discussing the health problems premature infants face 
due to their underdeveloped organs and immune systems). 
39 1 See supra notes 323-24, 345-39 and accompanying text. 
392 See supra note 350 and accompanying text. 
393 See supra notes 320, 382 and accompanying text. 
394 See generally Market Implications, supra note 5, at 33 (predicting that the increased pressure 
the biotechnology industry faces will lead to increased risks for human subjects). In September 2003 , 
NIH announced a multi-billion-dollar commitment to integrate academia and commercial application 
yet further. See supra note 252. For information about these companies and the commercial application 
of biotechnology by multinational sectors such as pharmaceuticals and agriculture, visit the sites of the 
Biotechnology Industry Organization ("BlO"), the major biotechnology trade association, at 
http://www.bio.org (last visited Sept. 24, 2003) (on file with the Connecticut Law Review), and the site 
of the Pharmaceutical Research and Manufacturers Association ("PhRMA"), the multinational 
pharmaceutical trade association, at http://www.phrma.org (last visited Sept. 24, 2003) (on file with the 
Connecticut Law Review). See also Genomics Players: From Discovery to Integration-Business and 
Technology Assessment, 2002, M2 PRESSWJRE, Feb. 1 9, 2003, LEXIS, News Library, M2pw file (dis-
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emergence was recent enough to escape meaningful self-regulation by the 
medical profession, the mechanism traditionally relied upon heavily to 
ensure quality medical care, for the spread of managed care and the con­
solidation and for-profit conversions of health care institutions throughout 
the 1 990s has weakened that mechanism immensely.395 Also, managed 
care has grown in conjunction with ART, but as an accompaniment rather 
than as a mechanism for control, for ART draws patients willing to pay out 
of pocket.396 As stated previously, no state has fully implemented the 
CDC' s  Model Legislation for regulation of ART, and professional certifi­
cation and licensing are not prerequisites to provide ART in the direct-pay, 
private market that is driving these services. In addition, ART introduces 
complicated patient care issues, especially for a generation of health care 
providers grappling with the novelty of contemporary, dynamic genetic 
medicine.397 Advances in genetics are permeating throughout the practice 
of medicine.398 At least according to the perception of a significant portion 
of the general population, standard of care has expanded to encompass 
cussing new business models and profiling key bioinfonnatics cof11Janies and estimating that the bioin­
formatics market, valued at $360 million in 1 999, will surpass $2 billion by 2007); FUKUYAMA, supra 
note 6, at 214 ("The U.S. biotech ind1,1stry by itself spent nearly $1 1 billion on research in 2000, em­
ploys over 1 50,000 people, and has doubled" over the last decade). 
395 In fact, the control held by care managers has inspired a flurry of legislative initiatives, state 
and federal, ranging from prohibitions on ''gag rules" to review of coverage denials by independent 
third party bodies and a range of "patient bill of rights" protections. For example, California has ere­
. ated a Department of Managed Healtl:t Care to oversee private managed care organizations, including 
HMOs. See Department of Managed Health Care, at http://www.hmohelp.ca.gov (last visited Mar. 23, 
2003) (on file with the Connecticut Law Review). As observed by Daniel Callaghan ·and Mark Han-
son: 
(w]hile medicine still has the capacity from within significantly to determine its own 
course, it is highly influenced by the mores, values, economics, and politics of the 
societies of which it is a part. The border between the realm of medicine and the 
realm of society is increasingly porous. Medicine is fed by the large amounts of 
money spent by government and private industry, and no less by the power of adver­
tising and the media, as well as popular tastes, fantasies, and desires. 
GoALS, supra note 224, at 13 .  396 But see Adamson, supra note 21 ,  at 934 (stating "[ o ]ther mandatory nonmedical regulations 
include insurance company, HMO, and other healthcare organization requirements" and then relying on 
examples drawn from Massachusetts, one of the few states that legislatively require IVF coverage by 
insurers). 391 See ge11erally MARY 8. MAHOWALD ET AL., GENETICS IN THE CLINIC: CLINICAL, ETHICAL, 
AND SOCIAL IMPLICATIONS FOR PRIMARY CARE (Liz Fathman ed., 200 I )  [hereinafter GENETICS IN THE 
CLINIC] (aiming to assist primary caregivers with the needed integration of genetics into their routine 
practice). "Specialists in genetics are needed for the education of primary care physicians, who will be 
responsible for providing established medical genetics practice." !d. at xi; see also Snake Oil, supra 
note 5, at 45 ("Ultimately, application of [predictive genetic testing] is patient-specific."). 398 FUKUY AMA, supra note 6, at 72-83 (discussing existing and potential medical advances in­
volving genetics); GENOMICS AND WORLD HEALTH: REPORT OF THE ADVISORY COMMITTEE ON 
HEALTH REsEARCH 5 (World Health Organization 20;02), available at http://www.who.int ("It is now 
believed that the information generated by genomics will . . .  have major benefits for the prevention, 
diagnosis and management of many diseases which hitherto have been difficult or impossible to con­
trol.") (last visited Sept. 24, 2003) (on file with the Connecticut Law Review). 
2003] OUR EUGENICS PAST-PRESENT. AND FUTURE? 201 
advanced clinical trials,399 and the probabilities introduced by the results of 
genetic screening pose an interpretation challenge for providers and pa­
tients accustomed to the definitive results of traditional diagnostics.400 Re­
alizing informed consent under such circumstances poses an ominous chal­
lenge in many cases,401 which has proven a chronic focus of ongoing mul­
tidisciplinary debate.402 
399 Institutional Conflicts, supra note 19, at 53-54 (discussing the public's perception of clinical 
research as offering the most innovative treatment options). For identification of ongoing clinical trials, 
visit http://clinicaltritls.gov (providing details on approximately 8,400 mostly government-funded 
clinical trials) (last visited · Sept. 24, 2003) (on file with the Connecticut Law Review); 
http://cancer.gov/clinicaltrials (giving the National Cancer Institute's clinical trial listing) (last visited 
Sept. 24, 2003) (on file with the Connecticut Law Review); htt])://aidsinfo.nih.gov (the AIDS clinical 
trials information service ("ACTIS")) (last visited Sept. 24, 2003) (on file with the Connecticut Law 
Review); http://www.veritasmedicine:com (discussing trials and standard treatments for numerous 
.diseases) (last visited Sept. 24, 2003) (on file with the Connecticut Law Review); 
http://www.americasdoctor.com (trials in seven disease categories, excluding cancer) (last visited Sept. 
24, 2003) (on file with the Connecticut Law Review); and http://www.acurian.com/patient (developing 
lists oftrials in various disease categories) (last visited Sept. 24, 2003) (on file with the Connecticut 
Law Review). 
400 MAHOWALD, supra note 397, at 2 (discussing the difficulties facing clinicians with regard to 
communicating genetic diagnoses, "(g}ood news does not preclude a bad outcome and vice versa"). As 
stated by author Dani.el Kev1es! .. . . . 
· 
The advance of genetic kilowledge has already increased the range of medical and 
procreative opportunities, and the choices raised by their advent can be discomfiting. 
Genetic screeners worry that the publicity given screening programs may cause 
needless apprehension among people whoin the roll of the genetic dice has favored, 
and that the genetic information obtained may lead to unreliable anxiety among 
those whom it has not. Many more genetic diseases can now be identified than can 
be cured or even treated. . . . The revelation of genetic hazard has been observed to 
result not only in repression but in anxiety, depression, and a sense of 
· stigmatization. 
Some genetic counselors report that their patients show no difficulty in compre­
hending the information they are given, but various studies by psychologists and 
psychiatrists have concluded that a large fraction of counselees are likely not to un­
derstand, assimilate, or remember analyses relevant to their own genetic constitu-
tions. 
· 
KEVLEs, supra note 28, at 297-98 (citations omitted); see also PRIMER, supra note 2, at 15 1  ("At pre­
sent, however, there are only about one thousand genetic counselors in the United States, most within 
university centers. The general population will seek help in interpreting genetic tests from their pri­
mary care physicians. . . . Is there hope that physicians will be able to achieve this knowledge?"). 
401 See generally Fleetwood, supra note 233 (arguing that patients are rarely informed of or pro­
tected against a doctor's conflict of interest); MAHOWALD, supra note 397 (analyzing the issue of 
informed consent in a variety of circumstances). 
1 402 See, e.g., Ruth Chadwick, THE ETHICS OF GENETIC SCREENING at xv (Ruth Chadwick et al. 
eds., 1999) (highlighting projects to raise public awareness of genetic screening); Ruth Chadwick et al., 
Genetic Screening and Ethics: European Perspectives, 23 J. MED. & PHIL. 255 ( 1 998) (highlighting 
projects to raise public awareness of genetic screening); Mark A. Rothstein & Sharona Hoffman, Ge­
netic Testing, Genetic Medicine, and Managed Care, 34 WAKE FOREST L. REv. 849 (1999) (maintain­
ing that increased patient education is necessary); Sonia M. Souter, The Routinization of Prenatal 
Testing, 28 AM. J.L. & MED. 233 (2002); NUFFIELD COUNCIL ON BIOETHICS, GENETIC SCREENING 
ETHICAL IsSUES at i-ii ( 1993) available at http://www.nufieldbioethics.org/filelibrary/pdf/ 
genetic_screening.pdf (arguing for increased patient consideration of moral implications of prenatal 
testing) (last visited Sept. 18, 2003) (on file with the Connecticut Law Review). 
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Third, additional regulatory safeguards must be introduced to effec­
tively regulate ART as an alternative to categorically prohibiting ongoing 
stem cell and other tissue research-for example, through express prohibi­
tions on therapeutic cloning or protections for embryos that accomplish the 
same.403 According to Nlli, one in three Americans have health conditions, 
many life-threatening and highly debilitating, that could be improved 
through this research, and others have reported that number to be as high as 
one in two Americans.404 Regulatory oversight and control over assisted 
reproduction with perhaps criminal penalties for violations would provide 
some assurance that techniques · perfected through therapeutic cloning 
would not have immediate carryover into the "wild, wild West" of medi­
cine.40s 
Fourth, meaningful regulation is a prerequisite for full observation, ac­
countability, societal reflection, and collective, democratic decision­
making. 406 Genetic manipulation in procreation, even at the level of ge­
netic screening and embryo selection, is ·something that we as a society 
should know about and contemplate at least as it is transpiring, and pref­
erably beforehand. This is especially true in our aggressively competitive, 
· Darwinian society with its premium on perfection407 and its difficulties 
accepting people with observable health care challenges.408 The potential 
social ramifications of doing otherwise are well documented and all too 
vivid in our past.409 The opportunity to proactively consider social implica-
403 See Brainard, supra note 377, at A25 ("Any new director of [OHRP] will almost certainly 
have to be comfortable with extending regulations to protect embryos and fetuses, say several 
university officials involved in human-subjects protection."). But see generally KAss, supra note 356 
(suggesting non-technological ideas and practices are needed to prevent tragedy from biotechnology). 
For discussion of stem cell research and an overview of related moral and ethical problems, see gener­
ally THE NATIONAL REsEARCH COUNCIL, INSTITUTE OF MEDICINE, STEM CELLS AND THE fUTURE OF 
REGENERATIVE MEDICINE (2002) available al http://www.nap.edu/books/0309076307/html. 
404 See How to Build a Human: Predictor (BBC television broadcast, 2002). The potential of this 
area of science has inspired Stanford University to establish a new center for stem cell research. Ar­
guably, the mission of the center includes perfecting cloning techniques. William Kristol & Eric Cohen, 
.A Clone by .Any Other Name, WKLY. STANDARD, Dec. 16, 2002, at 9, LEXIS, News Library, Wklyst 
�L . 
40s See supra note 277 and accompanying text (George Annas quote). 
406 For discussion of the importance of this, see generally MCKIBBEN, supra note 1 4  (arguing de­
bate is needed regarding societal controls on genetic technology). 
407 See Coming into Being, supra note 9, at 15 17  ("The availability of prenatal genetic screening 
technology is likely to reinforce insecurities arising from our survival..of-the-fittest norms, and those 
same norms may compel prospective parents to act on the insecurity.") (citations omitted). 
408 Cf Haniet McBryde Johnson, Unspeakable Conversations Or How I Spent One Day as a To­
ken Cripple at Princeton University, N.Y. TIMES, Feb. 16, 2003, § 6 (Magazine) at 50 (providing the 
first-person narrative of attorney Harriet McBryde Johnson discussing Professor Peter Singer's support 
of infanticide and her visit to Princeton as his guest). 
409 See discussion supra Parts II and III. 
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tions and legalities including family law considerations4 10 accompanying 
use of this technology in a non-speculative manner will remain marginal­
ized unless use of ART is observed and fully reported. 
Fifth, and overshadowing each of the preceding reasons, we have a 
moral obligation to reflect on our not-too-distant eugenics past · and our 
· present tendency to make value judgments about the quality of the lives of 
people with visible differences.41 1  As stated by Nancy Gallagher, author of 
Breeding Better Vermonters: 
The boundary between private rights and the public inter­
est is a negotiable one . . . .  As eugenics sentiments emerge, as 
they frequently do, our best safeguard against the injustices 
of the past rests with our willingness to confront our connec­
tion to this history prior to disowning it and with our recogni­
tion of the enduring power of research fmdings and the con­
sensus of experts over perceptions of other people's prob-
lems.412 
. 
Through ART, procreative liberty is at a historical high.413 In the 
United States, procreative liberty generally is recognized as a valued prin­
ciple and often as a hard-earned right,414 which is at least a partial explana-
410 See supra note 1 2  and accompanying text (addressing the Buzzaca case and referencing the 
work of Janet Dolgin). For example, there has been a marked increase .in surrogacy arrangements in 
conjunction with usc of ART. · See supra note 12 an(J accompanying text. 
41 1  See generally Adrienne Asch, Reproductive Technology and Disability, in REPRODUCTIVE 
LAws FOR THE 1 990s (Sherrill Cohen & Nadine Taub eds., 1989) (arguing that women and people with 
disabilities have a common interest in ensuring biology is not controlling of life opportunities); Adri­
enne Asch, Disability, Equality, and Prenatal Testing: Contrqdictory or Compatible?, 30 FLA. ST. U. 
L. REv. 315  (2003) (concluding change is needed to make the climate in which prenatal testing takes 
place consistent with a society inclusive of the disabled); Johnson, supra note 408. "Human genetic 
engineering raises most directly the prospect of a new kind of eugenics, with all the moral implications 
with which that word is fraught, and ultimately the ability to change human nature." FUKUYAMA, 
supra note 6, at 72. 
4 12 GALLAGHER, supra note 24, at 8. 
413 See CARRICK, supra note 1 65, at 1 99 ("[N]evcr in human history has reproductive freedom 
been greater: we arc now providing a single person or a couple the leeway to choose not only with 
whom, but when, and by what means conception will take place."). 
4 14 As explained by Daniel Kcvlcs, although amniocentesis was developed in the 1 960s, there 
was little demand for it until the Supreme Court legalized abortion. Since Roe v. Wade in 1973, the 
number of women undergoing prenatal di�gnosis had continually grown, as have the kinds of fetal 
anomalies detected. KEVLES, supra note 28, at 257. Sirrrilarly, Daniel Callahan and Mark Hanson have 
observed that: 
modem contraceptives have brought about a striking change in the role of women 
and of procreation as a part of life. Genetic enhancements will add to those devel­
opments the prospect of manipulating fundamental human traits-improvements in 
intelligence and memory, and a reduction in violence, are among the speculative 
dreams-just as human growth hormone can already increase the height of those 
who, not abnormally short in the first place, want to be taller for personal or social 
reasons. 
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tion for the present dearth of regulatory oversight in the field of ART.415 
Another partial explanation is the premium placed on autonomy in health 
care decision-making, which also is rooted in libertarian ideals. 
Contemporary genetic medicine promises to add scientific substance 
and practicality to what eugenicists set out to accomplish at the outset of 
the 20th century-· . . improve the . human condition through genetic selec­
tion. 416 Given the now dominant ethos of autonomy and self-determination 
in medicine,417 which is underscored by the libertarian elements of United 
States culture, there is meaningful assurance that eugenics will not be im­
posed by a government body in the United States.418 However, we must at 
least recognize the danger that through ART,. the genetics revolution, and 
carte blanche procreative liberty we could do Unto ourselves via the collec­
tive impact of individual decision-making what governments have imposed 
in the past in the name ofbettering the human condition.419 In the context 
of ART, Ol,lf libertarian culture and the premium we place on procreative 
liberty must be tempered by social reflection.420 "Traditional medical eth-
GOALS, supra note 224, at 1 2. See generally THE CHOICES WE MADE, TWENTY-FIVE WOMEN AND 
MEN SPEAK OUT ABOUT ABORTION {Angela Bonavoglia ed., 2001 ) (discussing the increasing power of 
women resulting from reproductive freedom). 
415 Some commentators, including Daniel Kevles, believe that the role for law in procreation will 
remain minimal: 
· · The willingness of individuals to use rapidly developing genetic and reproductive 
knowledge may have more subtle effects. Genetic screening and counseling, amnio­
centesis and abortion, and attempts at genetic therapy will probably long remain 
matters of private, voluntary choice, to be arrived at by consultation between indi­
vidual families and their physicians. 
KEVLES, supra note 28, at 300 (addressing the private-public tension over the introduction of advances 
in human genetics). 416 See generally discussion supra Part II. 
417 See supra note 228 and accompanying text (the ethos trilogy). 
4 18 See KEVLES, supra note 28, at 300; discussion supra Part IV. 
419 See PAUL, supra note 13 ,  at 1 35 (discussing past projects in compulsory sterilization and Nazi 
breed in* programs). 42 See FuKUYAMA, supra note 6, at 99-100, 102 {"What is ultimately at stake with biotechnol­
ogy is . . .  the very grounding of human moral sense . . .  .if so, we need to accept the consequences of 
the abandonment of natural standards for right and wrong."). See generally McKlBBEN, supra note 14 
{arguing that debate is needed regarding societal controls on genetic technology); Suzanne Holland, 
Selecting Against Difference: Assisted Reproduction, Disability and Regulation, 30 FLA. ST. U. L. REv. 
401 (2003) (arguing that social obligations, including obligations to vuJnerable populations, check the 
right to reproduction); Mary B. Mahowald, Aren 't We All Eugenicists? Commentary on Paul Lom­
bardo 's "Taking Eugenics Seriously", 30 FLA. ST. U. L REv. 219, 224 n. 22 (2003) ("our ongoing 
relationships to others are inseparable from our �&utonornous decisions"); Dolgin, supra note 12, 
(concluding that prospective parents should understand the moral complications that go with prenatal 
genetic testing). 
As even proponents acknowledge, the line between repair and enhancement is too 
murky to be meaningful. Soon you're headed toward a world where Kathy's lungs 
work fine [even though she has cystic fibrosis], but where her goodness, her kind­
ness, don't mean what they did. Where someone's souping up her brains or regulat­
ing her temper, not just clearing up her mucus. 
Nicholas D. Kristof, The New Eugenics, N.Y. TIMES, July 4, 2003, at A21 .  
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ics . . . has relied on principles other than utility in determining what is and 
is not ethically appropriate in the practice of medicine in the research and 
therapeutic settings," and such must be the case with ART.421 The eugenics 
implications of ART underscore the proposals made .above to protect pa­
tients who participate in experimental procedures �d to ensure the practice 
of good medicine in the field. At the very least, eugenics considerations 
prioritize the need to ensure that ART, now a largely private endeavor, is 
practiced within full view of the general public and subject to related scru-
tiny.422 . 
The social impact of combining ART and broad gen�tic screening 
could prove profound, especially if that happens quickly. Arguably, there 
is a moral imperative to not assume the luxury of time. 423 Given experi­
ence with assisted reproduction over the last several decades,424 we should 
anticipate that, assuming availability, prospective parents will utilize PGD 
to the fullest extent their financial means allow. Present cultural and scien­
tific trends support this assumption. For example, consider the competition 
among upper and even middle-class families to get their children into the 
"right" preschools-the "Baby Ivies"-and elementary schools in order to 
give them early advantages in life, resulting in waiting lists for some of 
these schools nearly reaching back to the child's conception and regardless 
of the extraordinary tuitions they charge. 425 Now consider that, with dis-
421 PRIMER, supra note 2, at 1 93. But see Palmer, supra note 289, at 263 (concluding that legisla­
tures and liability doctrine development should guide genetic research). 
422 CARRICK, supra note 1 65, at 2 1 1  {emphasizing the need for an informed public). 
423 Cf Snake Oil, supra note 5, at 39-41 (describing parents need to camp-out to enroll their chil-
dren in preschool). · 
424 GOALS, supra note 224, at 3 1  ("The use of medical skills for family planning purposes (which 
may, but also may not, have direct health purposes), including contraception and sterilization as well as 
abortion, is now well accepted throughout much of the world."). 
425 See Anne Marie Owens, A Child 's Future is Set by Nursery School: Forget the Rich and Fa­
mous. In Manhattan, .the Directors of Pre-Schools Have Beco.me the New Power Brokers, NAT' L POST, 
Mar. 8, 2003, available. at 2003 WL 14864604 (describing coffipetition to get into preschools in Man­
hattan, including planning at birth); Elaine Rivera, An Eye-OJ)etling Experiencefor Parents; In Compe­
tition for Preschool Slots, Restless Camp-Out Ends with Handful of Victors, WASH. POST, Feb. 3, 2003, 
at 803, 2003, LEXIS, News Library, Wpost File {descnbing parents need to camp-out to entoll their 
children in preschool); Marco R. della Cava, Parents and Preschool: Schmooze or Lose, USA TODAY, 
Aug. 28, 2002, at I D, LEXIS, News Library, Usatdy File (noting that demand for expensive preschools 
has increased across the country); Mary McNamara, Southern California Living: Learn, Baby, Learn as 
More Kids than Ever are Identified as "Gifted" the Programs Designed to Teach Them are Becoming 
Ever More Complex, L.A. TIMES, Apr. 1 ,  200 1 ,  at E l ,  LEXIS, News Library, Lat File (describing 
parents efforts to get their children into nursery school); Claire Martin, A Tense Time for Parents Has 
Implications for Their Children That May Last a Lif�time, DENVER POST, Jan. Z1 , 2001 ,  at F-0 1 ,  
LEXIS, News Library, Dpost File (describing the lengths that parents go to enroll children during 
Denver's open school enrollment); Maureen Freely, Creche Course, TIMES (London), May 28, 2000, 
LEXIS, News Library, Ttimes File. Some parents even are paying thousands of dollars (hourly rates of 
$300 an hour and $3,000 package services) to private school advisors. Jane Gross; Right &hoolfor 4-
Year-Oid? Find an Adviser, N.Y. TIMES, May 28, 2003, at A t .  But see Pinker, supra note 21 
206 CONNECTICUT LA W  REVIEW [Vol. 36: 125 
covery that there are only about 30,000 genes in the human genome and 
with bioinformatics capabilities in hand, the research community is work­
ing on a more intricate level, which includes identifying and valuing even 
slight genetic variations such as SNPs. 426 Given the human complexity and 
variation attributable to-such a small number of genes� it appears likely that 
genes multitask exponentially more and are much more responsive to envi­
ronmental stimuli than previously appreciated. It also is likely, therefore, 
that the result of genomics and proteomics will be a multitude of identified 
genetic factors that will generate an exponentially greater magnitude of 
individually minute probabilities made manageable for extensive PGD and 
other health care use through bioinformatics.427 Experience with genetic 
testing to date suggests that these PGD results, in spite · of their intricacy 
and lack of defmitiveness, may translate into parental expectations.428 If 
difficult choices have to be made among embryos, why not make them 
with this added information? So now (or yesterday) is the time to ponder 
questions such as how broad PGD may impact the best interests of chil­
dren.429 Prospective parents and their resulting children may get what the 
parents wish for, but one commentator warns, "Recall the mouse whose 
intelligence was genetically boosted . . .  but which seems also to have felt 
greater pain as a result.'t430 - Also, presumably market forces will drive 
competing parents to utilize the same technology even though many of the 
prizes sought-for example, the limited admission tickets into the most 
prestigious schools-will remain the same regardless of PGD, meaning 
(suggesting that genetic enhancement is not likely in our lifetimes because people will be rational about 
limitations of the technology and will not be as receptive to it as some anticipate). 426 . 0 0  Se� supra note 256 and accompanying text (SNPs references); PRIMER, supra note 2, at 149-
50 ("More and more information is available concerning our genetic makeup and the diseases that 
result from genetic malfunction . . . .  Not only will testing for diseases that may occur later change the 
practice of medicine; predictive pre-symptomatic testing is expected to become 'a boom industry."'). 427 See supra notes 1 7, 238, 245, 253, 254, 264, 360, 369 and accompanying text (bioinformatics 
references). 
0 -. 
428 "Genetic modification is mo� like giving your child a tattoo that she can never subsequently 
remove and will have to hand down not just to her own children but to all subsequent descendants." 
FUKUY AMA, supra note 6, at 94; see also ROBERT J. MOSS ET AL., Genetic Testing as a Family Affair. 
in GENETICS IN THE CLINIC, supra note 397, at 1 97 (warning that prenatal genetic testing may distort 
parent-child or sibling-sibling relationships). 429 Professor Wins lade and Judith Ross observe that the best interest of the child is seldom con-
sidered by those providing ART services: 0 
Born into a society that is already fragmented by divorce and confused about alterna­
tive life styles, morals and sexual choices, the child may well have serious identity 
problems at a later time. Does such a possibility have to be seriously con,idered by 
those who want to undertake unusual reproductive methods . . . ? 
The interests and well-being of the baby-to-be-made seem to be the last issues con­
sidered, and sometimes (when physicians promise anonymity to the donor or parents 
require it of the surrogate) seem not to be considered at all. 
MCCORMICK, supra note 308, at 171 .  430 FUKUY AMA, supra note 6, at 92. 
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more tension for all.431 Alternatively, will prospective parents who condi­
tion procreation on aggressive control over the genes of their offspring 
prove less inclined to assume and exercise responsibility for the resulting 
child when characteristics they do not desire materialize, or when charac­
teristics they invested in prove rnissing?432 Again, in the vast majority of 
instances, it is likely that PGD will offer lots of probabilities and very few 
medical certainties. How will parental choices based on PGD impact other 
children, perhaps including preexisting children in the same family who 
possess characteristics the parents choose to avoid in subsequent progeny? 
When the price of PGD drops low enough to make the technology standard . 
care--and the pace of advancement of bioinforrnatics suggests it will and 
perhaps more quickly than many estimate433-will the pressure to have a 
baby as healthy and desirable as medically possible actually compel pro­
spective parents to use PGD even · "beyond their levels of comfort­
meaning, ironically, could PGD become an imposition and reduce the free­
dom of parents to choose?434 
43 1 "Another important type of negative externality is related to the competitive, zero-sum nature 
of many human activities and characteristics. . . . People want smarter kids so that they will get into 
Harvard, for example, but competition for places at Harvard is zero sum." I d. at 97. 
432 See In re Marriage of Buzzanca, 72 Cal. Rptr. 2d 280, 293 (Ct. App. 1998). As Francis Fuku­
yama observes, the decision recognized that: 
Children who are the subjects of genetic mOdification, obviously without consent, 
are the most clear class of potentially injured third parties. . . . Libertarians argue 
that since the vast majority of pltrents would want only what is best for their chil­
dren, there is a kind of implied consent on the part of children who are the benefici­
aries of greater intelligence, goOd looks, or other desirable genetic characteristics. 
FUKUY AMA, supra note 6, at 93. As explained by Diane Paul, "A spate of recent books and articles has 
warned of eugenics as the unintended result of individual choices. On this view, the greatest danger 
arises not from coercion but its reverse: our enhanced ability to choose the kind of children we want." 
PAUL, supra note 13, at 4. See generally TROY DUSTER, BACKDOOR TO EUGENICS ( 1 990) (warning of 
serious s ocial consequences arising from eugenics). Parental choice may prove disparate from the 
interests of children and society as experience to date substantiates: 
Cultural norms may also lead parents to make choices that harm their children. 
One example was alluded to earlier, the use in Asia of sonograms and abortion to se­
lect the sex of offspring. In many Asian cultures, having a son confers clear cut ad­
vantages to the parents in terms of social pre�tige and security for old age. 
FUKUY AMA, supra note 6, at 96. But see Wasserman, supra note 387, at 313 (stating that "the tendency 
to treat children as commOdities will be largely offset by the transformative effect of actually raising 
them'2· 
33 "Designer babies will be expensive at first and an option only for the well-to-do. Whether 
having a designer baby will ever become cheap and relatively popular will depend on how rapidly 
technologies like preimplantation diagnosis come down the cost curve." FUKUY AMA, supra note 6, at 
80. But see PRIMER, supra note 2, at 152 ("Will genetic testing and the ability to combat some future 
genetic anomaly be available to uninsured persons? Underlying every advance in health care technol­
ogy should be the realization that more than forty million people in the United States have limited 
access to health care."). 
434 It is misguided to assume that parental interests and the best interests of their offspring will 
be harmonious: 
Policy makers generally assume that individual and social interests are congruent, 
that families will act 'rationally.' . . . As we have seen, the assumption that normal 
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Deference to practice of medicine is very vivid in Roe v. Wade435 and 
the recent late-term abortion case, Stenberg v. Carhart.436 That said, 
women would have a right to terminate and procreate independent of ART 
and to utilize ART. Introduction of a reliable regulatory baseline in the 
practice of ART with the express objectives of ensuring good medicine, the 
safety of women, and public accountability of those who perform ART and 
their practices would not constitute an undue burden. While an early term 
abortion is safer for women than carrying the child and delivery, aggressive 
ART is not safer for women than no ART for it encompasses often intense 
use of fertility drugs and often results in multiple pregnancies and un­
healthy children.437 In addition to protecting the health of women, the state 
certainly has a recognizable interest in the latter.438 
Moreover, the social implications of PGD extend beyond the prospec­
tive parents who choose to utilize this technology and their families. The 
combination of genetics and ART will affect us economically, politically, 
and culturally.439 At the commencement of HGP, Nobel Laureate James 
Watson, co-discoverer of the double-helix structure of DNA and HOP's 
first director, raised this caution: 
The power of the information to be gained from mapping and 
sequencing projects raises concerns about how it will be 
people will do what they can to avoid the birth of children with disabilities has a 
long history . . . .  Subtle pressures to make. the 'right' choice are what many people 
have in mind when they characterize contemporary genetic medicine as a form of 
eugenics. Of course many women welcome the opportunities to learn more about 
their fetus and to act on the results. But some women also feel that they have no re­
alistic alternatives to the decision to be tested or to aport a genetically imperfect fe­
tus. Of course they are under no legal coercion. But they may nevertheless feel 
pressured to be tested and avoid haVirig children with disabilities-by their doctors, 
who fear being sued if the child is born with a genetic disorder, by anxiety over the 
potential loss of health or life insurance, by their inability to bear the enormous fi­
nancial costs of caring for a severely disabled child, or by the lack of social serVices 
(even with national health insurance) for handicapped children. 
PAUL, supra note 13, at 1 32-33 (citations omitted); cf KAss, supra note 356, at 130. 
435 410 U.S. 1 1 3, 140-44, 148-50 (1973) (relying on medical proee4ures and the position of the 
AMA). 
436 530 U.S. 914, 930-38 (2000) (discussing the amici curae brief by the American College of 
Obstetricians and Gynecologists). 
437 See, e.g., supra notes 341 (implantation of multiple embryos), 344 (multiple pregnancies), 353 
(hormone injections) and accompanying text. Clinical studies have raised concerns about consumption 
of hormones to offset effects of rpenopause. National Cancer Institute, Cancer Facts: Menopausal 
Hormone Use: Questions and Answers, at http://www.cancer.gov/newscenter/estrogenplus (last visited 
Oct. 27, 2003) (on file with the Connecticut Law Review). The maturation of the first critical mass 
generation of ART mothers could trigger significant, yet undiagnosed, human health problems. 
438 Roe, 4 1 0  U.S. at 150. See generally supra note 8 and accompanying text. 
439 FuKUY AMA, supra note 6, at 83 ("[H]uman nature is fundamental to our notions of justice, 
morality, and the good life, and all of these will undergo change if this technology becomes wide­
spread. "). See generally Symposium, Genes and Disability: Defining Health and the Goals of Medi­
cine, 30 FLA. ST. U. L. REv. 1 91 (2003) (examining the ethical and social considerations of genetic 
medicine). 
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used. There is no avoiding the fact that arguments drawn in 
part from eugenics have been politically nusused in the past, 
most egregiously by the Nazis but also elsewhere in Europe 
and North America. Indeed the specter of coercive govern-
ment eugenics programs persists even today in the statutes 
still on the books in several nations . . . .  The only way to en-
sure that history does not repeat itself is for the scientific and 
medical communities to remain constantly vigilant for abuses 
of genetics.440 
209 
As suggested by scholars such as Adrienne Asch and EEOC Commis­
sioner Paul Miller well before the advent of bioinformatics and completion 
of a draft map of the human genome, a proliferation of genetic information 
will change attitudes toward.s life, death, and disability:441 
'' ·� . . . . 
[I]n the future, how will we look upon those who have ge­
netic defects? At present, we tend to sympathize with people 
who ·have genetic defects am� offer compassionate care. . . . 
In the future, however, will we be as concerned about people 
with disabilities if we .think their disability could have been 
avoided?442 
Also, recall that one of the guidin$ rationales for the early eugenics move­
ment was to lessen financial and medical demands on society, especially 
during the Great Depression.443 The financial pressures introduced by the 
� . 
. 
. 
James D. Watson, & Robert Mullan Cook-Deegan, The Human Genome Project and Interna-
tional Health, 263 JAMA 3322; 3324 (1990). "[T)he )Jrgest amount of money ever allocated for bio­
ethical research (5 percent of the annual HGP budget), signals ari admirably responsible public admis­
sion of the likely hornets' nest of problems that the HGP will unleash." CARRICK, supra note 165, at 
210. See generally WATSON, supra note 20 (offering an historical overvi�w of the discovery of DNA 
and the �enetics revolution). · ·. · ·  . · . ' 44 For references to Adrienne Asch's work, see iupra note 4i 1 .  See, e.g. , Paul Steven MiJier, 
Genetic Discrimination in the Workplace, 26 J.L. MED. & ETHICS 18,  1 89-90 (1998) (outliniqg grow­
ing concerns about discrimination based on genetic information); Paul Steven Miller, Is There a Pink 
Slip in My Genes: Genetic Discrimination in the Workplace, 3 J. HEALTH CARE L. & POL'Y 225 
(2000). See also Paul Steven Miller, AJtalyzing Genetic Discrimination in the Workplace, Remarks at 
the EINSHAC Int'l Working Conversation on Enviro/Genetics Disputes and Issues (July 200 1), in 
HUMAN GENOME NEWS, Feb. 2002, · at 9, available at http://www.oml.gov/hgmislpublicat 
/hgnlvl 2n l/09workplace.html (last visited Sept. 24, 2003) (on file with the Connecticut Law Review); 
Paul Steven Miller, O�metic Discrif!lination in the Workplace; 3 GENETICS MED. 1 65 (2001), reprinted 
in AAPD NEWS, June 2001, at 8 (providing a description of the first genetic discrimination lawsuit 
settled by the EEOC); Paul Steven Miller, Coming Up Short: Employment Discrimination Against 
Little People, 22 HARV. C.R.-C.L. L. REv. 23 1 (1987) (suggesting legal strategies for overcoming 
emplo�t discrimination against short people). 
PRIMER, supra note 2, at 1 52. 
443 See supra note 61 and accompanying text. As explained by Diane Paul, 
When asylums were first established in the mid.nineteenth century, the ''feeble­
minded" were thought to be trainable, and their education was stressed. Later in the 
century they came to be viewed as objects of pity, in need of protection from an of­
ten cruel world. By the tum of the twentieth century, they were perceived as a social 
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genomics revolution over the next few decades may prove unprecedented, 
for our graying population#$ will continue to increase and demand the 
forthcoming· generation of much more precise and expensive phannaceuti­
cals.445 Genetic precision will fracture traditional disease . classifications 
and markets, introduce genetic profiling and monitoring services and added 
demands on health care providers, and generally add complexitY and raise 
costs446-at least until the advent of cures through gene therapies.447 An 
increasing number of Americans with no insurance or who are underin­
sured and general exacerbation of health care fmance tensions, may lesson 
collective social tolerance for those born with health conditions presumed 
preventable through PGD and raise expectations that prospective parents 
menace and drain on the public purse. Over time, noble sentiments came increas­
ingly to clash with economic demands. Chariiable impulses gave way to utilitarian 
practices, and the economic value of the inmates' work came more and more to be 
stressed. But despite their superintendents' best efforts, the asylums never achieved 
self-sufficiency. During the world economic crisis of the 1 930s, they everywhere 
came to be viewed as an unnecessary burden on society. And segregation gave way 
to compulsory sterilization. 
PAUL, supra note 13, at 134 (citation omitted). 
· 
444 See Scientific American Frontiers: Never Say Die (PBS television broadcast, 2000); How to 
Build a Human: Predictor, supra note 6; Tom Kirkwood, As Society Gets Older and Healthier a Survey 
Shows That-Far From Dreading Their Retirement, Young People Relish the Prospect: Why Age is All 
the Rage, EXPRESS, Apr. 4, 2001,  at 30, LEXIS, News Library, Xpress File ("Even without recent 
breakthroughs in understanding the ageing process, our lifespan is continuing to climb and shows no 
sign of stopping."). ·,· .•. 
445 See supra note 5 and accompanying text. 
446 See Noah, supra note 5, at 1 ,  4-1 1 ;  Market Implications, supra note 5 at 32-34 (detailing the 
impacts of pharmacogenetics on research, testing, labeling and marketing of new drugs). 
447 
' . ,  . 
' ' 
The announcement in 2003 that French researchers reported curing four boys of severe com-
.bined immunodeficiency ("SCIDs" or "bubble boy disease") was tempered following an announcement 
months later that some of the genes delivered ended up in the wrong places and caused two of the boys 
to develop leukemia. Jeffrey L. Fox, US Authorities Uphold Suspension of SCJD Gene Therapy, 21 
NATURE BIOTECHNOLOGY 217 (Mar. 2003) [hereinafter Suspension of S.CID Gene Therapy]; Paul 
Elias, New Gene Therapy Technique Shows Promise, Journal Says, at A06, DESERET MORNING NEWS 
(Salt Lake City, Utah), June 30, 2003, LEXIS, Ne-ws Ubrary, Desnws File; see also Andrew Pollack, 
Cancer Risk Exceeds Outlook in Gene Therap)', Studies Find, N.Y. TIMES, June 1 3, 2003, at A29 
("New studies suggest that gene therapy might have a greater chance of causing cancer than previously 
thought, adding to safety concerns that have troubled· the fledgling field."). However, 
[c]urrently, gene therapy is being used in an effort to treat approximately fifteen dis­
. eases. Researchers have identified up to five thousand genes that may be linked to at 
least fqur hundred diseases, including breast cancer, cystic fibrosis, Huntington's 
disease, and sickle cell imemia. Also, genetic screening tests are available or under 
development for many of these diseases, even though, tragically, no cures now exist 
for the vast majprity. 
CARRICK, supra note 165, at 208-09 (citation omitted). In February 2003, the National Institutes of 
Health Recombinant DNA Advisory Committee (''NIHRAC") and the Biological Response Modifiers 
Advisory Committee ("BRMAC"), an advisory panel of the FDA, recommended continuing suspension 
of X-lined SCID trials, but resuming others. Suspension of SCID Gene Therapy, supra, at 217; Jeffrey 
L Fox, FDA Panel Recommends Easing Gene Therapy Trial Limits, 21 NATURE BIOTECHNOLOGY 
344-45 (Apr. 2003). Also, an anno\lncement in June 2003 that a team of Japanese and Belgian scien­
tists had temporarily treated hemophiliac mice using just tiny fragments (nanoparticles) of the hepatitis 
B virus has renewed some enthusiasm. See Elias, supra. 
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will utilize this technology.448 Perhaps government policy will encourage 
"healthy choices" in procreation. In zero-sum health care fmance decision­
making, collective intolerance for procreation without genetic screening as 
preventive care is likely to shape health finance policy,449 meaning that 
there may be added costs to pay for choosing a PGD-free pregnancy. 
Although experience with eugenics during the first half of the twenti­
eth century may be cited as authority for the proposition that t:eproduction 
should remain a private affair free from ·government intrusion, that experi­
ence also is authority for the proposition that science may be used against 
people deemed less. desifaple-to the point of actually threatening their 
448 Priorities in health policy appear to have shifted: 
Whereas ethical questions in the past were directed toward medical procedures (for 
example, informed consent, transplantation of organs, and allowing patients to die), 
today and in the immediate future the more prominent ethical issues in health care 
will be social issues: why and how to provide health care for the poor, how to pre­
serve quality of eire in the face of government controls and fiscal constraints, how to 
preserve the values of medicine i!J the face of efforts to cqmmercialize health care, 
and how to choose which health · care services should be' covered from the many 
valuable services that are available. 
PRIMER, supra note 2, at xii. Some h!lve . asserted that a deluge of additional costs associated with 
medical innovation will force "economic triage" in heal� p�licy: 
' .. 
· 
As the limited supply, growing demand, and rising costs associated with many types 
of high-tech, life-sustaining therapies such as kidney dialysis, neonatal intensive 
care, and open-heart surgery become increasingly parasitic on our nation's economy, 
this conflict of duty may well lead to a new fonn of economic triage, according to 
which those who could not personally pay for certain costlier maladies would simply 
be economically doomed to die of them. In the United States, most citizens are pain­
fully aware of the rising costs· of medical care, and they continue to harbor doubts 
about reversing this trend. 
CARRICK, supra note 1 65, at 217 . . However, l)thers point out that the victims of genetic disease arc the 
strongest proponents for the genomics revolution: 
One of the most powerful sources of pressure for further research and treatment in 
medical genetics has come from the victims of genetic diseases and their 
families. . . . They not only support research but also lobby for their constituencies. 
Not surprisingly, they tend to take a skeptical view of the distress voiced in recent 
years over interference with the human genome, and they welcome the powerful new 
tools for prenatal diagnosis emerging from the accelerating advance of biolncdical 
knowledge and techniques, especially the methods of recombinant DNA. 
K.EVLES, supra note 28, at 293 (footnote and citations omitted); see also id. at 291 (citations omitted) 
("In 1983, at a conference on gene therapy, Ola Huntley, the mpthcr of thrc:c: sickle-cell anemic children 
and a counselor of sickle.:Cell patients, declared, 'I am angry that anyone presumes to deny my children 
the essenti81 genetic treatment of a genetic disease. I see such persons as simplistic moralists."'). 
449 For example, as observed by Francis Fukuyama: ' . 
If large numbers of people . make . the choice to, for example, extend . their lives for 
another ten years at the cost of, say, a 30 percent decrease in functionality, then soci­
ety as a whole will have to pick up the tab for keeping them alive . . . .  While any in­
dividual will want to postpone death as long as possible, people in the aggregate may 
not enjoy living in a society whose median age is 80 or 90, where sex and reproduc­
tion become activities engaged in by a small minority of the population, or where the 
natural cycle of birth, growth, maturity, and death has been interrupted. In one ex­
treme scenario, the indefinite postponement of death will force societies to put se­
vere constraints on the number of births allowed. 
FUKUY AMA, supra note 6, at 96-97; cf. John V. Jacobi, Genetic Discrimination in a Time of False 
Hopes, 30 FLA. ST. U. L. REV. 363, 363-64 (2003) (arguing that genetic equity should be regarded as 
an aim consistent with the broader movement toward equitable access to health care). 
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very existence.450 Available technology has been limited in relative terms, 
but our experience to date validates these concerns. Now routine prenatal 
diagnostics such as sonograms and anmiocentesis, technology introduced 
to- increase the· knowledge and choice of prospective parents, already have 
introduced pressures against bearing potentially health-impaired children 
and inspired practices such as aborting female fetuses in many parts of the 
world.451 We must draw from this experience when trying to discern the 
contours of the rapidly approaching horizon: 
.. The temptation to use medical knowle_dge and skills to ma­
nipulate or coerce entire classes of people or whole societies 
in the name of improved health, social well-beillg, or cost 
control is likely to become increasingly potent, and enor­
mously seductive, ill the years ahead� With the terrible ex­
ample of the el1gellics.movement ofthe late'nine�eenth and 
early twentieth' centuries in mind, it is a development to be 
watched carefully anq generally_ resisted., Coerced abortions, 
mandated genetic screening and prenatal diagnosis, and ex­
cessive press1.lfe to change health-related habits are not theo­
r etical. haz,ar� ... The coercion of people by medical means 
represents a potential threat that is already in many places 
cleat: andpl"escmt: athreat to the institution of medicine and 
to human liberty and dignity.452 
To reap the health care potential 9fadvances in genetic· medicine and 
ART, the interests of individuals wishing to ·control genetics during their 
procreation must be tempered against the broader, cumulative interests of 
society: 
lnde�d, i(\ve irisist on absolute reproductive autonomy vve 
must accept the use of genetic technologies to prevent the 
birtl:l <;>.fthose' who are unwante4 for any reason: that they will 
be the "wrong". gender, or sexual orientation, or of short stat­
ure, _
or prone to obesity, or ... Used this way, medical genet­
ics will surely reinforce a·host of social prejudices� A history 
of eugenic� that is sensitive to its complexities alerts us to the 
fact that genetic technologies present mote than one kind of 
danger-and· tha� if we are not very careful, we may avoid 
One only t() COl.J.rt llnOther;453 
450 See slq]ra noies 411-13 and accompanying text. 
451 .. . . .  ·., .. GOALS, supra note 224, at 33. 
452 /d. at 33-34. 
453 PAUL, supra note 13, at 135 . .  St!e generally Asch, Contradictory or Compatible?, supra note 
410 (examining the impact of selective abortion to prevent disability on equality for disabled people); 
Dolgin, supra note 12 (t!xploring the ideological implications of maintaining a pro-choice position on 
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The Ethics Committee of the ASRM already has observed this tension 
between individual and societal choices in procreation and issued a respon­
sive guidance: "[l]n applying the personal criterion, one must take into 
account that the human person is both individual and social. Hence, what 
is [beneficial] or detrimental to the person cannot be assessed solely in 
terms of individual impact but must take into account overall social impact 
as well."454 
While meaning is being added to the map of the human genome, we 
must determine what role, if any, government and law are to play in the 
field of ART beyond protecting the safety of human subjects and the prac­
tice of good medicine. Especially given that HGP was a U.S. government­
launched and sponsored initiative and that the U.S government, federal and . 
state, has and continues to fuel the biotechnology economy directly and 
through responsive policy,455 the ethical, legal, and social implications of · 
folding this technology into the field of ART de�erve immediate and seri­
ous consideration.456 Given our �ugenics past and the possibilities of a 
eugenics future, the coupling of technology and assisted reproduction 
should not be allowed to remain adrift in the free market: 
Free markets work well much of the time, but there are also 
market failures that require government intervention to cor­
rect. Negative externalities do not simply take care of them­
selves. We do not know at this point whether these external­
ities will be large or small, but we. should not assume them 
away out of a rigid commitment to markets and individual 
choice.457 
Though our meaningful knowledge about human genetics is nascent 
and humble, a map of the human genome and solid, empirically measur-
abortion generally while discouraging selective abortion); Holland, supra note 420 (recommending 
regulation of ART due to the soeial and historic implications of genetic testing); Mahowald, supra note 
420 (examing a range of eugenic practices and what makes them "good" or ''bad"). 
454 THE ETHICS COMMITTEE OF THE AMERICAN FERTILITY SOCIETY, ETHICAL CONSIDERATIONS 
OF ASSISTED REPRODUCTIVE TECHNOLOGIES 1 5  (Nov. 1994). 
455 See Michael J. Malinowski, Biotechnology in the USA: Responsive Regulation in the Life 
Science Industry, 2 INT. J. BIOTECHNOLOGY 1 6, 1 8-20 (2000) (describing how responsive policy has 
allowed biotechnology to flourish in the U.S.); Michael J. Malinowski & Nick Littlefield, Transforma­
tion of a Research Platform into Commercial Products: The Impact of United States Federal Policy on 
Biotechnology, in THE COMMERCIALIZATION OF GENETIC REsEARCH: ETHICAL, LEGAL, AND POLICY 
ISSUES 29, 32-45 (Timothy A. Caulfield & Bryn Williams-Jones cds., 1 999) (detailing U.S. policy 
measures that have facilitated development of biotechnology). 
456 The very existence of tJ:te ESLI program supports this proposition. See supra note 440 and 
accompanying text (comments of James Watson, founder of HOP); CARRICK, supra note 165, at 2 1 0  
(discussing need based on past political misuse o f  eugenics for science and medical communities to 
remain vigilant for abuses). 
451 FuKUYAMA, supra note 6, at 100. But see Wasserman, supra note 396, at 313 (arguing for an 
unrestricted regime of prenatal testing over one restricted by the criterion of severity). 
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able natural science now replace the murky concoction of social science 
and speculation that drove our eugenics past so forcefully.4S8 The mere 
possibility that externalities driving the flow of the free market will turn 
out to be an unprecedented level of social intolerance of genetic differences 
is a potential cost too great to be ignored.459 Therefore, we must overcome 
the contemporary tendency to reduce the role of government in procrea­
tion-related health services where "[t]he integrity of medicine itself is at 
stake. An excessive and unbalanced commercialization and privatization 
of medicine is a dire threat to the very goals of medicine. '�60 Government 
must assume a meaningful role; the combination of ART and the genetics 
revolution cannot be trusted to medicine and market forces: 
It is not within the capacity of medicine to determine what is 
the overall good of society. For it to play a general role in 
the promotion of social well being beyond that of enhancing 
the health of citizens, medicine would need the capacity to 
make such judgments, to determine when its skills could be 
put to the service of, or subordinated to, social goals. It has 
no such capacity and, indeed, would run the severest dangers 
to its own integrity and goals were it to allow itself to be so 
458 See supra notes 14, 37-38, 47, 156 and accompanying text. 
459 As explained by Francis Fukuyarna: 
A utilitarian framework has particular difficulty encompassing moral imperatives, 
which tend to be regarded as just another type of preference . . . . There are, in other 
words, things that people believe to be morally wrong regardless of the utilitarian 
benefits that might flow from them. So it  is with biotechnology . . . .  What is ulti­
mately at stake with biotechnology is not just some utilitarian cost-benefit calculus 
concerning future medical technologies, but the very grounding of the human moral 
sense, which has been a constant ever since there were human beings. 
FUKUYAMA, supra note 6, at 100-02. See generally Asch, supra note 41 1 (examining the impact of 
selective abortion to prevent disability on equality for disabled people); Dolgin, supra note 12 (explor­
ing the ideological implications of maintaining a pro-choice position on abortion generally while dis­
couraging selective abortion); Holland, supra note 419 (recommending regulation of ART due to the 
social and historic implications of genetic testing); Mahowald, supra note 419 (examing a range of. 
eugenic practices and what makes them "good" or ''bad"). 
� 
460 GOALS, supra note 224, at 43. "More broadly, the hazards of the market include the introduc­
tion of an alien set of economic values into the institution of medicine, whose inherent ends have his­
torically been philanthropic and altruistic, not commercial; despite market ideology, an actual decrease 
in patient choice." /d. ; see also PHIUP J. HILTS, PROTECTING AMERICA'S HEALTH 342 (2003) ("We 
must recognize the roles business managers are required to play, and simply set in counterposition to 
them a group with a fundamentally different role. Against businesses, whose first job is profit, we must 
set groups whose first job is safety."). But see FDA, IMPROVING INNOVATION IN MEDICAL TECHNOL­
OGY: BEYOND 2002 (2003) [hereinafter IMPROVING INNOVATION] available at 
www.fda.gov/bbs/topics/news/2003/beyond2002/report.html. (last visited Sept. 24, 2003) (on file with 
the Connecticut Law Review) (the FDA's agency-wide initiative to accelerate product review); Busi­
ness and Regulatory News: FDA Releases Bold Plan, 21 NATURE BIOTECHNOLOGY 21 9 (Mar. 2003) 
[hereinafter Bold Plan] (reporting that Commissioner Mark McClellan announced bold plans to accel­
erate FDA product reviews); Alan Dove, Walking the Drug Regulatory Tightrope, 21 NATURE BIO­
TECHNOLOGY 495, 495 (May 2003) ("Regiii atory agencies are being pulled in several directions at 
once, and drug developers must learn to adapt swiftly to a rapidly changing landscape."). 
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used. A society that used medicine to weed out the Wlfit, to 
serve partisan political goals, to become the handmaiden of 
political authority, or even a servant of the will of the people 
would soon cease to have its own center and its own integ-
rity.461 
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At the very least, govei'lUllent regulation of ART must be extensive 
enough to ensure public awareness of emerging practices. Given the pace 
of advancement of PGD enabling technologies and the fact that some of 
this technology already has matured into application, we no longer can rely 
on less direct approaches such as HGP's ESLI program.462 We also cannot 
rely so heavily on national commissions staffed with professional bioethi­
cists and subject so heavily to political, professional, and personal influ­
ences.463 "We need institutions with real enforcement powers."464 Mean­
ingful legislation is a prerequisite to creating such institutions.465 "A num­
ber of coWttries have in fact moved beyond the stage of national commis­
sions and study groups to actual legislation[,]" and in the field of ART we 
must follow their lead.466 Many opinions wholly opposed to the imposition 
of law into areas of life science and medical technology have been shifted 
461 GoALS, supra note 224, at 34-35; see also FUKUYAMA, supra note 6, at 2 15-16 (referring to 
the mistakes made by the agriculture sector in trying to wholly self-regulate, and addressing how the 
government regulation came after the product was in commerce, and on the thrust of public demand); 
HILTS, supra note 460, at 342 ("We must recognize the roles business managers are required to play, 
, and siniply set in counterposition to them a group with a fundamentally different role. Against busi­
nesses, whose first job is profit, we must set groups whose first job is safety."). But su Botkin, supra 
note 280, at 265-66 (proposing heavy reliance on professional medical standards for regulation of 
assisted reproduction). 
462 See FuKUY AMA, supra note 6, at 204. 
463 For example, bioethicists often "face an uphill struggle winning the respect of the scientists 
they must deal with, and are hardly likely to do so if they tell them they are morally wrong or if they 
depart significantly from the materialist world view that the scientists hold dear." /d. 
464 !d. 
. 
465 For example, as pointed out by one commentator, the FDA's present legislative authority is 
not broad enough to enable the agency to grapple with pressing issues such as human cloning and 
genetic enhancement: 
The FDA is not set up to make politically sensitive decisions concerning the point at 
which selection for characteristics like intelligence and height ceases to be therapeu­
tic and becomes enhancing, or whether these characteristics can be considered thera­
peutic at all. The FDA can disapprove a procedure only on the grounds of effective­
ness and safety, but there will be many safe and effective procedures that will none­
theless require regulatory scrutiny. The limits of the FDA's mandate are already 
· evident: it has asserted a right to regulate human cloning on the legally questionable 
grounds that a cloned child constitutes a medical "product" over which it has author­
ity. 
/d. at 213.  
466 /d. at  205. Often cited examples include the Human Fertilization and Embryology Authority 
("HFEA") in England and the Reproductive Technology Accreditation Committee ("RT AC") in Aus­
tralia. Adamson, supra note 2 1 ,  at 932. 
216  CONNECTICUT LAW REVIEW [Vol. 36: 1 25 
by recent positive experiences including modernization of the Food and 
Drug Administration.467 The United States should follow this example in 
the area of ART. Rather than attempt to enact extensive technical legisla­
tion (consider legislative chaos over cloning and stem cells},468 the United 
States should enact legislation that creates sufficient regulatory jurisdiction 
over this technology implen::l�ted by those with scientific expertise, who 
should become directly engaged in ART through the dynamism of ongoing 
regulation reflective of the changing nature of the underlying science and 
public opinion.469 With such authority in the hands of those with technical 
scientific expertise, it may even be possible to draw often strained distinc­
tions between therapy and ellbancement and impose , greater restraints on 
the latter.470 As stated by on� commentator in support of this position: 
The original purpose .of medicine is, after all, to heal the sick, 
not to turn healthy people into gods. We don't want star ath­
letes to be hobbled by bad lmees or torn ligaments, but we 
461 See generally IMPROVING INNOVATION, supra note 460 (discussing the FDA's plan to im­
prove and expedite the approval process); Bold Plan, supra note 460 (discussing announcement of the 
FDA's new plan). See also Michael J. Malinowski, Overview of FDA Regulation of Human Medicinal 
Products Developed with Biotechnology, in BIOTECHNOLOGY LAW 2002: BIOTECHNOLOGY PATENTS & 
BUSINESS STRATEGIES 979, 997-1 000 (2002) (addressing the current state of FDAMA and acknowl-
edginf&ressing concerns). • • 
· Examples include legislative attempts to ban abuses of genetic testing and genetic information 
while not impeding research and responsible medical use of this technology, with the ultimate goal of 
utilizing the technology to maximize human health benefits. See generally Snake Oil, supra note 5 
(describing how regulation of predictiVe genetic testing threatened development and use of the technol­
ogy). Another angle was added to the stern cell controversy in May 2003 when scientists working with 
mice announced that they had successfully derived egg cells from embryonic stem cells through a 
process called parthenogenesis. William Hathaway, Creating Life from Scratch in the Laboratory, 
HARTFORD COURANT, June 8, 2003, •at 13.  In the U.S., federal funding may be used to engage in 
research with human cell lines in existence as of9 p.m. on August 9, 2001 .  See Raja Mishra, Stem Cell 
Research Runs inio Roadblocks, BOSTON GLOBE; May 12, 2002, at AI,  LEXIS, News Library, Bglobe 
File (identifying holders of stem ceJI lines eligible for government funded research, but noting that 
"nearly three-quarters of the 78 stem cell batches that met Bush's conditions for support remain un­
available to US researchers . . . .  "). Therefore, theoretically, these cells lines and federal money could 
be used to create human embryos. 
469 Cf. Snake Oil, supra note 5 (discussing the benefits of regulation over legislation in the field 
of predictive genetic testing). , .
·
. · ·· 
470 "Regulators are called on all the time to make complex 'judgments that cannot be held up to 
precise theoretical scrutiny." FuKUYAMA, supra note 6, at 21 1 .  Consider, for example, that standards 
are set for water and air quality: . . 
[A) properly functioning democratic political system allows people with a stake in 
the regulator's decision to push and shove against one another until a compromise is 
reached. Once we agree in pnnciple that we will need a capability to draw red lines, 
it will not be a fruitful exercise to spend a Jot of time arguing precisely where they 
should be placed. As in other areas of regu Jation, many of these decisions will have 
to be made on a trial-and-error basis by administrative agencies, based on Jmowledge 
and experience not available to us at present. 
!d. But see Palmer, supra note 289, at 242, 263 (proposing reliance on the judiciary and theories of 
liability rather than regulation). 
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also don't want them to compete on the basis of who has 
taken the most steroids. This general principle. would allow 
us to use biotechnologies to, , for example, cure genetic dis-
eases like Huntington's chorea or cystic fibrosis, but not to 
make our children more intelligent or taller.471 
Although some commentators support the creation of entirely new 
government institutions to regulate the combination of ART and the genet­
ics revolution,472 much could be accomplished by �xpanding our existing 
regulatory infrastructures to endompass ART. Proposals set forth below 
include recognizing that experimental ART procedures constitute experi­
mentation on human subjects and regulating them as such, and otherwise 
expanding the roles of CDC and FDA to ensure the practice of good medi­
cine in the field of ART. 
A. Recognition and Regulation of Experimentation on Human Subjects 
Experimentation on human beings in the context of assisted reproduc­
tion �hould be deemed and regulated as such, meaning that this experimen­
tation should only take place with the oversight of a qualifying IRB that 
reports to OHRP.473 In recent years, with the increased privatization of 
biomedical R&D,474 there has been measurable support for removing the 
federal funding prerequisite on the Common Rule applicability and extend-
471 FUKUY AMA, supra note 6, at 208-09. This commentator challenges the notion that, pragmati-
cally, the distinction between therapy and enhancement is unworkable, observing: 
While it is the case that certain conditions do not lend themselves to neat distinc­
tions between pathological and nonnal, it is also true that there is such a thing as 
health . . . .  It has often seemed to me that the only people who can argue that there is 
no difference in principle between disease and health are those who have never been 
sick: if you have a virus or fracture your leg, you know perfectly well that something 
is wrong. And even in the cases where the borderline between sickness and health, 
therapy and enhancement; is murkier, regulatory agencies are routinely able to make 
these distinctions in practice. 
/d. at 209-10. 
472 See supra note 466 and accompanying text. Francis Fukuyama suggests such an approach: 
. (A)ny new regulatory agency not only would have to have a mandate to regulate bio­
technology on grounds broader than efficacy and safety but also would have to have 
statutory authority over all research and development, and not just research that is 
federally funded. Such an agency, the Human Fertilisation and Embyology Author­
ity, has already been created in Britain for this purpose. Unification of regulatory 
powers into a single new agency will end the practice of complying with federal 
funding restrictions by finding private sponsors and, it is hoped, will shed a more 
unifonn light on the whole biotech sector. 
FUKUY AMA, supra note 6, at 215. 
473 ., d' . p IV �ee JscussJon supra art . 
474 Academia and industry have integrated in the midst of a proliferation of biotechnology com­
panies, most of them private, directly engaged in biomedical research. See CONVERGENCE, supra note 
251 ;  BOSTON CONSULTING GROUP, THE PHARMACEUTICAL INDUSTRY INTO ITS SECOND CENTURY: 
FROM SERENDIPITY TO STRATEGY 38·39 (1 999); Genomics Players: From Discovery to Integration­
Business and Technology Assessment, M2 PRESSWJRE, Feb. 1 9, 2003, LEXIS, News Library, M2pw 
file. 
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ing the scope of the Rule to all instances allowable under the Commerce 
Clause of the United States Constitution:m As an incremental beginning 
for this kind of broader reform, the scope of the Common Rule should be 
extended to cover experimentation in ART. Alternatively, or perhaps addi­
tionally, the scope ofFDA's definition of "human subject" should be ex­
panded to fully encm;npass ART, which would necessitate expansion or 
increased enforcement of FDA's jurisdiction over biologics.476 The ART 
commercial sector is extremely intrastate and, in fact, intemational.477 The 
sector engages in aggressive DTC marketing and does so regionally, na­
tionally and even i11temationally. Regardless of absence of federal funding 
and the involvement of academic institutions, those who engage in experi­
mentation on human beings should report to independent IRBs which, in 
tum, should report directly to OHRP. 
B. Further Regulation to Ensure the Practice of Good Medicine, and On­
going Accountability and Public Oversight 
The non-experimental practice of ART also must be regulated to en­
sure oversight and accountability and compliance with good laboratory and 
good medicine practices. There are several options to accomplish compre­
hensive regulation of ART. The first option is federal regulation through 
expansion of the roles of CDC, FDA, or both. Given that the most mean­
ingful direct federal government regulation of ART presently in place is 
CLIA which is implemented under CDC,478 expanding CLIA or introduc-
47S NATIONAL BIOETHICS ADVISORY COMMISSION e'NBAC"), REPORT INVOLVING HUMAN BIO­
LOGICAL MATERIALS: ETHICAL ISSUES AND POLICY GUIDANCE, VOL. I, REPORT AND RECOMMENDA· 
TJON OF THE NATIONAL BIOETHICS ADVISORY COMMISSION, 59-60 (1999), available at 
http://www.georgetown.edu/researchlnrcbl/nbac/hbm.pdf; Helena Gail Rubinstein, If I Am Only for 
Myself. What Am I? A Communitarian Look at the Pn"vacy Stalemate, 25 AM. J.L. & MED. 203, 221 
(1999). 476 See discussion infra Part VII.B. FDA's definition of "human subject'' is tied to the license 
applications it receives for access to the market to engage in research and also to the products it  
reviews. See Malinowski & Rose, supra note 174, at 9-3 to 9-4, 9-8, 9-18. FDA implements that latter 
by requiring an assurance of compliance with human subject protection regulations as a prerequisite for 
accepting data for new product applications. This proposal for an expanded role for FDA is addressed 
below. See discussion infra P�rt VII.B. 477 See FINAL REPORT, supra note 1 1 ,  at 1. For ongoing information about the sector, visit the 
sites of the ASRM at http://www.asnn.org (last visited Sept. 24, 2003) (on file with the Connecticut 
Law Review), and SART, at http://www.sart.org/home_texthtml (last visited Sept. 24, 2003) (on file 
with the Connecticut Law Review). Also visit the site of the National Infertility Association, referred 
to as Resolve, at http://www.resolve.org/main/nationallindex.jsp?name=home (last visited Sept. 24, 
2003) (on file with the Connecticut Law Review). Resolve is a national consumer organization with 
the mission of helping people who are considering ART. 478 Pub. L. No. 100-578, 102 Stat. 2903, § ) , (1988) (codified at 42 U.S.C. § 201 (1 994)); CEN­
TER FOR MEDICARE AND MEDICAID SERVICES, CLINICAL LABORATORY IMPROVEMENT AMENDMENTS, 
available at http://crns.hhs.gov/clia (last visited Sept. 24, 2003) (on file with the Connecticut Law 
Review). The scope of CLIA regulation is limited to clinical proficiency via imposition of standards 
for laboratory performance, personnel, and so forth. 
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ing parallel legislation to encompass some consideration of good medicine 
practice standards for ART is an obvious consideration. Some of the more 
troubling aspects of ART center on use of rapidly expanding predictive 
genetic testing capabilities, and proposals have been made to introduce 
regulation of "home-brew"479 predictive genetic testing services through 
the introduction of a clinical utility standard for such tests via CLIA.480 
However, arguments also have been made to the contrary (by this author 
and others) based upon the observations that there are an overwhelming 
number of laboratories regulated under CLIA, and the reliability of CLIA 
is marred by reporting deficiencies and inconsistent enforcement_481 Also, 
one must pay serious attention to the very nature ofCLIA and question 
whether CLIA is "the appropriate mechanism to resolve complicated pa­
tient care issues such as informed consent, confidentiality, counseling, and 
the clinical soundness of medical decisions to use [this technology] .'>482 
Alternatively, or perhaps additionally, the scope of FDA's definition of 
tissue products regulated as biologics should be expanded to include 
ART-for example, the example should include the manipulation of sex 
cells in any manner, extending to manipulation through hormone therapy, 
or the creation of embryos as tissue products, or both.483 A defined FDA 
479 These �re tests performed in-house by their manufacturers and generally sold to the public 
through health care providers. Such tests escape the FDA's "device" category under present agency 
enforcement practices, meaning federal regulation of them is limited to CLIA. As stated by Professor 
Robertson and his co-authors: 
The Food and Drug Administration (FDA) has primary responsibility for regulating 
· POx tests to ensure their validity and utility. POx tests sold as kits are medical diag­
nostics, which require FDA prernarket review. Tests kits also may be used as inves­
tigational devices. To date, however, most genetic tests have been sold as "clinical 
services" by the academic centers and laboratories that have developed "home 
brews"-chemicals and reagents that a lab develops on its own....:to test DNA sam­
ples sent to them. The FDA has been less dili.ent With policing ''home brews" than 
test kits, although it now requires the reagents used in "home brews" be registered. 
Robertson; supra note 245, at 1 59; see also Anny Huang, FDA Regulation of Genetic Testing: 
Institutional Reluctance and Public Guardianship, 53 FOOD & DRUG L.J. 555, 551 n. l 5  (1 998). See 
generally Genetic Testing Under the Clinical Laboratory Improvement Amendments, 65 Fed. Reg. 
25,928 (May 4, 2000); SACOT RECOMMENDATIONS, supra note 299; SACOT, PRELIMINARY 
RECOMMENDATIONS ON THE ADEQUACY OF OVERSIGHT OF GENETIC TESTS (2000); NATIONAL HUMAN 
GENOME RESEARCH INSTITUTE, FINAL REPORT OF THE TASK FOR.CE ON GENETIC TESTING: PROMOT­
ING SAFE AND EFFECTNE GENETIC TESTING IN THE U.S. (Sept. 1997), available at 
http://www.genome.gov/1 0001733 (last visited Sept 24, 2003) (on file with the Connecticut Law 
Review). 
480 See Snake Oil, supra note 5, at 41 -42. 
48 1 /d. at 42. 
482 /d. (emphasis omitted). 
483 Given that FDA's definition of ''human subject" is tied to the license applications it receives 
for access to the market it controls, this modification would also extend the applicability of FDA's 
regulations to protect human subjects who participate in clinical research under INDs and IDEs and in 
the context of data churned in anticipation of filing New Biologics Applications (''NBLAs") and New 
· Device Applications (''NDAs"). See 21 C.F.R. §§ 50.1 -.56 (laying out the FDA's version of the Com­
mon Rule). 
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track for tissue products has been forthcoming for years now, and those 
efforts have included collaboration among FDA and sister agencies that has 
generated tangible -proposals.484 And now the FDA is under increased pres­
sure. In May 2003, FDA was sharply criticized for failing to meaningfully 
regulate human tissue products following - the death of Brian Lykins, a 
young man who received contaminated knee cartilage harvested from a 
cadaver.485 This tragedy prompted testimony before a Senate Investigative 
Committee and a legislative proposal.486 Moreover, the decision by the 
Bush Administration to consolidate review of all drugs, biologics and tra­
ditional drugs, in the Centers for Drug Evaluation and Research ("COER") 
could emancipate CBER resources in a manner conducive to better ena­
bling the FDA to rise to enact and implement meaningful tissue track regu­
lations.487 However, it must be noted that this reform has been made in the 
context of imposition of extraordinary responsibility on FDA and CDC for 
homeland security initiatives and epidemiological challenges like West 
Nile Virus, SARS, and monkeypox.488 Given that FDA has not voluntarily 
assumed regulatory responsibility over predictive genetic testing services 
beyond those put before the FDA for approval as medical devices,489 the 
agency is not likely to do so here. Nevertheless, the Bush-appointed 
Commissioner of FDA, Mark B. McClellan, has a background in sophisti­
cated research and certainly is capable of recognizing this need and taking 
484 See WORLD TECHNOlOGY EVALUATION CENTER ("WTEC''), FINAL REPORT: TISSUE ENGI· 
NEERJNG REsEARCH (Jan. 2002) (noting the collaboration of the DARPA, FDA, National Aeronautics 
and Space Agency ("NASA"), National Institutes of Health (''NIH"), National Institute of Science and 
Technology ("NIST''), National Science Foundation (''NSF')), available at 
http://www.wtec.orglloyolalte/finallte_final .pdf; see also Center for Biologics Evaluation and Research 
at http://www.fda.gov/cber/index.html (website for the Center for Biologics Evaluation and Research, a 
branch of the FDA) (last visited Sept 24, 2003) (on file with the Connecticut Law Review). For dis­
cussion of FDA regulation of human tissues and reproductive cloning in a case-study manner, see 
generally Richard A. Merrill, Human TISsues and ReprQducti,ve Cloning: New Technologies Challenge 
FDA, 3 HOUS. J. HEALTH L. & POl'Y I (2002). 
485 The FDA was criticized "for failing to issue regulations governing hundreds of tissue banks 
despite at least one death linked to infected tissue and investigations that have found widespread prob­
lems." Laura Meckler, FDA Criticized as Lax on Soft-Tissue Rules, BOSTON GLOBE, May 15, 2003, at 
A9, LEXIS, News Library, Bglobe file; see also Jerome Groopman, Do You Know Where That Carti­
lage Came from?, N.Y. UMES, May 1 7, 2003, at 1 (commenting on how the FDA had failed to regulate 
human tissue transplants despite an increase in the number of procedures performed}. 
486 Brian Lykins Tissue Transplant Safety Act of 2003, S. I 063, 1 08th Con g. (2003). 
487 See FDA Completes Final Phase of Planning for ColiSolidation of Certain Products from 
CBER to CDER, M2 PRESSWIRE, Mar. 18, 2003, LEXIS, News Library, M2pw file. · 
488 Malinowski, supra note 467, at 14, 35-36; see also Daniel Yee, 15 U.S. States Tracing Mon­
keypox, TORONTO STAR, June 12, 2003, at A08, LEXIS, News Library, Tstar file (reporting that the 
CDC rose to the challenge of meeting the public health challenges of SARS and monkeypox). 
489 See supra note 479 and accompanying text. 
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action.490 
To make such added governmental responsibilities workable, at least 
as an interim measure, the government could draw from its experience im­
plementing CLIA-. meaning implementation through considerable self­
regulation by delegating certification and compliance inspection responsi­
bilities to qualifying professional entities that adhere to government speci­
fications. CDC already has moved in this direction by contracting with 
SAR T to collect data on ART practices in the United States, and the federal 
government relies heavily on those compilations.491 However, this would 
require significantly changing the essence of SART -ASRM from a volun­
tary professional society that strongly encourages data reporting by mem­
bers to an entity that enforces technical government requirements or stan­
dards and imposes sanctions for noncompliance, or placing the responsibil­
ity elsewhere. S�T -ASRM and other professional organizations in the 
field of ART would be well advised to strengthen their efforts at meaning­
ful self7regulation through increased technical requirements and rigorous 
enforcement, even at the cost of members, before they lose that option.492 
This could be readily accomplished by drawing from and expanding upon 
the standard-setting and enforcement experiences of organizations such as 
the College of American Pathologists ("CAP") and the National Commit­
tee on . Clinical Laboratory Standards.493 Nevertheless, ultimately, reliance 
on self-regulation is questionable, especially in light of the CLIA experi­
ence.494 The fact that ART has burgeon«?ci into a major commercial and 
medical presence largely without the restraint of controlling regulatory 
checks suggestsJhose vested and benefiting ar� noi likely to give up inde­
pendence willingly, especially in the absence df dependence on third-party . . ' ' . . . . 
payers. . 
Another option, an option also embodied in . CLIA but seldom exer­
cised,495 is to delegate implementation respo11,sibility to the states and en­
force that responsibility through funding ofState Medicare and · Medicaid 
programs. The federal government could tfa.risform the CDC's model cer­
tification prognltlLdeveloped in accordance with the Fertility Clinic Sue-
490 Comments of James T. O'Reilly, Visiting Professor of Law, University o f  Cincinnati, College 
of Law, at the ABA event, New Frontiers, supra note 280, in the context of a question and answer 
session with the panel, including the author. 
491 FINAL REPORT, supra note 1 1 , 11,t 1 ;  Adamson, supra note 2 1 ,  at 933. 
492 SART-ASRM efforts to date are identified suprii in Figure 4, and these and additional profes­
sional society ethical guidelines pertaining to ART are summarized supra in Figure 3. In addition to 
SART-ASRM, relevant professional organizations include the American College of Obstetrics and 
Gynecology ("ACOG"), the Society of Reproductive Endocrinologists ("SRE"), the Reproductive 
Biologists Professional Group ("RBPG"), and the Reproductive Laboratories Technology Professional 
Group ("RL TPG"). See Adamson, supra note 2 1 ,  at 940-41 . 
493 Snake Oil, supra note 5, at 45 & n.98. 
494 /d. at 42. 
495 See Malinowski & Rose, supra note 303, at I 0-25 to I 0-26. 
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cess and Certification Act of 1992496 into a mandatory program and en­
hance relevant requirements. However, the resources, capabilities, and 
reliability of state departments of public health vary immensely throughout 
the country, especially in the midst of regional epidemiological problems 
such as West Nile Virus and challenges associated with realizing homeland 
security.497 A consistent blanket of federal regulation is desirable to offer 
the public balanced access to quality ART services regardless of where 
they live. Too much reliance on state regulation in such a controversial 
area could result in a "race to the bottom" where states that offer higher 
standards push ART providers into other jurisdictions . 
. · · Vill. CONCLUSION 
ART is a distinguishable area of clinical service: rapidly emerging 
technology and medicine are inherently mixed, the patient group is ex­
traordinarily vulnerable, commercial influences are intense, and standard 
accountability and good medj9ine checks on clinical practice through third­
party payer scrutiny do not pertain.498 
Assisted reproduction has become a burgeoning, multi-billion-dollar 
industry that often commingles clinical care and experimentation.499 The 
range of consequences includes expansion of procreative liberty, successful 
deliveries, dangerous multiple pregnancies, arid the birth of premature and 
otherwise health-compromised cl:lildren. 500 
This article has set forth re�latory proposals to ensure that ART is 
practiced with enforcement <)[good research and medicine standards.50 1 
Emphasized objectives are to protect the health of mothers and resulting 
children, to check influences 'on and the practices of ART providers, and to 
replace the present voluntary reporting by ART clinics with public ac­
countability. 502 The latter is . ess�ntial to regulate present practices and to 
contemplate our eugenics future before it arrives.503 Our eugenics legacy 
speaks loudly to the seduction of capabilities to combine genetic interven­
tion and procreation with the' potential of improving the human condition, 
the need to question our present insufficient regulation of ART in the midst 
of the genomics revolution, and the moral imperative to contemplate the 
496 Fertility Clinic Success Rate and Certification Act of 1992, 42 U.S.C. § 263a-l to -7 (2000). 
497 This statement is based upon the author's observations working in regions as varied as Ari­
zona, Delaware, Louisiana, Massachllsetts, and New York. The work of the New York State Task 
Force on Life and The Law has been cited as evidence that states can and in some instances have as­
sumed a meaningful role in ART. See, e.g. , Adamson, supra note 21,  at 937. 
498 See generally discussion supra Part VI. . 
499 See generally discussion supra Part VI. B. 
500 See generally discussion supra Part VI.B. 
501 See generally discus�ion supra Part VII. 
502 See generally discussion supra Part VII. 
503 See generally discussion supra Part VII. 
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implications of present actions for the future we are shaping today.504 Con­
scious of this legacy, recent Nobel Laureate Sir Paul Nurse, in the context 
of honoring the 50th anniversary of the discovery of the double helix shape 
of DNA by James Watson and Jim Crick, warned, given the complexity of 
interpreting the influence of genes in combination with environmental fac­
tors, "[W]e need to be extremely careful how this technology is used to 
shape our society. This is why it is so important to have a proper public 
debate-we need to discuss what genetics can and can't deliver and what 
sort of society we want as a result."505 
The 1 997 motion picture GA TI ACA depicts a United States society in 
the not-too-distant future obsessed with genetic perfection in which ART 
and PGD are the standard of care for conceiving a child. 506 Everyone's 
genetic diary is an open book.507 The main character, Vincent, portrayed 
by Ethan Hawke, has the misfortune of being an "In-Valid"-meaning one 
conceived in the back seat of an automobile the "old-fashioned way" rather 
than via the use of pipettes and computers. At the outset of the movie, 
Vincent reflects, "I'll never understand what possessed my mother to put 
her faith in God's hands rather than those of the local geneticist. Ten fin­
gers, ten toes-that's all that used to matter. Not now. Now, only seconds 
old, the exact time and cause of my death was already known."508 As we 
listen to Vincent' s  voice-over, a nurse in the delivery room collects a drop­
let of blood from his heel, feeds that into a computer, and shares the analy­
sis: "Neurological condition-60 percent probability. Manic Depression-
42 percent probability. Attention deficit disorder-89 percent probability. 
Heart disorder\(pause)-99 percent probability . . .  early fatal potential. 
Life expectancy . . .30.2 years."509 Vincent's parents are careful to engage 
their local geneticist for the conception of their second child, and Vincent 
and his brother are r:aised commensurate with their genetic expectations. 
But, alas, Y.incent beats his genetic 6dds: he does not succumb to a heart 
condition. Rather he assumes the identity of a member of the genetic elite 
and travels into space with the Gattaca Aerospace Corporation. 
When GATIACA was released, spokespeople for the biotechnology 
industry were quick to characterize the film as a work of "science fiction, 
504 See discussion supra Parts II and Ill; supra notes 423-72 and accompanying text. 
505 Tim Radford, Fear of Genetic Apartheid: Debate Urged on Consequences of Health Predic­
tions, GUARDIAN, Mar. 4; 2003, at 2, LEXJS,. News Library, Guardn file. Sir Paul shared the 2001 
Nobel prize for genetic research and chairs the U.K. Royal Society's Science in Society Programme. 
!d. 
506 GATIACA (Columbia Pictures 1 998). 
507 Jd. 
508 ld. 
509 ld. 
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not fact."510 With a map of the human genome in hand, a SNPs consor­
tium, the DNA of nearly entire populations such as those of Iceland and 
Estonia available for a price, and bioinformatics capabilities almost unfa­
thomable five years ago, scenes from GATTACA are being shown at law 
and policy conferences and interpretations have changed to "science fic­
tion?"51 1  Renowned bioethicists such as George Annas and Lee Silver, 
respected broadcast journalists, and others are referring to GATT ACA as a 
prophetic depiction of the society we could become.m Their message has 
been echoed throughout this article: Now is the time for us to reflect upon 
our eugenics past, ponder our present practices in ART in the context of 
ongoing biomedical R&D, and ask ourselves what kind of society we want 
to become. 
510 The author was managing government affairs for the Massachusetts Biotechnology Council, 
Inc., a biotechnology trade organization, at this time and speaks from that personal experience. 
Sl l  E.g. , Cracldng the Code, supra note 238; Making Babies, supra note 6; Michael J. Mali­
nowski, Presentation: Genes and Disability Through a Historic Lens, Symposium: Florida State Uni­
versi� School of Law, (Mar. 4, 2003) (on file with the Connecticut Law Review). 
12 E.g., 60 Minutes, Secrets of the Code (CBS television broadcast, Apr. 1 7, 2002); Making Ba­
bies, supra note 6; Cracking the Code, supra note 238. See generally KAss, THE CHALLENGE, supra 
note 355 (discussing society's tendency towards a Jack of bioethical control and its effect on the fu­
ture); MCKIBBEN, supra note 14 (discussing advances in biotechnology and their necessary societal 
limiations). 
